                         SEQUENCE LISTING

<110>  Iovance Biotherapeutics, Inc.
       VOGT, Frederick G.
       FARDIS, Maria
       CHARTIER-COURTAUD, Cecile
       CUBAS, Rafael
       ZHANG, Yongliang
 
<120>  CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSTIONS 
       AND METHODS

<130>  116983-5086-WO

<140>  PCT/US22/14425
<141>  2022-01-28

<150>  US 63/143,736
<151>  2021-01-29

<150>  US 63/146,486
<151>  2021-02-05

<150>  US 63/224,360
<151>  2021-07-21

<150>  US 63/277,571
<151>  2021-11-09

<150>  US 63/285,956
<151>  2021-12-03

<160>  331   

<170>  PatentIn version 3.5

<210>  1
<211>  450
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of the heavy chain of muromonab

<400>  1

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr 
        115                 120                 125             


Pro Leu Ala Pro Val Cys Gly Gly Thr Thr Gly Ser Ser Val Thr Leu 
    130                 135                 140                 


Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp 
145                 150                 155                 160 


Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu 
                165                 170                 175     


Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser 
            180                 185                 190         


Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser 
        195                 200                 205             


Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Pro Lys Ser Cys Asp 
    210                 215                 220                 


Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 
225                 230                 235                 240 


Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 
                245                 250                 255     


Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 
            260                 265                 270         


Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 
        275                 280                 285             


Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 
    290                 295                 300                 


Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 
305                 310                 315                 320 


Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 
                325                 330                 335     


Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 
            340                 345                 350         


Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 
        355                 360                 365             


Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 
    370                 375                 380                 


Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 
385                 390                 395                 400 


Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 
                405                 410                 415     


Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 
            420                 425                 430         


Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 
        435                 440                 445             


Gly Lys 
    450 


<210>  2
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of the light chain of muromonab

<400>  2

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn Arg Ala Asp Thr Ala Pro 
            100                 105                 110         


Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly 
        115                 120                 125             


Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn 
    130                 135                 140                 


Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn 
145                 150                 155                 160 


Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser 
                165                 170                 175     


Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr 
            180                 185                 190         


Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe 
        195                 200                 205             


Asn Arg Asn Glu Cys 
    210             


<210>  3
<211>  134
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a recombinant human IL-2 protein

<400>  3

Met Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu 
1               5                   10                  15      


His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr 
            20                  25                  30          


Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro 
        35                  40                  45              


Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu 
    50                  55                  60                  


Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His 
65                  70                  75                  80  


Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu 
                85                  90                  95      


Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr 
            100                 105                 110         


Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser 
        115                 120                 125             


Ile Ile Ser Thr Leu Thr 
    130                 


<210>  4
<211>  132
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of aldesleukin

<400>  4

Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu 
1               5                   10                  15      


Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn 
            20                  25                  30          


Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys 
        35                  40                  45              


Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro 
    50                  55                  60                  


Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg 
65                  70                  75                  80  


Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys 
                85                  90                  95      


Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr 
            100                 105                 110         


Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile 
        115                 120                 125             


Ser Thr Leu Thr 
    130         


<210>  5
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IL-2 form

<400>  5

Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His 
1               5                   10                  15      


Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys 
            20                  25                  30          


Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys 
        35                  40                  45              


Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys 
    50                  55                  60                  


Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu 
65                  70                  75                  80  


Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu 
                85                  90                  95      


Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala 
            100                 105                 110         


Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile 
        115                 120                 125             


Ile Ser Thr Leu Thr 
    130             


<210>  6
<211>  303
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of nemvaleukin alfa

<400>  6

Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn 
1               5                   10                  15      


Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu 
            20                  25                  30          


Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile 
        35                  40                  45              


Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr Gly Gly Ser Ser Ser 
    50                  55                  60                  


Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln 
65                  70                  75                  80  


Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg 
                85                  90                  95      


Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys 
            100                 105                 110         


His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu 
        115                 120                 125             


Asn Leu Ala Gln Gly Ser Gly Gly Gly Ser Glu Leu Cys Asp Asp Asp 
    130                 135                 140                 


Pro Pro Glu Ile Pro His Ala Thr Phe Lys Ala Met Ala Tyr Lys Glu 
145                 150                 155                 160 


Gly Thr Met Leu Asn Cys Glu Cys Lys Arg Gly Phe Arg Arg Ile Lys 
                165                 170                 175     


Ser Gly Ser Leu Tyr Met Leu Cys Thr Gly Asn Ser Ser His Ser Ser 
            180                 185                 190         


Trp Asp Asn Gln Cys Gln Cys Thr Ser Ser Ala Thr Arg Asn Thr Thr 
        195                 200                 205             


Lys Gln Val Thr Pro Gln Pro Glu Glu Gln Lys Glu Arg Lys Thr Thr 
    210                 215                 220                 


Glu Met Gln Ser Pro Met Gln Pro Val Asp Gln Ala Ser Leu Pro Gly 
225                 230                 235                 240 


His Cys Arg Glu Pro Pro Pro Trp Glu Asn Glu Ala Thr Glu Arg Ile 
                245                 250                 255     


Tyr His Phe Val Val Gly Gln Met Val Tyr Tyr Gln Cys Val Gln Gly 
            260                 265                 270         


Tyr Arg Ala Leu His Arg Gly Pro Ala Glu Ser Val Cys Lys Met Thr 
        275                 280                 285             


His Gly Lys Thr Arg Trp Thr Gln Pro Gln Leu Ile Cys Thr Gly 
    290                 295                 300             


<210>  7
<211>  452
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IL-2 form

<400>  7

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 
1               5                   10                  15      


Ala Val Phe Val Ser Ala Arg Arg Pro Ser Gly Arg Lys Ser Ser Lys 
            20                  25                  30          


Met Gln Ala Phe Arg Ile Trp Asp Val Asn Gln Lys Thr Phe Tyr Leu 
        35                  40                  45              


Arg Asn Asn Gln Leu Val Ala Gly Tyr Leu Gln Gly Pro Asn Val Asn 
    50                  55                  60                  


Leu Glu Glu Lys Ile Asp Val Val Pro Ile Glu Pro His Ala Leu Phe 
65                  70                  75                  80  


Leu Gly Ile His Gly Gly Lys Met Cys Leu Ser Cys Val Lys Ser Gly 
                85                  90                  95      


Asp Glu Thr Arg Leu Gln Leu Glu Ala Val Asn Ile Thr Asp Leu Ser 
            100                 105                 110         


Glu Asn Arg Lys Gln Asp Lys Arg Phe Ala Phe Ile Arg Ser Asp Ser 
        115                 120                 125             


Gly Pro Thr Thr Ser Phe Glu Ser Ala Ala Cys Pro Gly Trp Phe Leu 
    130                 135                 140                 


Cys Thr Ala Met Glu Ala Asp Gln Pro Val Ser Leu Thr Asn Met Pro 
145                 150                 155                 160 


Asp Glu Gly Val Met Val Thr Lys Phe Tyr Phe Gln Glu Asp Glu Ser 
                165                 170                 175     


Gly Ser Gly Gly Ala Ser Ser Glu Ser Ser Ala Ser Ser Asp Gly Pro 
            180                 185                 190         


His Pro Val Ile Thr Glu Ser Arg Ala Ser Ser Glu Ser Ser Ala Ser 
        195                 200                 205             


Ser Asp Gly Pro His Pro Val Ile Thr Glu Ser Arg Glu Pro Lys Ser 
    210                 215                 220                 


Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 
225                 230                 235                 240 


Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 
                245                 250                 255     


Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 
            260                 265                 270         


His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 
        275                 280                 285             


Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 
    290                 295                 300                 


Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 
305                 310                 315                 320 


Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 
                325                 330                 335     


Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 
            340                 345                 350         


Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 
        355                 360                 365             


Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 
    370                 375                 380                 


Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 
385                 390                 395                 400 


Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 
                405                 410                 415     


Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 
            420                 425                 430         


Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 
        435                 440                 445             


Ser Pro Gly Lys 
    450         


<210>  8
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mucin domain polypeptide

<400>  8

Ser Glu Ser Ser Ala Ser Ser Asp Gly Pro His Pro Val Ile Thr Pro 
1               5                   10                  15      


<210>  9
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a recombinant human IL-4 protein

<400>  9

Met His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys Thr Leu Asn 
1               5                   10                  15      


Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr Asp 
            20                  25                  30          


Ile Phe Ala Ala Ser Lys Asn Thr Thr Glu Lys Glu Thr Phe Cys Arg 
        35                  40                  45              


Ala Ala Thr Val Leu Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr 
    50                  55                  60                  


Arg Cys Leu Gly Ala Thr Ala Gln Gln Phe His Arg His Lys Gln Leu 
65                  70                  75                  80  


Ile Arg Phe Leu Lys Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly 
                85                  90                  95      


Leu Asn Ser Cys Pro Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn 
            100                 105                 110         


Phe Leu Glu Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys 
        115                 120                 125             


Ser Ser 
    130 


<210>  10
<211>  153
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a recombinant human IL-7 protein

<400>  10

Met Asp Cys Asp Ile Glu Gly Lys Asp Gly Lys Gln Tyr Glu Ser Val 
1               5                   10                  15      


Leu Met Val Ser Ile Asp Gln Leu Leu Asp Ser Met Lys Glu Ile Gly 
            20                  25                  30          


Ser Asn Cys Leu Asn Asn Glu Phe Asn Phe Phe Lys Arg His Ile Cys 
        35                  40                  45              


Asp Ala Asn Lys Glu Gly Met Phe Leu Phe Arg Ala Ala Arg Lys Leu 
    50                  55                  60                  


Arg Gln Phe Leu Lys Met Asn Ser Thr Gly Asp Phe Asp Leu His Leu 
65                  70                  75                  80  


Leu Lys Val Ser Glu Gly Thr Thr Ile Leu Leu Asn Cys Thr Gly Gln 
                85                  90                  95      


Val Lys Gly Arg Lys Pro Ala Ala Leu Gly Glu Ala Gln Pro Thr Lys 
            100                 105                 110         


Ser Leu Glu Glu Asn Lys Ser Leu Lys Glu Gln Lys Lys Leu Asn Asp 
        115                 120                 125             


Leu Cys Phe Leu Lys Arg Leu Leu Gln Glu Ile Lys Thr Cys Trp Asn 
    130                 135                 140                 


Lys Ile Leu Met Gly Thr Lys Glu His 
145                 150             


<210>  11
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a recombinant human IL-15 protein

<400>  11

Met Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu 
1               5                   10                  15      


Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val 
            20                  25                  30          


His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu 
        35                  40                  45              


Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val 
    50                  55                  60                  


Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn 
65                  70                  75                  80  


Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn 
                85                  90                  95      


Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile 
            100                 105                 110         


Asn Thr Ser 
        115 


<210>  12
<211>  132
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a recombinant human IL-21 protein

<400>  12

Met Gln Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile Val 
1               5                   10                  15      


Asp Gln Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu Pro 
            20                  25                  30          


Ala Pro Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser Cys 
        35                  40                  45              


Phe Gln Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu Arg 
    50                  55                  60                  


Ile Ile Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser Thr 
65                  70                  75                  80  


Asn Ala Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys Asp 
                85                  90                  95      


Ser Tyr Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser 
            100                 105                 110         


Leu Leu Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly 
        115                 120                 125             


Ser Glu Asp Ser 
    130         


<210>  13
<211>  153
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IL-2 sequence

<400>  13

Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 
1               5                   10                  15      


Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 
            20                  25                  30          


Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 
        35                  40                  45              


Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe 
    50                  55                  60                  


Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 
65                  70                  75                  80  


Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 
                85                  90                  95      


Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 
            100                 105                 110         


Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 
        115                 120                 125             


Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 
    130                 135                 140                 


Cys Gln Ser Ile Ile Ser Thr Leu Thr 
145                 150             


<210>  14
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IL-2 mutein sequence

<400>  14

Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His 
1               5                   10                  15      


Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys 
            20                  25                  30          


Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys 
        35                  40                  45              


Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys 
    50                  55                  60                  


Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu 
65                  70                  75                  80  


Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu 
                85                  90                  95      


Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala 
            100                 105                 110         


Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile 
        115                 120                 125             


Ile Ser Thr Leu Thr 
    130             


<210>  15
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IL-2 mutein sequence

<400>  15

Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His 
1               5                   10                  15      


Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys 
            20                  25                  30          


Asn Pro Lys Leu Thr Arg Met Leu Thr Ala Lys Phe Tyr Met Pro Lys 
        35                  40                  45              


Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys 
    50                  55                  60                  


Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu 
65                  70                  75                  80  


Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu 
                85                  90                  95      


Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala 
            100                 105                 110         


Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile 
        115                 120                 125             


Ile Ser Thr Leu Thr 
    130             


<210>  16
<211>  145
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR1_IL-2 for IgG.IL2R67A.H1

<400>  16

Gly Phe Ser Leu Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 
1               5                   10                  15      


Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 
            20                  25                  30          


Asn Asn Tyr Lys Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe 
        35                  40                  45              


Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 
    50                  55                  60                  


Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 
65                  70                  75                  80  


Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 
                85                  90                  95      


Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 
            100                 105                 110         


Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 
        115                 120                 125             


Cys Gln Ser Ile Ile Ser Thr Leu Thr Ser Thr Ser Gly Met Ser Val 
    130                 135                 140                 


Gly 
145 


<210>  17
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR2 for IgG.IL2R67A.H1

<400>  17

Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  18
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR3 for IgG.IL2R67A.H1

<400>  18

Ser Met Ile Thr Asn Trp Tyr Phe Asp Val 
1               5                   10  


<210>  19
<211>  141
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR1_IL-2 kabat for IgG.IL2R67A.H1

<400>  19

Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His 
1               5                   10                  15      


Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys 
            20                  25                  30          


Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys 
        35                  40                  45              


Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys 
    50                  55                  60                  


Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu 
65                  70                  75                  80  


Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu 
                85                  90                  95      


Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala 
            100                 105                 110         


Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile 
        115                 120                 125             


Ile Ser Thr Leu Thr Ser Thr Ser Gly Met Ser Val Gly 
    130                 135                 140     


<210>  20
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR2 kabat for IgG.IL2R67A.H1

<400>  20

Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  21
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR3 kabat for IgG.IL2R67A.H1

<400>  21

Ser Met Ile Thr Asn Trp Tyr Phe Asp Val 
1               5                   10  


<210>  22
<211>  142
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR1_IL-2 clothia for IgG.IL2R67A.H1

<400>  22

Gly Phe Ser Leu Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 
1               5                   10                  15      


Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 
            20                  25                  30          


Asn Asn Tyr Lys Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe 
        35                  40                  45              


Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 
    50                  55                  60                  


Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 
65                  70                  75                  80  


Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 
                85                  90                  95      


Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 
            100                 105                 110         


Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 
        115                 120                 125             


Cys Gln Ser Ile Ile Ser Thr Leu Thr Ser Thr Ser Gly Met 
    130                 135                 140         


<210>  23
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR2 clothia for IgG.IL2R67A.H1

<400>  23

Trp Trp Asp Asp Lys 
1               5   


<210>  24
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR3 clothia for IgG.IL2R67A.H1

<400>  24

Ser Met Ile Thr Asn Trp Tyr Phe Asp Val 
1               5                   10  


<210>  25
<211>  143
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR1_IL-2 IMGT for IgG.IL2R67A.H1

<400>  25

Gly Phe Ser Leu Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 
1               5                   10                  15      


Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 
            20                  25                  30          


Asn Asn Tyr Lys Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe 
        35                  40                  45              


Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 
    50                  55                  60                  


Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 
65                  70                  75                  80  


Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 
                85                  90                  95      


Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 
            100                 105                 110         


Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 
        115                 120                 125             


Cys Gln Ser Ile Ile Ser Thr Leu Thr Ser Thr Ser Gly Met Ser 
    130                 135                 140             


<210>  26
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR2 IMGT for IgG.IL2R67A.H1

<400>  26

Ile Trp Trp Asp Asp Lys Lys 
1               5           


<210>  27
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR3 IMGT for IgG.IL2R67A.H1

<400>  27

Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe Asp Val 
1               5                   10          


<210>  28
<211>  253
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH chain for IgG.IL2R67A.H1

<400>  28

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ala Pro Thr 
            20                  25                  30          


Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu 
        35                  40                  45              


Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys 
    50                  55                  60                  


Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr 
65                  70                  75                  80  


Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu 
                85                  90                  95      


Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg 
            100                 105                 110         


Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser 
        115                 120                 125             


Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val 
    130                 135                 140                 


Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr 
145                 150                 155                 160 


Leu Thr Ser Thr Ser Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro 
                165                 170                 175     


Gly Lys Ala Leu Glu Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys 
            180                 185                 190         


Asp Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr 
        195                 200                 205             


Ser Lys Asn Gln Val Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp 
    210                 215                 220                 


Thr Ala Thr Tyr Tyr Cys Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe 
225                 230                 235                 240 


Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser 
                245                 250             


<210>  29
<211>  533
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain for IgG.IL2R67A.H1

<400>  29

Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr 
1               5                   10                  15      


Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu 
            20                  25                  30          


Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val 
        35                  40                  45              


Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu 
    50                  55                  60                  


Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr 
65                  70                  75                  80  


Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe 
                85                  90                  95      


Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr Leu Thr 
            100                 105                 110         


Ser Thr Ser Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys 
        115                 120                 125             


Ala Leu Glu Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr 
    130                 135                 140                 


Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys 
145                 150                 155                 160 


Asn Gln Val Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala 
                165                 170                 175     


Thr Tyr Tyr Cys Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe Asp Val 
            180                 185                 190         


Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly 
        195                 200                 205             


Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 
    210                 215                 220                 


Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 
225                 230                 235                 240 


Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 
                245                 250                 255     


Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 
            260                 265                 270         


Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 
        275                 280                 285             


Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 
    290                 295                 300                 


Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 
305                 310                 315                 320 


Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 
                325                 330                 335     


Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Ala Val 
            340                 345                 350         


Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 
        355                 360                 365             


Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 
    370                 375                 380                 


Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 
385                 390                 395                 400 


Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Ala Ala 
                405                 410                 415     


Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 
            420                 425                 430         


Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 
        435                 440                 445             


Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 
    450                 455                 460                 


Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 
465                 470                 475                 480 


Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 
                485                 490                 495     


Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 
            500                 505                 510         


Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 
        515                 520                 525             


Leu Ser Pro Gly Lys 
    530             


<210>  30
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR1 kabat for IgG.IL2R67A.H1

<400>  30

Lys Ala Gln Leu Ser Val Gly Tyr Met His 
1               5                   10  


<210>  31
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR2 kabat for IgG.IL2R67A.H1

<400>  31

Asp Thr Ser Lys Leu Ala Ser 
1               5           


<210>  32
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR3 kabat for IgG.IL2R67A.H1

<400>  32

Phe Gln Gly Ser Gly Tyr Pro Phe Thr 
1               5                   


<210>  33
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR1 chothia for IgG.IL2R67A.H1

<400>  33

Gln Leu Ser Val Gly Tyr 
1               5       


<210>  34
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR2 chothia for IgG.IL2R67A.H1

<400>  34

Asp Thr Ser 
1           


<210>  35
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR3 chothia for IgG.IL2R67A.H1

<400>  35

Gly Ser Gly Tyr Pro Phe 
1               5       


<210>  36
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL chain

<400>  36

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Gln Leu Ser Val Gly Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp 
65                  70                  75                  80  


Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  37
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain

<400>  37

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Gln Leu Ser Val Gly Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp 
65                  70                  75                  80  


Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 
            100                 105                 110         


Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 
        115                 120                 125             


Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 
    130                 135                 140                 


Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 
145                 150                 155                 160 


Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 
                165                 170                 175     


Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 
            180                 185                 190         


Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 
        195                 200                 205             


Asn Arg Gly Glu Cys 
    210             


<210>  38
<211>  583
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain

<400>  38

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ala Pro Thr 
            20                  25                  30          


Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu 
        35                  40                  45              


Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys 
    50                  55                  60                  


Leu Thr Arg Met Leu Thr Ala Lys Phe Tyr Met Pro Lys Lys Ala Thr 
65                  70                  75                  80  


Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu 
                85                  90                  95      


Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg 
            100                 105                 110         


Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser 
        115                 120                 125             


Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val 
    130                 135                 140                 


Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr 
145                 150                 155                 160 


Leu Thr Ser Thr Ser Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro 
                165                 170                 175     


Gly Lys Ala Leu Glu Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys 
            180                 185                 190         


Asp Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr 
        195                 200                 205             


Ser Lys Asn Gln Val Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp 
    210                 215                 220                 


Thr Ala Thr Tyr Tyr Cys Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe 
225                 230                 235                 240 


Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr 
                245                 250                 255     


Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 
            260                 265                 270         


Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 
        275                 280                 285             


Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 
    290                 295                 300                 


Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 
305                 310                 315                 320 


Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 
                325                 330                 335     


Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu 
            340                 345                 350         


Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 
        355                 360                 365             


Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
    370                 375                 380                 


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
385                 390                 395                 400 


Ala Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 
                405                 410                 415     


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 
            420                 425                 430         


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
        435                 440                 445             


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 
    450                 455                 460                 


Ala Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
465                 470                 475                 480 


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 
                485                 490                 495     


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
            500                 505                 510         


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
        515                 520                 525             


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
    530                 535                 540                 


Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 
545                 550                 555                 560 


Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
                565                 570                 575     


Leu Ser Leu Ser Pro Gly Lys 
            580             


<210>  39
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain

<400>  39

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Gln Leu Ser Val Gly Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp 
65                  70                  75                  80  


Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 
            100                 105                 110         


Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 
        115                 120                 125             


Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 
    130                 135                 140                 


Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 
145                 150                 155                 160 


Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 
                165                 170                 175     


Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 
            180                 185                 190         


Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 
        195                 200                 205             


Asn Arg Gly Glu Cys 
    210             


<210>  40
<211>  255
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of human 4-1BB

<400>  40

Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu 
1               5                   10                  15      


Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro 
            20                  25                  30          


Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys 
        35                  40                  45              


Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile 
    50                  55                  60                  


Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser 
65                  70                  75                  80  


Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly 
                85                  90                  95      


Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu 
            100                 105                 110         


Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln 
        115                 120                 125             


Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys 
    130                 135                 140                 


Ser Val Leu Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro 
145                 150                 155                 160 


Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro Pro Ala 
                165                 170                 175     


Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Ser Phe Phe Leu 
            180                 185                 190         


Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu Leu Phe Phe Leu Thr Leu 
        195                 200                 205             


Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe 
    210                 215                 220                 


Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly 
225                 230                 235                 240 


Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 
                245                 250                 255 


<210>  41
<211>  256
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of murine 4-1BB

<400>  41

Met Gly Asn Asn Cys Tyr Asn Val Val Val Ile Val Leu Leu Leu Val 
1               5                   10                  15      


Gly Cys Glu Lys Val Gly Ala Val Gln Asn Ser Cys Asp Asn Cys Gln 
            20                  25                  30          


Pro Gly Thr Phe Cys Arg Lys Tyr Asn Pro Val Cys Lys Ser Cys Pro 
        35                  40                  45              


Pro Ser Thr Phe Ser Ser Ile Gly Gly Gln Pro Asn Cys Asn Ile Cys 
    50                  55                  60                  


Arg Val Cys Ala Gly Tyr Phe Arg Phe Lys Lys Phe Cys Ser Ser Thr 
65                  70                  75                  80  


His Asn Ala Glu Cys Glu Cys Ile Glu Gly Phe His Cys Leu Gly Pro 
                85                  90                  95      


Gln Cys Thr Arg Cys Glu Lys Asp Cys Arg Pro Gly Gln Glu Leu Thr 
            100                 105                 110         


Lys Gln Gly Cys Lys Thr Cys Ser Leu Gly Thr Phe Asn Asp Gln Asn 
        115                 120                 125             


Gly Thr Gly Val Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Arg 
    130                 135                 140                 


Ser Val Leu Lys Thr Gly Thr Thr Glu Lys Asp Val Val Cys Gly Pro 
145                 150                 155                 160 


Pro Val Val Ser Phe Ser Pro Ser Thr Thr Ile Ser Val Thr Pro Glu 
                165                 170                 175     


Gly Gly Pro Gly Gly His Ser Leu Gln Val Leu Thr Leu Phe Leu Ala 
            180                 185                 190         


Leu Thr Ser Ala Leu Leu Leu Ala Leu Ile Phe Ile Thr Leu Leu Phe 
        195                 200                 205             


Ser Val Leu Lys Trp Ile Arg Lys Lys Phe Pro His Ile Phe Lys Gln 
    210                 215                 220                 


Pro Phe Lys Lys Thr Thr Gly Ala Ala Gln Glu Glu Asp Ala Cys Ser 
225                 230                 235                 240 


Cys Arg Cys Pro Gln Glu Glu Glu Gly Gly Gly Gly Gly Tyr Glu Leu 
                245                 250                 255     


<210>  42
<211>  441
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain for the 4-1BB agonist monoclonal antibody utomilumab 
       (PF-05082566)

<400>  42

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 
            20                  25                  30          


Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125             


Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu 
    130                 135                 140                 


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
145                 150                 155                 160 


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
                165                 170                 175     


Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe 
            180                 185                 190         


Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr 
        195                 200                 205             


Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro 
    210                 215                 220                 


Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro 
225                 230                 235                 240 


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
                245                 250                 255     


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp 
            260                 265                 270         


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
        275                 280                 285             


Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val 
    290                 295                 300                 


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
305                 310                 315                 320 


Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly 
                325                 330                 335     


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
            340                 345                 350         


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
        355                 360                 365             


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
    370                 375                 380                 


Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe 
385                 390                 395                 400 


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
                405                 410                 415     


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
            420                 425                 430         


Gln Lys Ser Leu Ser Leu Ser Pro Gly 
        435                 440     


<210>  43
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain for the 4-1BB agonist monoclonal antibody utomilumab 
       (PF-05082566)

<400>  43

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gln Asp Lys Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Thr Gly Phe Gly Ser Leu 
                85                  90                  95      


Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys 
            100                 105                 110         


Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln 
        115                 120                 125             


Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly 
    130                 135                 140                 


Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly 
145                 150                 155                 160 


Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala 
                165                 170                 175     


Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser 
            180                 185                 190         


Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val 
        195                 200                 205             


Ala Pro Thr Glu Cys Ser 
    210                 


<210>  44
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the 4-1BB agonist monoclonal
       antibody utomilumab (PF-05082566).

<400>  44

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 
            20                  25                  30          


Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  45
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the 4-1BB agonist monoclonal
       antibody utomilumab (PF-05082566).

<400>  45

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gln Asp Lys Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Thr Gly Phe Gly Ser Leu 
                85                  90                  95      


Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  46
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 for the 4-1BB agonist monoclonal antibody 
       utomilumab (PF-05082566)

<400>  46

Ser Thr Tyr Trp Ile Ser 
1               5       


<210>  47
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 for the 4-1BB agonist monoclonal antibody 
       utomilumab (PF-05082566)

<400>  47

Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  48
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 for the 4-1BB agonist monoclonal antibody 
       utomilumab (PF-05082566)

<400>  48

Arg Gly Tyr Gly Ile Phe Asp Tyr 
1               5               


<210>  49
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 for the 4-1BB agonist monoclonal antibody 
       utomilumab (PF-05082566)

<400>  49

Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala His 
1               5                   10      


<210>  50
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 for the 4-1BB agonist monoclonal antibody 
       utomilumab (PF-05082566)

<400>  50

Gln Asp Lys Asn Arg Pro Ser 
1               5           


<210>  51
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 for the 4-1BB agonist monoclonal antibody 
       utomilumab (PF-05082566)

<400>  51

Ala Thr Tyr Thr Gly Phe Gly Ser Leu Ala Val 
1               5                   10      


<210>  52
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain for the 4-1BB agonist monoclonal antibody urelumab 
       (BMS-663513)

<400>  52

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr 
            20                  25                  30          


Tyr Trp Ser Trp Ile Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Gly Gly Tyr Val Thr Tyr Asn Pro Ser Leu Glu 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Tyr Gly Pro Gly Asn Tyr Asp Trp Tyr Phe Asp Leu Trp Gly 
            100                 105                 110         


Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 
    210                 215                 220                 


Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 
225                 230                 235                 240 


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
                245                 250                 255     


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 
            260                 265                 270         


Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
        275                 280                 285             


Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 
    290                 295                 300                 


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
305                 310                 315                 320 


Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 
                325                 330                 335     


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
            340                 345                 350         


Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 
        355                 360                 365             


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
    370                 375                 380                 


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
385                 390                 395                 400 


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 
                405                 410                 415     


Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
            420                 425                 430         


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440                 445             


<210>  53
<211>  216
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain for the 4-1BB agonist monoclonal antibody urelumab 
       (BMS-663513)

<400>  53

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Ala Leu Thr Phe Cys Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val 
            100                 105                 110         


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
        115                 120                 125             


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
    130                 135                 140                 


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
145                 150                 155                 160 


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
                165                 170                 175     


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
            180                 185                 190         


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
        195                 200                 205             


Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215     


<210>  54
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the 4-1BB agonist monoclonal
       antibody urelumab (BMS-663513)

<400>  54

Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp 
1               5                   10                  15      


Val Leu Ser Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys 
            20                  25                  30          


Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe 
        35                  40                  45              


Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Ser Pro Glu Lys Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Glu Ile Asn His Gly Gly Tyr Val Thr Tyr Asn Pro 
65                  70                  75                  80  


Ser Leu Glu Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln 
                85                  90                  95      


Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr 
            100                 105                 110         


Tyr Cys Ala Arg Asp Tyr Gly Pro 
        115                 120 


<210>  55
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the 4-1BB agonist monoclonal
       antibody urelumab (BMS-663513)

<400>  55

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro 
1               5                   10                  15      


Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser 
            20                  25                  30          


Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser 
        35                  40                  45              


Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
    50                  55                  60                  


Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala 
65                  70                  75                  80  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
                85                  90                  95      


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln 
            100                 105                 110 


<210>  56
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 for the 4-1BB agonist monoclonal antibody 
       urelumab (BMS-663513)

<400>  56

Gly Tyr Tyr Trp Ser 
1               5   


<210>  57
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 for the 4-1BB agonist monoclonal antibody 
       urelumab (BMS-663513)

<400>  57

Glu Ile Asn His Gly Gly Tyr Val Thr Tyr Asn Pro Ser Leu Glu Ser 
1               5                   10                  15      


<210>  58
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 for the 4-1BB agonist monoclonal antibody 
       urelumab (BMS-663513)

<400>  58

Asp Tyr Gly Pro Gly Asn Tyr Asp Trp Tyr Phe Asp Leu 
1               5                   10              


<210>  59
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 for the 4-1BB agonist monoclonal antibody 
       urelumab (BMS-663513)

<400>  59

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  60
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 for the 4-1BB agonist monoclonal antibody 
       urelumab (BMS-663513)

<400>  60

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  61
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 for the 4-1BB agonist monoclonal antibody 
       urelumab (BMS-663513)

<400>  61

Gln Gln Arg Ser Asp Trp Pro Pro Ala Leu Thr 
1               5                   10      


<210>  62
<211>  230
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc domain for a TNFRSF agonist fusion protein

<400>  62

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 
1               5                   10                  15      


Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 
            20                  25                  30          


Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 
        35                  40                  45              


Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 
    50                  55                  60                  


Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 
65                  70                  75                  80  


Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 
                85                  90                  95      


Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 
            100                 105                 110         


Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 
        115                 120                 125             


Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 
    130                 135                 140                 


Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 
145                 150                 155                 160 


Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 
                165                 170                 175     


Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 
            180                 185                 190         


Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 
        195                 200                 205             


Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 
    210                 215                 220                 


Ser Leu Ser Pro Gly Lys 
225                 230 


<210>  63
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  63

Gly Gly Pro Gly Ser Ser Lys Ser Cys Asp Lys Thr His Thr Cys Pro 
1               5                   10                  15      


Pro Cys Pro Ala Pro Glu 
            20          


<210>  64
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  64

Gly Gly Ser Gly Ser Ser Lys Ser Cys Asp Lys Thr His Thr Cys Pro 
1               5                   10                  15      


Pro Cys Pro Ala Pro Glu 
            20          


<210>  65
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  65

Gly Gly Pro Gly Ser Ser Ser Ser Ser Ser Ser Lys Ser Cys Asp Lys 
1               5                   10                  15      


Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 
            20                  25          


<210>  66
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  66

Gly Gly Ser Gly Ser Ser Ser Ser Ser Ser Ser Lys Ser Cys Asp Lys 
1               5                   10                  15      


Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 
            20                  25          


<210>  67
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  67

Gly Gly Pro Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Lys Ser Cys 
1               5                   10                  15      


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 
            20                  25                  


<210>  68
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  68

Gly Gly Ser Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Lys Ser Cys 
1               5                   10                  15      


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 
            20                  25                  


<210>  69
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  69

Gly Gly Pro Gly Ser Ser Gly Ser Gly Ser Asp Lys Thr His Thr Cys 
1               5                   10                  15      


Pro Pro Cys Pro Ala Pro Glu 
            20              


<210>  70
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  70

Gly Gly Pro Gly Ser Ser Gly Ser Gly Ser Asp Lys Thr His Thr Cys 
1               5                   10                  15      


Pro Pro Cys Pro Ala Pro Glu 
            20              


<210>  71
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  71

Gly Gly Pro Ser Ser Ser Gly Ser Asp Lys Thr His Thr Cys Pro Pro 
1               5                   10                  15      


Cys Pro Ala Pro Glu 
            20      


<210>  72
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  72

Gly Gly Ser Ser Ser Ser Ser Ser Ser Ser Gly Ser Asp Lys Thr His 
1               5                   10                  15      


Thr Cys Pro Pro Cys Pro Ala Pro Glu 
            20                  25  


<210>  73
<211>  246
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc domain for a TNFRSF agonist fusion protein

<400>  73

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Ala Gly Asn Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 
            20                  25                  30          


Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
        35                  40                  45              


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
    50                  55                  60                  


Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 
65                  70                  75                  80  


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 
                85                  90                  95      


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
            100                 105                 110         


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 
        115                 120                 125             


Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
    130                 135                 140                 


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 
145                 150                 155                 160 


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
                165                 170                 175     


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
            180                 185                 190         


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
        195                 200                 205             


Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 
    210                 215                 220                 


Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
225                 230                 235                 240 


Leu Ser Leu Ser Pro Gly 
                245     


<210>  74
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  74

Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser 
1               5                   10      


<210>  75
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  75

Ser Ser Ser Ser Ser Ser Gly Ser Gly Ser Gly Ser 
1               5                   10          


<210>  76
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker for a TNFRSF agonist fusion protein

<400>  76

Ser Ser Ser Ser Ser Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser 
1               5                   10                  15      


<210>  77
<211>  254
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  4-1BB ligand (4-1BBL) amino acid sequence

<400>  77

Met Glu Tyr Ala Ser Asp Ala Ser Leu Asp Pro Glu Ala Pro Trp Pro 
1               5                   10                  15      


Pro Ala Pro Arg Ala Arg Ala Cys Arg Val Leu Pro Trp Ala Leu Val 
            20                  25                  30          


Ala Gly Leu Leu Leu Leu Leu Leu Leu Ala Ala Ala Cys Ala Val Phe 
        35                  40                  45              


Leu Ala Cys Pro Trp Ala Val Ser Gly Ala Arg Ala Ser Pro Gly Ser 
    50                  55                  60                  


Ala Ala Ser Pro Arg Leu Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp 
65                  70                  75                  80  


Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val 
                85                  90                  95      


Ala Gln Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp 
            100                 105                 110         


Pro Gly Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu 
        115                 120                 125             


Asp Thr Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe 
    130                 135                 140                 


Phe Gln Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser 
145                 150                 155                 160 


Val Ser Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala 
                165                 170                 175     


Ala Ala Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala 
            180                 185                 190         


Arg Asn Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala 
        195                 200                 205             


Gly Gln Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His 
    210                 215                 220                 


Ala Trp Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val 
225                 230                 235                 240 


Thr Pro Glu Ile Pro Ala Gly Leu Pro Ser Pro Arg Ser Glu 
                245                 250                 


<210>  78
<211>  168
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  soluble portion of 4-1BBL polypeptide

<400>  78

Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu 
1               5                   10                  15      


Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val 
            20                  25                  30          


Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val 
        35                  40                  45              


Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg 
    50                  55                  60                  


Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His 
65                  70                  75                  80  


Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr 
                85                  90                  95      


Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly 
            100                 105                 110         


Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val 
        115                 120                 125             


His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln 
    130                 135                 140                 


Gly Ala Thr Val Leu Gly Leu Phe Arg Val Thr Pro Glu Ile Pro Ala 
145                 150                 155                 160 


Gly Leu Pro Ser Pro Arg Ser Glu 
                165             


<210>  79
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the 4-1BB agonist antibody 
       4B4-1-1 version 1

<400>  79

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Val Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Gly Asn Gly His Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Phe Thr Thr Ala Arg Gly Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser 
        115             


<210>  80
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the 4-1BB agonist antibody 
       4B4-1-1 version 1

<400>  80

Asp Ile Val Met Thr Gln Ser Pro Ala Thr Gln Ser Val Thr Pro Gly 
1               5                   10                  15      


Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Thr Ile Ser Asp Tyr 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Pro 
65                  70                  75                  80  


Glu Asp Val Gly Val Tyr Tyr Cys Gln Asp Gly His Ser Phe Pro Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  81
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the 4-1BB agonist antibody 
       4B4-1-1 version 2

<400>  81

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Val Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Gly Asn Gly His Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Phe Thr Thr Ala Arg Gly Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ala 
        115                 


<210>  82
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the 4-1BB agonist antibody 
       4B4-1-1 version 2

<400>  82

Asp Ile Val Met Thr Gln Ser Pro Ala Thr Gln Ser Val Thr Pro Gly 
1               5                   10                  15      


Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Thr Ile Ser Asp Tyr 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Pro 
65                  70                  75                  80  


Glu Asp Val Gly Val Tyr Tyr Cys Gln Asp Gly His Ser Phe Pro Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  83
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the 4-1BB agonist antibody 
       H39E3-2

<400>  83

Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly 
1               5                   10                  15      


Ala His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Ser Asp Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 
    50                  55                  60                  


Glu Trp Val Ala Asp Ile Lys Asn Asp Gly Ser Tyr Thr Asn Tyr Ala 
65                  70                  75                  80  


Pro Ser Leu Thr Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 
                85                  90                  95      


Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Glu Leu Thr 
        115                 120 


<210>  84
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the 4-1BB agonist antibody 
       H39E3-2

<400>  84

Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro 
1               5                   10                  15      


Asp Thr Thr Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala 
            20                  25                  30          


Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser 
        35                  40                  45              


Leu Leu Ser Ser Gly Asn Gln Lys Asn Tyr Leu Trp Tyr Gln Gln Lys 
    50                  55                  60                  


Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Thr Arg Gln 
65                  70                  75                  80  


Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 
                85                  90                  95      


Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala 
            100                 105                 


<210>  85
<211>  277
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of human OX40

<400>  85

Met Cys Val Gly Ala Arg Arg Leu Gly Arg Gly Pro Cys Ala Ala Leu 
1               5                   10                  15      


Leu Leu Leu Gly Leu Gly Leu Ser Thr Val Thr Gly Leu His Cys Val 
            20                  25                  30          


Gly Asp Thr Tyr Pro Ser Asn Asp Arg Cys Cys His Glu Cys Arg Pro 
        35                  40                  45              


Gly Asn Gly Met Val Ser Arg Cys Ser Arg Ser Gln Asn Thr Val Cys 
    50                  55                  60                  


Arg Pro Cys Gly Pro Gly Phe Tyr Asn Asp Val Val Ser Ser Lys Pro 
65                  70                  75                  80  


Cys Lys Pro Cys Thr Trp Cys Asn Leu Arg Ser Gly Ser Glu Arg Lys 
                85                  90                  95      


Gln Leu Cys Thr Ala Thr Gln Asp Thr Val Cys Arg Cys Arg Ala Gly 
            100                 105                 110         


Thr Gln Pro Leu Asp Ser Tyr Lys Pro Gly Val Asp Cys Ala Pro Cys 
        115                 120                 125             


Pro Pro Gly His Phe Ser Pro Gly Asp Asn Gln Ala Cys Lys Pro Trp 
    130                 135                 140                 


Thr Asn Cys Thr Leu Ala Gly Lys His Thr Leu Gln Pro Ala Ser Asn 
145                 150                 155                 160 


Ser Ser Asp Ala Ile Cys Glu Asp Arg Asp Pro Pro Ala Thr Gln Pro 
                165                 170                 175     


Gln Glu Thr Gln Gly Pro Pro Ala Arg Pro Ile Thr Val Gln Pro Thr 
            180                 185                 190         


Glu Ala Trp Pro Arg Thr Ser Gln Gly Pro Ser Thr Arg Pro Val Glu 
        195                 200                 205             


Val Pro Gly Gly Arg Ala Val Ala Ala Ile Leu Gly Leu Gly Leu Val 
    210                 215                 220                 


Leu Gly Leu Leu Gly Pro Leu Ala Ile Leu Leu Ala Leu Tyr Leu Leu 
225                 230                 235                 240 


Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly 
                245                 250                 255     


Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser 
            260                 265                 270         


Thr Leu Ala Lys Ile 
        275         


<210>  86
<211>  272
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of murine OX40

<400>  86

Met Tyr Val Trp Val Gln Gln Pro Thr Ala Leu Leu Leu Leu Gly Leu 
1               5                   10                  15      


Thr Leu Gly Val Thr Ala Arg Arg Leu Asn Cys Val Lys His Thr Tyr 
            20                  25                  30          


Pro Ser Gly His Lys Cys Cys Arg Glu Cys Gln Pro Gly His Gly Met 
        35                  40                  45              


Val Ser Arg Cys Asp His Thr Arg Asp Thr Leu Cys His Pro Cys Glu 
    50                  55                  60                  


Thr Gly Phe Tyr Asn Glu Ala Val Asn Tyr Asp Thr Cys Lys Gln Cys 
65                  70                  75                  80  


Thr Gln Cys Asn His Arg Ser Gly Ser Glu Leu Lys Gln Asn Cys Thr 
                85                  90                  95      


Pro Thr Gln Asp Thr Val Cys Arg Cys Arg Pro Gly Thr Gln Pro Arg 
            100                 105                 110         


Gln Asp Ser Gly Tyr Lys Leu Gly Val Asp Cys Val Pro Cys Pro Pro 
        115                 120                 125             


Gly His Phe Ser Pro Gly Asn Asn Gln Ala Cys Lys Pro Trp Thr Asn 
    130                 135                 140                 


Cys Thr Leu Ser Gly Lys Gln Thr Arg His Pro Ala Ser Asp Ser Leu 
145                 150                 155                 160 


Asp Ala Val Cys Glu Asp Arg Ser Leu Leu Ala Thr Leu Leu Trp Glu 
                165                 170                 175     


Thr Gln Arg Pro Thr Phe Arg Pro Thr Thr Val Gln Ser Thr Thr Val 
            180                 185                 190         


Trp Pro Arg Thr Ser Glu Leu Pro Ser Pro Pro Thr Leu Val Thr Pro 
        195                 200                 205             


Glu Gly Pro Ala Phe Ala Val Leu Leu Gly Leu Gly Leu Gly Leu Leu 
    210                 215                 220                 


Ala Pro Leu Thr Val Leu Leu Ala Leu Tyr Leu Leu Arg Lys Ala Trp 
225                 230                 235                 240 


Arg Leu Pro Asn Thr Pro Lys Pro Cys Trp Gly Asn Ser Phe Arg Thr 
                245                 250                 255     


Pro Ile Gln Glu Glu His Thr Asp Ala His Phe Thr Leu Ala Lys Ile 
            260                 265                 270         


<210>  87
<211>  451
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  87

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Ser Gly 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Lys His Pro Gly Lys Gly Leu Glu Tyr Ile 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Asn Gly Ile Thr Tyr His Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Ile Thr Ile Asn Arg Asp Thr Ser Lys Asn Gln Tyr Ser Leu 
65                  70                  75                  80  


Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Lys Tyr Asp Tyr Asp Gly Gly His Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 
    210                 215                 220                 


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
225                 230                 235                 240 


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
                245                 250                 255     


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
            260                 265                 270         


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
        275                 280                 285             


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
    290                 295                 300                 


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
305                 310                 315                 320 


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
                325                 330                 335     


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
            340                 345                 350         


Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 
        355                 360                 365             


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
    370                 375                 380                 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
385                 390                 395                 400 


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
                405                 410                 415     


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
            420                 425                 430         


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 
        435                 440                 445             


Pro Gly Lys 
    450     


<210>  88
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  88

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Lys Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ala Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  89
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody tavolixizumab (MEDI-0562)

<400>  89

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Ser Gly 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Lys His Pro Gly Lys Gly Leu Glu Tyr Ile 
        35                  40                  45              


Gly Tyr Ile Ser Tyr Asn Gly Ile Thr Tyr His Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Ile Thr Ile Asn Arg Asp Thr Ser Lys Asn Gln Tyr Ser Leu 
65                  70                  75                  80  


Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Lys Tyr Asp Tyr Asp Gly Gly His Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr 
        115             


<210>  90
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody tavolixizumab (MEDI-0562)

<400>  90

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Lys Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ala Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  91
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  91

Gly Ser Phe Ser Ser Gly Tyr Trp Asn 
1               5                   


<210>  92
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  92

Tyr Ile Gly Tyr Ile Ser Tyr Asn Gly Ile Thr Tyr His 
1               5                   10              


<210>  93
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  93

Arg Tyr Lys Tyr Asp Tyr Asp Gly Gly His Ala Met Asp Tyr 
1               5                   10                  


<210>  94
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  94

Gln Asp Ile Ser Asn Tyr Leu Asn 
1               5               


<210>  95
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  95

Leu Leu Ile Tyr Tyr Thr Ser Lys Leu His Ser 
1               5                   10      


<210>  96
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 for the OX40 agonist monoclonal antibody 
       tavolixizumab (MEDI-0562)

<400>  96

Gln Gln Gly Ser Ala Leu Pro Trp 
1               5               


<210>  97
<211>  444
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain for the OX40 agonist monoclonal antibody 11D4

<400>  97

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Asp Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Ser Gly Trp Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys 
    210                 215                 220                 


Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe 
225                 230                 235                 240 


Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 
                245                 250                 255     


Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe 
            260                 265                 270         


Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 
        275                 280                 285             


Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr 
    290                 295                 300                 


Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 
305                 310                 315                 320 


Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr 
                325                 330                 335     


Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 
            340                 345                 350         


Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 
        355                 360                 365             


Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 
    370                 375                 380                 


Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser 
385                 390                 395                 400 


Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 
                405                 410                 415     


Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 
            420                 425                 430         


Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        435                 440                 


<210>  98
<211>  180
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain for the OX40 agonist monoclonal antibody 11D4

<400>  98

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr 
            180 


<210>  99
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody 11D4

<400>  99

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Asp Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Ser Gly Trp Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  100
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody 11D4

<400>  100

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  101
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 for the OX40 agonist monoclonal antibody 11D4

<400>  101

Ser Tyr Ser Met Asn 
1               5   


<210>  102
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 for the OX40 agonist monoclonal antibody 11D4

<400>  102

Tyr Ile Ser Ser Ser Ser Ser Thr Ile Asp Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  103
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 for the OX40 agonist monoclonal antibody 11D4

<400>  103

Glu Ser Gly Trp Tyr Leu Phe Asp Tyr 
1               5                   


<210>  104
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 for the OX40 agonist monoclonal antibody 11D4

<400>  104

Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala 
1               5                   10      


<210>  105
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 for the OX40 agonist monoclonal antibody 11D4

<400>  105

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  106
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 for the OX40 agonist monoclonal antibody 11D4

<400>  106

Gln Gln Tyr Asn Ser Tyr Pro Pro Thr 
1               5                   


<210>  107
<211>  450
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain for the OX40 agonist monoclonal antibody 18D8

<400>  107

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Gln Ser Thr Ala Asp Tyr Tyr Phe Tyr Tyr Gly Met Asp 
            100                 105                 110         


Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 
        115                 120                 125             


Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu 
    130                 135                 140                 


Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 
145                 150                 155                 160 


Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 
                165                 170                 175     


Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 
            180                 185                 190         


Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn 
        195                 200                 205             


Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg 
    210                 215                 220                 


Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly 
225                 230                 235                 240 


Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 
                245                 250                 255     


Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 
            260                 265                 270         


Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 
        275                 280                 285             


Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg 
    290                 295                 300                 


Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys 
305                 310                 315                 320 


Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu 
                325                 330                 335     


Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 
            340                 345                 350         


Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 
        355                 360                 365             


Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 
    370                 375                 380                 


Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met 
385                 390                 395                 400 


Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 
                405                 410                 415     


Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 
            420                 425                 430         


Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 
        435                 440                 445             


Gly Lys 
    450 


<210>  108
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain for the OX40 agonist monoclonal antibody 18D8

<400>  108

Glu Ile Val Val Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro 
            100                 105                 110         


Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 
        115                 120                 125             


Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 
    130                 135                 140                 


Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 
145                 150                 155                 160 


Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 
                165                 170                 175     


Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 
            180                 185                 190         


Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 
        195                 200                 205             


Asn Arg Gly Glu Cys 
    210             


<210>  109
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody 18D8

<400>  109

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Gln Ser Thr Ala Asp Tyr Tyr Phe Tyr Tyr Gly Met Asp 
            100                 105                 110         


Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 


<210>  110
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody 18D8

<400>  110

Glu Ile Val Val Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105     


<210>  111
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 for the OX40 agonist monoclonal antibody 18D8

<400>  111

Asp Tyr Ala Met His 
1               5   


<210>  112
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 for the OX40 agonist monoclonal antibody 18D8

<400>  112

Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  113
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 for the OX40 agonist monoclonal antibody 18D8

<400>  113

Asp Gln Ser Thr Ala Asp Tyr Tyr Phe Tyr Tyr Gly Met Asp Val 
1               5                   10                  15  


<210>  114
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 for the OX40 agonist monoclonal antibody 18D8

<400>  114

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  115
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 for the OX40 agonist monoclonal antibody 18D8

<400>  115

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  116
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 for the OX40 agonist monoclonal antibody 18D8

<400>  116

Gln Gln Arg Ser Asn Trp Pro Thr 
1               5               


<210>  117
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody Hu119-122

<400>  117

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Tyr Glu Phe Pro Ser His 
            20                  25                  30          


Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Met 
    50                  55                  60                  


Glu Arg Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Tyr Asp Asp Tyr Tyr Ala Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  118
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody Hu119-122

<400>  118

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  119
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 for the OX40 agonist monoclonal antibody 
       Hu119-122

<400>  119

Ser His Asp Met Ser 
1               5   


<210>  120
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 for the OX40 agonist monoclonal antibody 
       Hu119-122

<400>  120

Ala Ile Asn Ser Asp Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Met Glu 
1               5                   10                  15      


Arg 
    


<210>  121
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 for the OX40 agonist monoclonal antibody 
       Hu119-122

<400>  121

His Tyr Asp Asp Tyr Tyr Ala Trp Phe Ala Tyr 
1               5                   10      


<210>  122
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 for the OX40 agonist monoclonal antibody 
       Hu119-122

<400>  122

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His 
1               5                   10                  15  


<210>  123
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 for the OX40 agonist monoclonal antibody 
       Hu119-122

<400>  123

Leu Ala Ser Asn Leu Glu Ser 
1               5           


<210>  124
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 for the OX40 agonist monoclonal antibody 
       Hu119-122

<400>  124

Gln His Ser Arg Glu Leu Pro Leu Thr 
1               5                   


<210>  125
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody Hu106-222

<400>  125

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Asn Pro Tyr Tyr Asp Tyr Val Ser Tyr Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  126
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody Hu106-222

<400>  126

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Leu Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  127
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 for the OX40 agonist monoclonal antibody 
       Hu106-222

<400>  127

Asp Tyr Ser Met His 
1               5   


<210>  128
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 for the OX40 agonist monoclonal antibody 
       Hu106-222

<400>  128

Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  129
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 for the OX40 agonist monoclonal antibody 
       Hu106-222

<400>  129

Pro Tyr Tyr Asp Tyr Val Ser Tyr Tyr Ala Met Asp Tyr 
1               5                   10              


<210>  130
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 for the OX40 agonist monoclonal antibody 
       Hu106-222

<400>  130

Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala 
1               5                   10      


<210>  131
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 for the OX40 agonist monoclonal antibody 
       Hu106-222

<400>  131

Ser Ala Ser Tyr Leu Tyr Thr 
1               5           


<210>  132
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 for the OX40 agonist monoclonal antibody 
       Hu106-222

<400>  132

Gln Gln His Tyr Ser Thr Pro Arg Thr 
1               5                   


<210>  133
<211>  183
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OX40 ligand (OX40L) amino acid sequence

<400>  133

Met Glu Arg Val Gln Pro Leu Glu Glu Asn Val Gly Asn Ala Ala Arg 
1               5                   10                  15      


Pro Arg Phe Glu Arg Asn Lys Leu Leu Leu Val Ala Ser Val Ile Gln 
            20                  25                  30          


Gly Leu Gly Leu Leu Leu Cys Phe Thr Tyr Ile Cys Leu His Phe Ser 
        35                  40                  45              


Ala Leu Gln Val Ser His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val 
    50                  55                  60                  


Gln Phe Thr Glu Tyr Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln 
65                  70                  75                  80  


Lys Glu Asp Glu Ile Met Lys Val Gln Asn Asn Ser Val Ile Ile Asn 
                85                  90                  95      


Cys Asp Gly Phe Tyr Leu Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu 
            100                 105                 110         


Val Asn Ile Ser Leu His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln 
        115                 120                 125             


Leu Lys Lys Val Arg Ser Val Asn Ser Leu Met Val Ala Ser Leu Thr 
    130                 135                 140                 


Tyr Lys Asp Lys Val Tyr Leu Asn Val Thr Thr Asp Asn Thr Ser Leu 
145                 150                 155                 160 


Asp Asp Phe His Val Asn Gly Gly Glu Leu Ile Leu Ile His Gln Asn 
                165                 170                 175     


Pro Gly Glu Phe Cys Val Leu 
            180             


<210>  134
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  soluble portion of OX40L polypeptide

<400>  134

Ser His Arg Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu 
1               5                   10                  15      


Tyr Lys Lys Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu 
            20                  25                  30          


Ile Met Lys Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe 
        35                  40                  45              


Tyr Leu Ile Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser 
    50                  55                  60                  


Leu His Tyr Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val 
65                  70                  75                  80  


Arg Ser Val Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys 
                85                  90                  95      


Val Tyr Leu Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His 
            100                 105                 110         


Val Asn Gly Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe 
        115                 120                 125             


Cys Val Leu 
    130     


<210>  135
<211>  128
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  alternative soluble portion of OX40L polypeptide

<400>  135

Tyr Pro Arg Ile Gln Ser Ile Lys Val Gln Phe Thr Glu Tyr Lys Lys 
1               5                   10                  15      


Glu Lys Gly Phe Ile Leu Thr Ser Gln Lys Glu Asp Glu Ile Met Lys 
            20                  25                  30          


Val Gln Asn Asn Ser Val Ile Ile Asn Cys Asp Gly Phe Tyr Leu Ile 
        35                  40                  45              


Ser Leu Lys Gly Tyr Phe Ser Gln Glu Val Asn Ile Ser Leu His Tyr 
    50                  55                  60                  


Gln Lys Asp Glu Glu Pro Leu Phe Gln Leu Lys Lys Val Arg Ser Val 
65                  70                  75                  80  


Asn Ser Leu Met Val Ala Ser Leu Thr Tyr Lys Asp Lys Val Tyr Leu 
                85                  90                  95      


Asn Val Thr Thr Asp Asn Thr Ser Leu Asp Asp Phe His Val Asn Gly 
            100                 105                 110         


Gly Glu Leu Ile Leu Ile His Gln Asn Pro Gly Glu Phe Cys Val Leu 
        115                 120                 125             


<210>  136
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody 008

<400>  136

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Arg Tyr Ser Gln Val His Tyr Ala Leu Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser 
        115                 120 


<210>  137
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody 008

<400>  137

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Ala Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Tyr 
                85                  90                  95      


Tyr Asn His Pro Thr Thr Phe Gly Gln Gly Thr Lys 
            100                 105             


<210>  138
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody 011

<400>  138

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Arg Lys Gly 
    50                  55                  60                  


Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln 
65                  70                  75                  80  


Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
                85                  90                  95      


Asp Arg Tyr Phe Arg Gln Gln Asn Ala Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser Ala 
        115                 120 


<210>  139
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody 011

<400>  139

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Ala Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Tyr 
                85                  90                  95      


Tyr Asn His Pro Thr Thr Phe Gly Gln Gly Thr Lys 
            100                 105             


<210>  140
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody 021

<400>  140

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Arg Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Arg Tyr Ile Thr Leu Pro Asn Ala Leu Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser 
        115                 120 


<210>  141
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody 021

<400>  141

Asp Ile Gln Met Thr Gln Ser Pro Val Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Tyr 
                85                  90                  95      


Lys Ser Asn Pro Pro Thr Phe Gly Gln Gly Thr Lys 
            100                 105             


<210>  142
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for the OX40 agonist monoclonal 
       antibody 023

<400>  142

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val His Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Gly Thr Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Met 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Asp Asn Val Met Gly Leu Tyr Trp Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  143
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for the OX40 agonist monoclonal 
       antibody 023

<400>  143

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  144
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for an OX40 agonist monoclonal 
       antibody

<400>  144

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Asn Tyr Tyr Gly Ser Ser Leu Ser Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  145
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for an OX40 agonist monoclonal 
       antibody

<400>  145

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  146
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for an OX40 agonist monoclonal 
       antibody

<400>  146

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Lys Asp Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Tyr Pro Asn Asn Gly Gly Ser Thr Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Phe Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Met Gly Tyr His Gly Pro His Leu Asp Phe Asp Val Trp Gly 
            100                 105                 110         


Ala Gly Thr Thr Val Thr Val Ser Pro 
        115                 120     


<210>  147
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for an OX40 agonist monoclonal 
       antibody

<400>  147

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Ala Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Thr Asp Tyr Phe Cys Gln Gln Tyr Ile Asn Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  148
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for a humanized OX40 agonist 
       monoclonal antibody

<400>  148

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Asn Pro Tyr Tyr Asp Tyr Val Ser Tyr Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly His Gly Thr Ser Val Thr Val Ser Ser 
        115                 120         


<210>  149
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for a humanized OX40 agonist 
       monoclonal antibody

<400>  149

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ser Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Asn Pro Tyr Tyr Asp Tyr Val Ser Tyr Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  150
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for a humanized OX40 agonist 
       monoclonal antibody

<400>  150

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Arg 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Leu Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Arg 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  151
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for a humanized OX40 agonist 
       monoclonal antibody

<400>  151

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Arg 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Leu Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Arg 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  152
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for a humanized OX40 agonist 
       monoclonal antibody

<400>  152

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Glu Ser Asn Glu Tyr Glu Phe Pro Ser His 
            20                  25                  30          


Asp Met Ser Trp Val Arg Lys Thr Pro Glu Lys Arg Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Met 
    50                  55                  60                  


Glu Arg Arg Phe Ile Ile Ser Arg Asp Asn Thr Lys Lys Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Tyr Asp Asp Tyr Tyr Ala Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  153
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for a humanized OX40 agonist 
       monoclonal antibody

<400>  153

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Tyr Glu Phe Pro Ser His 
            20                  25                  30          


Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val 
        35                  40                  45              


Ala Ala Ile Asn Ser Asp Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Met 
    50                  55                  60                  


Glu Arg Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Tyr Asp Asp Tyr Tyr Ala Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  154
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for a humanized OX40 agonist 
       monoclonal antibody

<400>  154

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110     


<210>  155
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for a humanized OX40 agonist 
       monoclonal antibody

<400>  155

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  156
<211>  138
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) for an OX40 agonist monoclonal 
       antibody

<400>  156

Met Tyr Leu Gly Leu Asn Tyr Val Phe Ile Val Phe Leu Leu Asn Gly 
1               5                   10                  15      


Val Gln Ser Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu 
    50                  55                  60                  


Glu Trp Val Ala Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr 
65                  70                  75                  80  


Tyr Ala Glu Ser Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser 
                85                  90                  95      


Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 
            100                 105                 110         


Gly Ile Tyr Tyr Cys Thr Trp Gly Glu Val Phe Tyr Phe Asp Tyr Trp 
        115                 120                 125             


Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 
    130                 135             


<210>  157
<211>  126
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) for an OX40 agonist monoclonal 
       antibody

<400>  157

Met Arg Pro Ser Ile Gln Phe Leu Gly Leu Leu Leu Phe Trp Leu His 
1               5                   10                  15      


Gly Ala Gln Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 
            20                  25                  30          


Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ser Ser Gln Asp 
        35                  40                  45              


Ile Asn Lys Tyr Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro 
    50                  55                  60                  


Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser 
65                  70                  75                  80  


Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser 
                85                  90                  95      


Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp 
            100                 105                 110         


Asn Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
        115                 120                 125     


<210>  158
<211>  440
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the PD-1 inhibitor nivolumab

<400>  158

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser 
        115                 120                 125             


Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 
    130                 135                 140                 


Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 
145                 150                 155                 160 


Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 
                165                 170                 175     


Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys 
            180                 185                 190         


Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp 
        195                 200                 205             


Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala 
    210                 215                 220                 


Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
225                 230                 235                 240 


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
                245                 250                 255     


Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val 
            260                 265                 270         


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
        275                 280                 285             


Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
    290                 295                 300                 


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 
305                 310                 315                 320 


Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
                325                 330                 335     


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr 
            340                 345                 350         


Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 
        355                 360                 365             


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
    370                 375                 380                 


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
385                 390                 395                 400 


Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe 
                405                 410                 415     


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
            420                 425                 430         


Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440 


<210>  159
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the PD-1 inhibitor nivolumab

<400>  159

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  160
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the PD-1 
       inhibitor nivolumab

<400>  160

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  161
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the PD-1 
       inhibitor nivolumab

<400>  161

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  162
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the PD-1 inhibitor 
       nivolumab

<400>  162

Asn Ser Gly Met His 
1               5   


<210>  163
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the PD-1 inhibitor 
       nivolumab

<400>  163

Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  164
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the PD-1 inhibitor 
       nivolumab

<400>  164

Asn Asp Asp Tyr 
1               


<210>  165
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the PD-1 inhibitor 
       nivolumab

<400>  165

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  166
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the PD-1 inhibitor 
       nivolumab

<400>  166

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  167
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the PD-1 inhibitor 
       nivolumab

<400>  167

Gln Gln Ser Ser Asn Trp Pro Arg Thr 
1               5                   


<210>  168
<211>  447
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  168

Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 
    210                 215                 220                 


Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 
225                 230                 235                 240 


Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 
                245                 250                 255     


Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 
            260                 265                 270         


Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 
        275                 280                 285             


Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 
    290                 295                 300                 


Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 
305                 310                 315                 320 


Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 
                325                 330                 335     


Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 
            340                 345                 350         


Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 
        355                 360                 365             


Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 
    370                 375                 380                 


Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 
385                 390                 395                 400 


Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 
                405                 410                 415     


Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 
            420                 425                 430         


His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440                 445         


<210>  169
<211>  218
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  169

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105                 110         


Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 
        115                 120                 125             


Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 
    130                 135                 140                 


Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 
145                 150                 155                 160 


Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 
                165                 170                 175     


Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 
            180                 185                 190         


His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 
        195                 200                 205             


Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215             


<210>  170
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the PD-1 
       inhibitor pembrolizumab

<400>  170

Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  171
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the PD-1 
       inhibitor pembrolizumab

<400>  171

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  172
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  172

Asn Tyr Tyr Met Tyr 
1               5   


<210>  173
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  173

Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 
1               5                   10                  15      


<210>  174
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  174

Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr 
1               5                   10      


<210>  175
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  175

Arg Ala Ser Lys Gly Val Ser Thr Ser Gly Tyr Ser Tyr Leu His 
1               5                   10                  15  


<210>  176
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  176

Leu Ala Ser Tyr Leu Glu Ser 
1               5           


<210>  177
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the PD-1 inhibitor 
       pembrolizumab

<400>  177

Gln His Ser Arg Asp Leu Pro Leu Thr 
1               5                   


<210>  178
<211>  451
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the PD-L1 inhibitor durvalumab

<400>  178

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 
    210                 215                 220                 


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly 
225                 230                 235                 240 


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
                245                 250                 255     


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
            260                 265                 270         


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
        275                 280                 285             


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
    290                 295                 300                 


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
305                 310                 315                 320 


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Ser Ile 
                325                 330                 335     


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
            340                 345                 350         


Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 
        355                 360                 365             


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
    370                 375                 380                 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
385                 390                 395                 400 


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
                405                 410                 415     


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
            420                 425                 430         


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 
        435                 440                 445             


Pro Gly Lys 
    450     


<210>  179
<211>  265
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the PD-L1 inhibitor durvalumab

<400>  179

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser 
    50                  55                  60                  


Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser 
65                  70                  75                  80  


Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg 
                85                  90                  95      


Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg 
            100                 105                 110         


Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg 
        115                 120                 125             


Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser 
    130                 135                 140                 


Leu Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 
145                 150                 155                 160 


Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 
                165                 170                 175     


Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 
            180                 185                 190         


Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 
        195                 200                 205             


Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr 
    210                 215                 220                 


Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 
225                 230                 235                 240 


Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val 
                245                 250                 255     


Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            260                 265 


<210>  180
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the PD-L1
       inhibitor durvalumab

<400>  180

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  181
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the PD-L1
       inhibitor durvalumab

<400>  181

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  182
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the PD-L1 inhibitor 
       durvalumab

<400>  182

Arg Tyr Trp Met Ser 
1               5   


<210>  183
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor 
       durvalumab

<400>  183

Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  184
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor 
       durvalumab

<400>  184

Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr 
1               5                   10          


<210>  185
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the PD-L1 inhibitor 
       durvalumab

<400>  185

Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu Ala 
1               5                   10          


<210>  186
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the PD-L1 inhibitor 
       durvalumab

<400>  186

Asp Ala Ser Ser Arg Ala Thr 
1               5           


<210>  187
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the PD-L1 inhibitor 
       durvalumab

<400>  187

Gln Gln Tyr Gly Ser Leu Pro Trp Thr 
1               5                   


<210>  188
<211>  450
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the PD-L1 inhibitor avelumab

<400>  188

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ile Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 
    210                 215                 220                 


Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 
225                 230                 235                 240 


Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 
                245                 250                 255     


Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 
            260                 265                 270         


Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 
        275                 280                 285             


Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 
    290                 295                 300                 


Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 
305                 310                 315                 320 


Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 
                325                 330                 335     


Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 
            340                 345                 350         


Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 
        355                 360                 365             


Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 
    370                 375                 380                 


Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 
385                 390                 395                 400 


Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 
                405                 410                 415     


Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 
            420                 425                 430         


Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 
        435                 440                 445             


Gly Lys 
    450 


<210>  189
<211>  216
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the PD-L1 inhibitor avelumab

<400>  189

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 
1               5                   10                  15      


Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 
            20                  25                  30          


Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 
        35                  40                  45              


Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 
    50                  55                  60                  


Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 
65                  70                  75                  80  


Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 
                85                  90                  95      


Ser Thr Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln 
            100                 105                 110         


Pro Lys Ala Asn Pro Thr Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 
        115                 120                 125             


Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 
    130                 135                 140                 


Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val Lys 
145                 150                 155                 160 


Ala Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys Tyr 
                165                 170                 175     


Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 
            180                 185                 190         


Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 
        195                 200                 205             


Thr Val Ala Pro Thr Glu Cys Ser 
    210                 215     


<210>  190
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the PD-L1
       inhibitor avelumab

<400>  190

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ile Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  191
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the PD-L1
       inhibitor avelumab

<400>  191

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 
1               5                   10                  15      


Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 
            20                  25                  30          


Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 
        35                  40                  45              


Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 
    50                  55                  60                  


Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 
65                  70                  75                  80  


Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 
                85                  90                  95      


Ser Thr Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 
            100                 105                 110 


<210>  192
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the PD-L1 inhibitor 
       avelumab

<400>  192

Ser Tyr Ile Met Met 
1               5   


<210>  193
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor 
       avelumab

<400>  193

Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val Lys 
1               5                   10                  15      


Gly 
    


<210>  194
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor 
       avelumab

<400>  194

Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr 
1               5                   10      


<210>  195
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the PD-L1 inhibitor 
       avelumab

<400>  195

Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 
1               5                   10                  


<210>  196
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the PD-L1 inhibitor 
       avelumab

<400>  196

Asp Val Ser Asn Arg Pro Ser 
1               5           


<210>  197
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the PD-L1 inhibitor 
       avelumab

<400>  197

Ser Ser Tyr Thr Ser Ser Ser Thr Arg Val 
1               5                   10  


<210>  198
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  198

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 
            20                  25                  30          


Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
225                 230                 235                 240 


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
                245                 250                 255     


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
            260                 265                 270         


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
        275                 280                 285             


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val 
    290                 295                 300                 


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
305                 310                 315                 320 


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
                325                 330                 335     


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
            340                 345                 350         


Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 
        355                 360                 365             


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
    370                 375                 380                 


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
385                 390                 395                 400 


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
                405                 410                 415     


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
            420                 425                 430         


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        435                 440                 445             


<210>  199
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  199

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  200
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the PD-L1
       inhibitor atezolizumab

<400>  200

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 
            20                  25                  30          


Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  201
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the PD-L1
       inhibitor atezolizumab

<400>  201

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  202
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  202

Gly Phe Thr Phe Ser Asp Ser Trp Ile His 
1               5                   10  


<210>  203
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  203

Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
1               5                   10                  15      


Lys Gly 
        


<210>  204
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  204

Arg His Trp Pro Gly Gly Phe Asp Tyr 
1               5                   


<210>  205
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  205

Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala 
1               5                   10      


<210>  206
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  206

Ser Ala Ser Phe Leu Tyr Ser 
1               5           


<210>  207
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the PD-L1 inhibitor 
       atezolizumab

<400>  207

Gln Gln Tyr Leu Tyr His Pro Ala Thr 
1               5                   


<210>  208
<211>  225
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  208

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Thr Phe Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Thr Gly Trp Leu Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


His 
225 


<210>  209
<211>  215
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  209

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Phe Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 
            100                 105                 110         


Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 
        115                 120                 125             


Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 
    130                 135                 140                 


Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 
145                 150                 155                 160 


Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 
                165                 170                 175     


Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 
            180                 185                 190         


Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 
        195                 200                 205             


Ser Phe Asn Arg Gly Glu Cys 
    210                 215 


<210>  210
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the 
       CTLA-4 inhibitor ipilimumab

<400>  210

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Thr Phe Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Thr Gly Trp Leu Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  211
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the 
       CTLA-4 inhibitor ipilimumab

<400>  211

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Phe Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  212
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  212

Gly Phe Thr Phe Ser Ser Tyr Thr 
1               5               


<210>  213
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  213

Thr Phe Ile Ser Tyr Asp Gly Asn Asn Lys 
1               5                   10  


<210>  214
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  214

Ala Arg Thr Gly Trp Leu Gly Pro Phe Asp Tyr 
1               5                   10      


<210>  215
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  215

Gln Ser Val Gly Ser Ser Tyr 
1               5           


<210>  216
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  216

Gly Ala Phe 
1           


<210>  217
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the CTLA-4 inhibitor 
       ipilimumab

<400>  217

Gln Gln Tyr Gly Ser Ser Pro Trp Thr 
1               5                   


<210>  218
<211>  451
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  218

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Pro Arg Gly Ala Thr Leu Tyr Tyr Tyr Tyr Tyr Gly Met 
            100                 105                 110         


Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr 
        115                 120                 125             


Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser 
    130                 135                 140                 


Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 
145                 150                 155                 160 


Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 
                165                 170                 175     


Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 
            180                 185                 190         


Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys 
        195                 200                 205             


Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu 
    210                 215                 220                 


Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala 
225                 230                 235                 240 


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
                245                 250                 255     


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
            260                 265                 270         


Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
        275                 280                 285             


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe 
    290                 295                 300                 


Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly 
305                 310                 315                 320 


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile 
                325                 330                 335     


Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val 
            340                 345                 350         


Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 
        355                 360                 365             


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
    370                 375                 380                 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
385                 390                 395                 400 


Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
                405                 410                 415     


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
            420                 425                 430         


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 
        435                 440                 445             


Pro Gly Lys 
    450     


<210>  219
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  219

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Ser Tyr 
            20                  25                  30          


Leu Asp Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Phe 
                85                  90                  95      


Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  220
<211>  167
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the 
       CTLA-4 inhibitor tremelimumab

<400>  220

Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser 
1               5                   10                  15      


Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro 
            20                  25                  30          


Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn 
        35                  40                  45              


Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp 
    50                  55                  60                  


Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu 
65                  70                  75                  80  


Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Arg Gly Ala Thr Leu 
                85                  90                  95      


Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val 
            100                 105                 110         


Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125             


Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu 
    130                 135                 140                 


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
145                 150                 155                 160 


Ala Leu Thr Ser Gly Val His 
                165         


<210>  221
<211>  139
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the 
       CTLA-4 inhibitor tremelimumab

<400>  221

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys 
1               5                   10                  15      


Arg Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asp Trp Tyr Gln Gln Lys 
            20                  25                  30          


Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln 
        35                  40                  45              


Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 
    50                  55                  60                  


Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr 
65                  70                  75                  80  


Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys 
                85                  90                  95      


Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro 
            100                 105                 110         


Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 
        115                 120                 125             


Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val 
    130                 135                 


<210>  222
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  222

Gly Phe Thr Phe Ser Ser Tyr Gly Met His 
1               5                   10  


<210>  223
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  223

Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
1               5                   10                  15  


<210>  224
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  224

Asp Pro Arg Gly Ala Thr Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10                  15      


<210>  225
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  225

Arg Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asp 
1               5                   10      


<210>  226
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  226

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  227
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the CTLA-4 inhibitor 
       tremelimumab

<400>  227

Gln Gln Tyr Tyr Ser Thr Pro Phe Thr 
1               5                   


<210>  228
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  228

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Gly Leu Met Gly Pro Phe Asp Ile Trp Gly Gln Gly Thr 
            100                 105                 110         


Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
225                 230                 235                 240 


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
                245                 250                 255     


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
            260                 265                 270         


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
        275                 280                 285             


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 
    290                 295                 300                 


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
305                 310                 315                 320 


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
                325                 330                 335     


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
            340                 345                 350         


Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 
        355                 360                 365             


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
    370                 375                 380                 


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
385                 390                 395                 400 


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
                405                 410                 415     


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
            420                 425                 430         


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        435                 440                 445             


<210>  229
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  229

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr 
            20                  25                  30          


Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  230
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain variable region (VH) amino acid sequence of the 
       CTLA-4 inhibitor zalifrelimab

<400>  230

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Gly Leu Met Gly Pro Phe Asp Ile Trp Gly Gln Gly Thr 
            100                 105                 110         


Met Val Thr Val Ser Ser 
        115             


<210>  231
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain variable region (VL) amino acid sequence of the 
       CTLA-4 inhibitor zalifrelimab

<400>  231

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr 
            20                  25                  30          


Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  232
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR1 amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  232

Gly Phe Thr Phe Ser Ser Tyr Ser 
1               5               


<210>  233
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR2 amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  233

Ile Ser Ser Ser Ser Ser Tyr Ile 
1               5               


<210>  234
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain CDR3 amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  234

Ala Arg Val Gly Leu Met Gly Pro Phe Asp Ile 
1               5                   10      


<210>  235
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR1 amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  235

Gln Ser Val Ser Arg Tyr 
1               5       


<210>  236
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR2 amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  236

Gly Ala Ser 
1           


<210>  237
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain CDR3 amino acid sequence of the CTLA-4 inhibitor 
       zalifrelimab

<400>  237

Gln Gln Tyr Gly Ser Ser Pro Trp Thr 
1               5                   


<210>  238
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD8a transmembrane domain

<400>  238

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 
1               5                   10                  15      


Ser Leu Val Ile Thr 
            20      


<210>  239
<211>  46
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  B7-1 transmembrane-intracellular domain

<400>  239

Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe 
1               5                   10                  15      


Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg 
            20                  25                  30          


Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val 
        35                  40                  45      


<210>  240
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  glycine-serine linkers

<400>  240

Gly Ser 
1       


<210>  241
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  glycine-serine linkers

<400>  241

Gly Ser Gly Gly Ser 
1               5   


<210>  242
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  glycine-serine linkers

<400>  242

Gly Gly Gly Ser 
1               


<210>  243
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  glycine-serine linkers

<400>  243

Gly Gly Gly Gly Ser 
1               5   


<210>  244
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  glycine-serine linkers

<400>  244

Gly Gly Gly Gly Gly Ser 
1               5       


<210>  245
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  glycine-serine linkers

<400>  245

Gly Gly Gly Gly Gly Gly Ser 
1               5           


<210>  246
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide linker

<400>  246

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15      


Gly Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln 
            20                  25          


<210>  247
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  2A peptide C-terminus sequence


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is any naturally occurring amino acid residue

<400>  247

Gly Asp Val Glu Xaa Asn Pro Gly Pro 
1               5                   


<210>  248
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  porcine teschovirus-1 2A peptide

<400>  248

Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val 
1               5                   10                  15      


Glu Glu Asn Pro Gly Pro 
            20          


<210>  249
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  quine rhinitis A virus 2A peptide

<400>  249

Gly Ser Gly Gln Cys Thr Asn Tyr Ala Leu Leu Lys Leu Ala Gly Asp 
1               5                   10                  15      


Val Glu Ser Asn Pro Gly Pro 
            20              


<210>  250
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  foot-and-mouth disease virus 2A peptide

<400>  250

Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu 
1               5                   10                  15      


Glu Asn Pro Gly Pro 
            20      


<210>  251
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  furin-cleavable 2A peptide

<400>  251

Arg Ala Lys Arg Ser Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys 
1               5                   10                  15      


Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro 
            20                  25          


<210>  252
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human IgE signal peptide sequences

<400>  252

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser 
        


<210>  253
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human IgE signal peptide sequences

<400>  253

Asn Ile Lys Gly Ser Pro Trp Lys Gly Ser Leu Leu Leu Leu Leu Val 
1               5                   10                  15      


Ser Asn Leu Leu Leu Cys Gln Ser Val Ala Pro 
            20                  25          


<210>  254
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human IL-2 signal peptide sequence

<400>  254

Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 
1               5                   10                  15      


Val Thr Asn Ser 
            20  


<210>  255
<211>  396
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  6X NFAT IL-2 minimal promoter

<400>  255
tcgaggtcga cggtatcgat aagcttgata tcgaattagg aggaaaaact gtttcataca       60

gaaggcgtca attaggagga aaaactgttt catacagaag gcgtcaatta ggaggaaaaa      120

ctgtttcata cagaaggcgt caattggtcc catcgaatta ggaggaaaaa ctgtttcata      180

cagaaggcgt caattaggag gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa      240

aactgtttca tacagaaggc gtcaattggt cccgggacat tttgacaccc ccataatatt      300

tttccagaat taacagtata aattgcatct cttgttcaag agttccctat cactctcttt      360

aatcactact cacagtaacc tcaactcctg gccacc                                396


<210>  256
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NFAT responsive element

<400>  256
ggaggaaaaa ctgtttcata cagaaggcgt                                        30


<210>  257
<211>  113
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Human IL-2 Promoter

<400>  257
cattttgaca cccccataat atttttccag aattaacagt ataaattgca tctcttgttc       60

aagagttccc tatcactctc tttaatcact actcacagta acctcaactc ctg             113


<210>  258
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human IL-15 (N72D mutant)

<400>  258

Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 
1               5                   10                  15      


Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 
            20                  25                  30          


Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 
        35                  40                  45              


Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 
    50                  55                  60                  


Asn Leu Ile Ile Leu Ala Asn Asp Ser Leu Ser Ser Asn Gly Asn Val 
65                  70                  75                  80  


Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 
                85                  90                  95      


Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 
            100                 105                 110         


Thr Ser 
        


<210>  259
<211>  297
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15R-alpha-Su/Fc domain

<400>  259

Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val 
1               5                   10                  15      


Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 
            20                  25                  30          


Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 
        35                  40                  45              


Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 
    50                  55                  60                  


Arg Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 
65                  70                  75                  80  


Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 
                85                  90                  95      


Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 
            100                 105                 110         


Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 
        115                 120                 125             


Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 
    130                 135                 140                 


Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 
145                 150                 155                 160 


Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 
                165                 170                 175     


Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 
            180                 185                 190         


Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 
        195                 200                 205             


Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 
    210                 215                 220                 


Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 
225                 230                 235                 240 


Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 
                245                 250                 255     


Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 
            260                 265                 270         


Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 
        275                 280                 285             


Lys Ser Leu Ser Leu Ser Pro Gly Lys 
    290                 295         


<210>  260
<211>  65
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15R-alpha-Su (65aa truncated extracellular domain)

<400>  260

Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val 
1               5                   10                  15      


Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 
            20                  25                  30          


Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 
        35                  40                  45              


Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 
    50                  55                  60                  


Arg 
65  


<210>  261
<211>  135
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15 isoform 2

<400>  261

Met Val Leu Gly Thr Ile Asp Leu Cys Ser Cys Phe Ser Ala Gly Leu 
1               5                   10                  15      


Pro Lys Thr Glu Ala Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys 
            20                  25                  30          


Ile Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr 
        35                  40                  45              


Glu Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe 
    50                  55                  60                  


Leu Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile 
65                  70                  75                  80  


His Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser 
                85                  90                  95      


Ser Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu 
            100                 105                 110         


Glu Glu Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val 
        115                 120                 125             


Gln Met Phe Ile Asn Thr Ser 
    130                 135 


<210>  262
<211>  162
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15 isoform 1

<400>  262

Met Arg Ile Ser Lys Pro His Leu Arg Ser Ile Ser Ile Gln Cys Tyr 
1               5                   10                  15      


Leu Cys Leu Leu Leu Asn Ser His Phe Leu Thr Glu Ala Gly Ile His 
            20                  25                  30          


Val Phe Ile Leu Gly Cys Phe Ser Ala Gly Leu Pro Lys Thr Glu Ala 
        35                  40                  45              


Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 
    50                  55                  60                  


Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 
65                  70                  75                  80  


Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 
                85                  90                  95      


Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 
            100                 105                 110         


Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val 
        115                 120                 125             


Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 
    130                 135                 140                 


Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 
145                 150                 155                 160 


Thr Ser 
        


<210>  263
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15 (without signal peptide)

<400>  263

Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 
1               5                   10                  15      


Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 
            20                  25                  30          


Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 
        35                  40                  45              


Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 
    50                  55                  60                  


Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val 
65                  70                  75                  80  


Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 
                85                  90                  95      


Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 
            100                 105                 110         


Thr Ser 
        


<210>  264
<211>  85
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15R-alpha (85 aa truncated extracellular domain)

<400>  264

Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val 
1               5                   10                  15      


Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 
            20                  25                  30          


Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 
        35                  40                  45              


Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 
    50                  55                  60                  


Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val 
65                  70                  75                  80  


Thr Thr Ala Gly Val 
                85  


<210>  265
<211>  182
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15R-alpha (182aa truncated extracellular domain)

<400>  265

Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val 
1               5                   10                  15      


Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 
            20                  25                  30          


Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 
        35                  40                  45              


Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 
    50                  55                  60                  


Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val 
65                  70                  75                  80  


Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly 
                85                  90                  95      


Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr 
            100                 105                 110         


Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro 
        115                 120                 125             


Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr 
    130                 135                 140                 


Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser 
145                 150                 155                 160 


His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr Val 
                165                 170                 175     


Ala Ile Ser Thr Ser Thr 
            180         


<210>  266
<211>  267
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-15R-alpha

<400>  266

Met Ala Pro Arg Arg Ala Arg Gly Cys Arg Thr Leu Gly Leu Pro Ala 
1               5                   10                  15      


Leu Leu Leu Leu Leu Leu Leu Arg Pro Pro Ala Thr Arg Gly Ile Thr 
            20                  25                  30          


Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser 
        35                  40                  45              


Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys 
    50                  55                  60                  


Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala 
65                  70                  75                  80  


Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp 
                85                  90                  95      


Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val Thr Thr 
            100                 105                 110         


Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu 
        115                 120                 125             


Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala 
    130                 135                 140                 


Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr 
145                 150                 155                 160 


Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser 
                165                 170                 175     


Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln 
            180                 185                 190         


Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr Val Ala Ile 
        195                 200                 205             


Ser Thr Ser Thr Val Leu Leu Cys Gly Leu Ser Ala Val Ser Leu Leu 
    210                 215                 220                 


Ala Cys Tyr Leu Lys Ser Arg Gln Thr Pro Pro Leu Ala Ser Val Glu 
225                 230                 235                 240 


Met Glu Ala Met Glu Ala Leu Pro Val Thr Trp Gly Thr Ser Ser Arg 
                245                 250                 255     


Asp Glu Asp Leu Glu Asn Cys Ser His His Leu 
            260                 265         


<210>  267
<211>  197
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-12 p35 subunit

<400>  267

Arg Asn Leu Pro Val Ala Thr Pro Asp Pro Gly Met Phe Pro Cys Leu 
1               5                   10                  15      


His His Ser Gln Asn Leu Leu Arg Ala Val Ser Asn Met Leu Gln Lys 
            20                  25                  30          


Ala Arg Gln Thr Leu Glu Phe Tyr Pro Cys Thr Ser Glu Glu Ile Asp 
        35                  40                  45              


His Glu Asp Ile Thr Lys Asp Lys Thr Ser Thr Val Glu Ala Cys Leu 
    50                  55                  60                  


Pro Leu Glu Leu Thr Lys Asn Glu Ser Cys Leu Asn Ser Arg Glu Thr 
65                  70                  75                  80  


Ser Phe Ile Thr Asn Gly Ser Cys Leu Ala Ser Arg Lys Thr Ser Phe 
                85                  90                  95      


Met Met Ala Leu Cys Leu Ser Ser Ile Tyr Glu Asp Leu Lys Met Tyr 
            100                 105                 110         


Gln Val Glu Phe Lys Thr Met Asn Ala Lys Leu Leu Met Asp Pro Lys 
        115                 120                 125             


Arg Gln Ile Phe Leu Asp Gln Asn Met Leu Ala Val Ile Asp Glu Leu 
    130                 135                 140                 


Met Gln Ala Leu Asn Phe Asn Ser Glu Thr Val Pro Gln Lys Ser Ser 
145                 150                 155                 160 


Leu Glu Glu Pro Asp Phe Tyr Lys Thr Lys Ile Lys Leu Cys Ile Leu 
                165                 170                 175     


Leu His Ala Phe Arg Ile Arg Ala Val Thr Ile Asp Arg Val Met Ser 
            180                 185                 190         


Tyr Leu Asn Ala Ser 
        195         


<210>  268
<211>  306
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-12 p40 subunit

<400>  268

Ile Trp Glu Leu Lys Lys Asp Val Tyr Val Val Glu Leu Asp Trp Tyr 
1               5                   10                  15      


Pro Asp Ala Pro Gly Glu Met Val Val Leu Thr Cys Asp Thr Pro Glu 
            20                  25                  30          


Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln Ser Ser Glu Val Leu Gly 
        35                  40                  45              


Ser Gly Lys Thr Leu Thr Ile Gln Val Lys Glu Phe Gly Asp Ala Gly 
    50                  55                  60                  


Gln Tyr Thr Cys His Lys Gly Gly Glu Val Leu Ser His Ser Leu Leu 
65                  70                  75                  80  


Leu Leu His Lys Lys Glu Asp Gly Ile Trp Ser Thr Asp Ile Leu Lys 
                85                  90                  95      


Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe Leu Arg Cys Glu Ala Lys 
            100                 105                 110         


Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp Leu Thr Thr Ile Ser Thr 
        115                 120                 125             


Asp Leu Thr Phe Ser Val Lys Ser Ser Arg Gly Ser Ser Asp Pro Gln 
    130                 135                 140                 


Gly Val Thr Cys Gly Ala Ala Thr Leu Ser Ala Glu Arg Val Arg Gly 
145                 150                 155                 160 


Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu Cys Gln Glu Asp Ser Ala 
                165                 170                 175     


Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Met Val Asp Ala 
            180                 185                 190         


Val His Lys Leu Lys Tyr Glu Asn Tyr Thr Ser Ser Phe Phe Ile Arg 
        195                 200                 205             


Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu Lys Pro Leu 
    210                 215                 220                 


Lys Asn Ser Arg Gln Val Glu Val Ser Trp Glu Tyr Pro Asp Thr Trp 
225                 230                 235                 240 


Ser Thr Pro His Ser Tyr Phe Ser Leu Thr Phe Cys Val Gln Val Gln 
                245                 250                 255     


Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr Asp Lys Thr 
            260                 265                 270         


Ser Ala Thr Val Ile Cys Arg Lys Asn Ala Ser Ile Ser Val Arg Ala 
        275                 280                 285             


Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser Val Pro 
    290                 295                 300                 


Cys Ser 
305     


<210>  269
<211>  157
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-18

<400>  269

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 
1               5                   10                  15      


Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 
            20                  25                  30          


Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 
        35                  40                  45              


Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 
    50                  55                  60                  


Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 
65                  70                  75                  80  


Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 
                85                  90                  95      


Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys 
            100                 105                 110         


Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu 
        115                 120                 125             


Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu 
    130                 135                 140                 


Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 
145                 150                 155         


<210>  270
<211>  156
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-18 variant

<400>  270

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 
1               5                   10                  15      


Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 
            20                  25                  30          


Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 
        35                  40                  45              


Ile Ser Lys Tyr Ser Asp Ser Arg Ala Arg Gly Leu Ala Val Thr Ile 
    50                  55                  60                  


Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 
65                  70                  75                  80  


Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys 
                85                  90                  95      


Ser Asp Ile Ile Phe Phe Ala Arg Val Pro Gly His Gly Arg Lys Thr 
            100                 105                 110         


Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu Lys 
        115                 120                 125             


Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu Gly 
    130                 135                 140                 


Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp 
145                 150                 155     


<210>  271
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-21

<400>  271

Gln Gly Gln Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile 
1               5                   10                  15      


Val Asp Gln Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu 
            20                  25                  30          


Pro Ala Pro Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser 
        35                  40                  45              


Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu 
    50                  55                  60                  


Arg Ile Ile Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser 
65                  70                  75                  80  


Thr Asn Ala Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys 
                85                  90                  95      


Asp Ser Tyr Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys 
            100                 105                 110         


Ser Leu Leu Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His 
        115                 120                 125             


Gly Ser Glu Asp Ser 
    130             


<210>  272
<211>  153
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IL-2

<400>  272

Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 
1               5                   10                  15      


Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 
            20                  25                  30          


Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 
        35                  40                  45              


Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe 
    50                  55                  60                  


Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 
65                  70                  75                  80  


Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 
                85                  90                  95      


Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 
            100                 105                 110         


Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 
        115                 120                 125             


Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 
    130                 135                 140                 


Cys Gln Ser Ile Ile Ser Thr Leu Thr 
145                 150             


<210>  273
<211>  261
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human CD40L

<400>  273

Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly 
1               5                   10                  15      


Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu 
            20                  25                  30          


Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg 
        35                  40                  45              


Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val 
    50                  55                  60                  


Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser 
65                  70                  75                  80  


Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys 
                85                  90                  95      


Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu 
            100                 105                 110         


Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser 
        115                 120                 125             


Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly 
    130                 135                 140                 


Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln 
145                 150                 155                 160 


Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr 
                165                 170                 175     


Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser 
            180                 185                 190         


Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala 
        195                 200                 205             


Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His 
    210                 215                 220                 


Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn 
225                 230                 235                 240 


Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe 
                245                 250                 255     


Gly Leu Leu Lys Leu 
            260     


<210>  274
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-human CD40 VH (Sotigalimab)

<400>  274

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Thr 
            20                  25                  30          


Tyr Val Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Ala Cys Ile Tyr Thr Gly Asp Gly Thr Asn Tyr Ser Ala Ser Trp Ala 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Lys Asp Ser Ser Lys Asn Thr Val Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Pro Asp Ile Thr Tyr Gly Phe Ala Ile Asn Phe Trp Gly Pro 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  275
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-human CD40 VL (Sotigalimab)

<400>  275

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Arg 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Cys Thr Gly Tyr Gly Ile Ser 
                85                  90                  95      


Trp Pro Ile Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  276
<211>  248
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-human CD40 scFv (Sotigalimab)

<400>  276

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Thr 
            20                  25                  30          


Tyr Val Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Ala Cys Ile Tyr Thr Gly Asp Gly Thr Asn Tyr Ser Ala Ser Trp Ala 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Lys Asp Ser Ser Lys Asn Thr Val Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Pro Asp Ile Thr Tyr Gly Phe Ala Ile Asn Phe Trp Gly Pro 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 
        115                 120                 125             


Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met 
    130                 135                 140                 


Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 
145                 150                 155                 160 


Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Arg Leu Ala Trp Tyr 
                165                 170                 175     


Gln Gln Lys Pro Gly Lys Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser 
            180                 185                 190         


Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 
        195                 200                 205             


Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala 
    210                 215                 220                 


Thr Tyr Tyr Cys Gln Cys Thr Gly Tyr Gly Ile Ser Trp Pro Ile Gly 
225                 230                 235                 240 


Gly Gly Thr Lys Val Glu Ile Lys 
                245             


<210>  277
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-human CD40 VH (Dacetuzumab)

<400>  277

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 
1               5                   10                  15      


Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Tyr Ile 
            20                  25                  30          


His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg 
        35                  40                  45              


Val Ile Pro Asn Ala Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly 
    50                  55                  60                  


Arg Phe Thr Leu Ser Val Asp Asn Ser Lys Asn Thr Ala Tyr Leu Gln 
65                  70                  75                  80  


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
                85                  90                  95      


Glu Gly Ile Tyr Trp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
            100                 105                 110         


<210>  278
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-human CD40 VL (Dacetuzumab)

<400>  278

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
65                  70                  75                  80  


Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Ser Gln Thr 
                85                  90                  95      


Thr His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  279
<211>  244
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-human CD40 scFv (Dacetuzumab)

<400>  279

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 
1               5                   10                  15      


Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Tyr Ile 
            20                  25                  30          


His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg 
        35                  40                  45              


Val Ile Pro Asn Ala Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly 
    50                  55                  60                  


Arg Phe Thr Leu Ser Val Asp Asn Ser Lys Asn Thr Ala Tyr Leu Gln 
65                  70                  75                  80  


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
                85                  90                  95      


Glu Gly Ile Tyr Trp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
            100                 105                 110         


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
        115                 120                 125             


Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 
    130                 135                 140                 


Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser 
145                 150                 155                 160 


Leu Val His Ser Asn Gly Asn Thr Phe Leu His Trp Tyr Gln Gln Lys 
                165                 170                 175     


Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe 
            180                 185                 190         


Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 
        195                 200                 205             


Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe 
    210                 215                 220                 


Cys Ser Gln Thr Thr His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys 
225                 230                 235                 240 


Val Glu Ile Lys 
                


<210>  280
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CD40 VH (Lucatutuzumab)

<400>  280

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Glu Glu Ser Asn Arg Tyr His Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ile Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Gly Gly Ile Ala Ala Pro Gly Pro Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  281
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CD40 VL (Lucatutuzumab)

<400>  281

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Thr Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser 
            20                  25                  30          


Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Ser Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
                85                  90                  95      


Arg Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Arg 
            100                 105                 110         


<210>  282
<211>  252
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CD40 scFv (Lucatutuzumab)

<400>  282

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Glu Glu Ser Asn Arg Tyr His Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ile Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Gly Gly Ile Ala Ala Pro Gly Pro Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 
        115                 120                 125             


Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met 
    130                 135                 140                 


Thr Gln Ser Pro Leu Ser Leu Thr Val Thr Pro Gly Glu Pro Ala Ser 
145                 150                 155                 160 


Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Tyr Asn 
                165                 170                 175     


Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Val Leu 
            180                 185                 190         


Ile Ser Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser 
        195                 200                 205             


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu 
    210                 215                 220                 


Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Arg Gln Thr Pro 
225                 230                 235                 240 


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Arg 
                245                 250         


<210>  283
<211>  126
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CD40 VH (Selicrelumab)

<400>  283

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro Asp Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Gln Pro Leu Gly Tyr Cys Thr Asn Gly Val Cys Ser Tyr 
            100                 105                 110         


Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125     


<210>  284
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CD40 VL (Selicrelumab)

<400>  284

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Tyr Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 
        35                  40                  45              


Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ile Phe Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  285
<211>  253
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-CD40 scFv (Selicrelumab)

<400>  285

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro Asp Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Gln Pro Leu Gly Tyr Cys Thr Asn Gly Val Cys Ser Tyr 
            100                 105                 110         


Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 
        115                 120                 125             


Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
    130                 135                 140                 


Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser 
145                 150                 155                 160 


Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Tyr 
                165                 170                 175     


Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu 
            180                 185                 190         


Leu Ile Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe 
        195                 200                 205             


Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu 
    210                 215                 220                 


Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ile Phe 
225                 230                 235                 240 


Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
                245                 250             


<210>  286
<211>  49
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Target PD-1 Sequence

<400>  286

Thr Thr Cys Thr Cys Cys Cys Cys Ala Gly Cys Cys Cys Thr Gly Cys 
1               5                   10                  15      


Thr Cys Gly Thr Gly Gly Thr Gly Ala Cys Cys Gly Ala Ala Gly Gly 
            20                  25                  30          


Gly Gly Ala Cys Ala Ala Cys Gly Cys Cys Ala Cys Cys Thr Thr Cys 
        35                  40                  45              


Ala 
    


<210>  287
<211>  49
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Target PD-1 Sequence

<400>  287
tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagaga                   49


<210>  288
<211>  530
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Repeat PD-1-left

<400>  288

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys 
1               5                   10                  15      


Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala 
            20                  25                  30          


His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly 
        35                  40                  45              


Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys 
    50                  55                  60                  


Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn 
65                  70                  75                  80  


Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val 
                85                  90                  95      


Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala 
            100                 105                 110         


Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu 
        115                 120                 125             


Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala 
    130                 135                 140                 


Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg 
145                 150                 155                 160 


Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val 
                165                 170                 175     


Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val 
            180                 185                 190         


Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu 
        195                 200                 205             


Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu 
    210                 215                 220                 


Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr 
225                 230                 235                 240 


Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala 
                245                 250                 255     


Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly 
            260                 265                 270         


Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys 
        275                 280                 285             


Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala 
    290                 295                 300                 


His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly 
305                 310                 315                 320 


Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys 
                325                 330                 335     


Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His 
            340                 345                 350         


Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val 
        355                 360                 365             


Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala 
    370                 375                 380                 


Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu 
385                 390                 395                 400 


Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala 
                405                 410                 415     


Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg 
            420                 425                 430         


Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val 
        435                 440                 445             


Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val 
    450                 455                 460                 


Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu 
465                 470                 475                 480 


Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu 
                485                 490                 495     


Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr 
            500                 505                 510         


Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala 
        515                 520                 525             


Leu Glu 
    530 


<210>  289
<211>  529
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Repeat PD-1-right

<400>  289

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys 
1               5                   10                  15      


Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala 
            20                  25                  30          


His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly 
        35                  40                  45              


Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys 
    50                  55                  60                  


Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn 
65                  70                  75                  80  


Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val 
                85                  90                  95      


Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala 
            100                 105                 110         


Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu 
        115                 120                 125             


Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala 
    130                 135                 140                 


Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg 
145                 150                 155                 160 


Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val 
                165                 170                 175     


Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val 
            180                 185                 190         


Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln 
        195                 200                 205             


Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu 
    210                 215                 220                 


Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr 
225                 230                 235                 240 


Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala 
                245                 250                 255     


Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly 
            260                 265                 270         


Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Gly Gly Lys Gln 
        275                 280                 285             


Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His 
    290                 295                 300                 


Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly 
305                 310                 315                 320 


Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln 
                325                 330                 335     


Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly 
            340                 345                 350         


Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu 
        355                 360                 365             


Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser 
    370                 375                 380                 


Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro 
385                 390                 395                 400 


Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile 
                405                 410                 415     


Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu 
            420                 425                 430         


Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val 
        435                 440                 445             


Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln 
    450                 455                 460                 


Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln 
465                 470                 475                 480 


Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr 
                485                 490                 495     


Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro 
            500                 505                 510         


Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala Leu 
        515                 520                 525             


Glu 
    


<210>  290
<211>  2814
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PD-1-left TALEN

<400>  290
atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt tccagattac       60

gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca ggagaagatc      120

aaaccgaagg ttcgttcgac agtggcgcag caccacgagg cactggtcgg ccacgggttt      180

acacacgcgc acatcgttgc gttaagccaa cacccggcag cgttagggac cgtcgctgtc      240

aagtatcagg acatgatcgc agcgttgcca gaggcgacac acgaagcgat cgttggcgtc      300

ggcaaacagt ggtccggcgc acgcgctctg gaggccttgc tcacggtggc gggagagttg      360

agaggtccac cgttacagtt ggacacaggc caacttctca agattgcaaa acgtggcggc      420

gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac tgacgggtgc cccgctcaac      480

ttgacccccc agcaggtggt ggccatcgcc agcaatggcg gtggcaagca ggcgctggag      540

acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg      600

gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca gcggctgttg      660

ccggtgctgt gccaggccca cggcttgacc ccccagcagg tggtggccat cgccagcaat      720

ggcggtggca agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc      780

cacggcttga ccccggagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg      840

ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccggag      900

caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg      960

ctgttgccgg tgctgtgcca ggcccacggc ttgaccccgg agcaggtggt ggccatcgcc     1020

agccacgatg gcggcaagca ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc     1080

caggcccacg gcttgacccc ggagcaggtg gtggccatcg ccagccacga tggcggcaag     1140

caggcgctgg agacggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc     1200

ccggagcagg tggtggccat cgccagcaat attggtggca agcaggcgct ggagacggtg     1260

caggcgctgt tgccggtgct gtgccaggcc cacggcttga ccccccagca ggtggtggcc     1320

atcgccagca ataatggtgg caagcaggcg ctggagacgg tccagcggct gttgccggtg     1380

ctgtgccagg cccacggctt gaccccggag caggtggtgg ccatcgccag ccacgatggc     1440

ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc     1500

ttgaccccgg agcaggtggt ggccatcgcc agccacgatg gcggcaagca ggcgctggag     1560

acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg     1620

gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca gcggctgttg     1680

ccggtgctgt gccaggccca cggcttgacc ccccagcagg tggtggccat cgccagcaat     1740

ggcggtggca agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc     1800

cacggcttga ccccccagca ggtggtggcc atcgccagca ataatggtgg caagcaggcg     1860

ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccggag     1920

caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg     1980

ctgttgccgg tgctgtgcca ggcccacggc ttgacccctc agcaggtggt ggccatcgcc     2040

agcaatggcg gcggcaggcc ggcgctggag agcattgttg cccagttatc tcgccctgat     2100

ccggcgttgg ccgcgttgac caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt     2160

cctgcgctgg atgcagtgaa aaagggattg ggggatccta tcagccgttc ccagctggtg     2220

aagtccgagc tggaggagaa gaaatccgag ttgaggcaca agctgaagta cgtgccccac     2280

gagtacatcg agctgatcga gatcgcccgg aacagcaccc aggaccgtat cctggagatg     2340

aaggtgatgg agttcttcat gaaggtgtac ggctacaggg gcaagcacct gggcggctcc     2400

aggaagcccg acggcgccat ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg     2460

gacaccaagg cctactccgg cggctacaac ctgcccatcg gccaggccga cgaaatgcag     2520

aggtacgtgg aggagaacca gaccaggaac aagcacatca accccaacga gtggtggaag     2580

gtgtacccct ccagcgtgac cgagttcaag ttcctgttcg tgtccggcca cttcaagggc     2640

aactacaagg cccagctgac caggctgaac cacatcacca actgcaacgg cgccgtgctg     2700

tccgtggagg agctcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag     2760

gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa           2814


<210>  291
<211>  2829
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PD-1-right TALEN

<400>  291
atgggcgatc ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc       60

gagagacagc acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag      120

cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca ccacgaggca      180

ctggtcggcc acgggtttac acacgcgcac atcgttgcgt taagccaaca cccggcagcg      240

ttagggaccg tcgctgtcaa gtatcaggac atgatcgcag cgttgccaga ggcgacacac      300

gaagcgatcg ttggcgtcgg caaacagtgg tccggcgcac gcgctctgga ggccttgctc      360

acggtggcgg gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag      420

attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg caatgcactg      480

acgggtgccc cgctcaactt gaccccccag caagtcgtcg caatcgccag caataacgga      540

gggaagcaag ccctcgaaac cgtgcagcgg ttgcttcctg tgctctgcca ggcccacggc      600

cttacccctg agcaggtggt ggccatcgca agtaacattg gaggaaagca agccttggag      660

acagtgcagg ccctgttgcc cgtgctgtgc caggcacacg gcctcacacc agagcaggtc      720

gtggccattg cctccaacat cggggggaaa caggctctgg agaccgtcca ggccctgctg      780

cccgtcctct gtcaagctca cggcctgact ccccaacaag tggtcgccat cgcctctaat      840

aacggcggga agcaggcact ggaaacagtg cagagactgc tccctgtgct ttgccaagct      900

catgggttga ccccccaaca ggtcgtcgct attgcctcaa acaacggggg caagcaggcc      960

cttgagactg tgcagaggct gttgccagtg ctgtgtcagg ctcacgggct cactccacaa     1020

caggtggtcg caattgccag caacggcggc ggaaagcaag ctcttgaaac cgtgcaacgc     1080

ctcctgcccg tgctctgtca ggctcatggc ctgacaccac aacaagtcgt ggccatcgcc     1140

agtaataatg gcgggaaaca ggctcttgag accgtccaga ggctgctccc agtgctctgc     1200

caggcacacg ggctgacccc ccagcaggtg gtggctatcg ccagcaataa tgggggcaag     1260

caggccctgg aaacagtcca gcgcctgctg ccagtgcttt gccaggctca cgggctcact     1320

cccgaacagg tcgtggcaat cgcctccaac ggagggaagc aggctctgga gaccgtgcag     1380

agactgctgc ccgtcttgtg ccaggcccac ggactcacac ctcagcaggt cgtcgccatt     1440

gcctctaaca acgggggcaa acaagccctg gagacagtgc agcggctgtt gcctgtgttg     1500

tgccaagccc acggcttgac tcctcaacaa gtggtcgcca tcgcctcaaa tggcggcgga     1560

aaacaagctc tggagacagt gcagaggttg ctgcccgtcc tctgccaagc ccacggcctg     1620

actccccaac aggtcgtcgc cattgccagc aacggcggag gaaagcaggc tctcgaaact     1680

gtgcagcggc tgcttcctgt gctgtgtcag gctcatgggc tgacccccca gcaagtggtg     1740

gctattgcct ctaacaatgg aggcaagcaa gcccttgaga cagtccagag gctgttgcca     1800

gtgctgtgcc aggcccacgg gctcacaccc cagcaggtgg tcgccatcgc cagtaacggc     1860

gggggcaaac aggcattgga aaccgtccag cgcctgcttc cagtgctctg ccaggcacac     1920

ggactgacac ccgaacaggt ggtggccatt gcatcccatg atgggggcaa gcaggccctg     1980

gagaccgtgc agagactcct gccagtgttg tgccaagctc acggcctcac ccctcagcaa     2040

gtcgtggcca tcgcctcaaa cggggggggc cggcctgcac tggagagcat tgttgcccag     2100

ttatctcgcc ctgatccggc gttggccgcg ttgaccaacg accacctcgt cgccttggcc     2160

tgcctcggcg ggcgtcctgc gctggatgca gtgaaaaagg gattggggga tcctatcagc     2220

cgttcccagc tggtgaagtc cgagctggag gagaagaaat ccgagttgag gcacaagctg     2280

aagtacgtgc cccacgagta catcgagctg atcgagatcg cccggaacag cacccaggac     2340

cgtatcctgg agatgaaggt gatggagttc ttcatgaagg tgtacggcta caggggcaag     2400

cacctgggcg gctccaggaa gcccgacggc gccatctaca ccgtgggctc ccccatcgac     2460

tacggcgtga tcgtggacac caaggcctac tccggcggct acaacctgcc catcggccag     2520

gccgacgaaa tgcagaggta cgtggaggag aaccagacca ggaacaagca catcaacccc     2580

aacgagtggt ggaaggtgta cccctccagc gtgaccgagt tcaagttcct gttcgtgtcc     2640

ggccacttca agggcaacta caaggcccag ctgaccaggc tgaaccacat caccaactgc     2700

aacggcgccg tgctgtccgt ggaggagctc ctgatcggcg gcgagatgat caaggccggc     2760

accctgaccc tggaggaggt gaggaggaag ttcaacaacg gcgagatcaa cttcgcggcc     2820

gactgataa                                                             2829


<210>  292
<211>  530
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Repeat PD-1-left

<400>  292

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys 
1               5                   10                  15      


Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala 
            20                  25                  30          


His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly 
        35                  40                  45              


Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys 
    50                  55                  60                  


Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His 
65                  70                  75                  80  


Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val 
                85                  90                  95      


Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala 
            100                 105                 110         


Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu 
        115                 120                 125             


Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala 
    130                 135                 140                 


Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg 
145                 150                 155                 160 


Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val 
                165                 170                 175     


Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val 
            180                 185                 190         


Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln 
        195                 200                 205             


Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu 
    210                 215                 220                 


Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr 
225                 230                 235                 240 


Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala 
                245                 250                 255     


Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly 
            260                 265                 270         


Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys 
        275                 280                 285             


Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala 
    290                 295                 300                 


His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly 
305                 310                 315                 320 


Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys 
                325                 330                 335     


Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn 
            340                 345                 350         


Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val 
        355                 360                 365             


Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala 
    370                 375                 380                 


Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu 
385                 390                 395                 400 


Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala 
                405                 410                 415     


Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg 
            420                 425                 430         


Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val 
        435                 440                 445             


Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val 
    450                 455                 460                 


Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu 
465                 470                 475                 480 


Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu 
                485                 490                 495     


Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr 
            500                 505                 510         


Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala 
        515                 520                 525             


Leu Glu 
    530 


<210>  293
<211>  529
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Repeat PD-1-right

<400>  293

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys 
1               5                   10                  15      


Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala 
            20                  25                  30          


His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly 
        35                  40                  45              


Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys 
    50                  55                  60                  


Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His 
65                  70                  75                  80  


Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val 
                85                  90                  95      


Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala 
            100                 105                 110         


Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu 
        115                 120                 125             


Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala 
    130                 135                 140                 


Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg 
145                 150                 155                 160 


Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val 
                165                 170                 175     


Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val 
            180                 185                 190         


Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln 
        195                 200                 205             


Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu 
    210                 215                 220                 


Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr 
225                 230                 235                 240 


Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala 
                245                 250                 255     


Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly 
            260                 265                 270         


Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys 
        275                 280                 285             


Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala 
    290                 295                 300                 


His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly 
305                 310                 315                 320 


Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys 
                325                 330                 335     


Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn 
            340                 345                 350         


Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val 
        355                 360                 365             


Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala 
    370                 375                 380                 


Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu 
385                 390                 395                 400 


Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala 
                405                 410                 415     


Ile Ala Ser Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu 
            420                 425                 430         


Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val 
        435                 440                 445             


Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln 
    450                 455                 460                 


Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln 
465                 470                 475                 480 


Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr 
                485                 490                 495     


Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro 
            500                 505                 510         


Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala Leu 
        515                 520                 525             


Glu 
    


<210>  294
<211>  2814
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PD-1-left TALEN

<400>  294
atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt tccagattac       60

gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca ggagaagatc      120

aaaccgaagg ttcgttcgac agtggcgcag caccacgagg cactggtcgg ccacgggttt      180

acacacgcgc acatcgttgc gttaagccaa cacccggcag cgttagggac cgtcgctgtc      240

aagtatcagg acatgatcgc agcgttgcca gaggcgacac acgaagcgat cgttggcgtc      300

ggcaaacagt ggtccggcgc acgcgctctg gaggccttgc tcacggtggc gggagagttg      360

agaggtccac cgttacagtt ggacacaggc caacttctca agattgcaaa acgtggcggc      420

gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac tgacgggtgc cccgctcaac      480

ttgaccccgg agcaggtggt ggccatcgcc agcaatattg gtggcaagca ggcgctggag      540

acggtgcagg cgctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg      600

gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca gcggctgttg      660

ccggtgctgt gccaggccca cggcttgacc ccggagcagg tggtggccat cgccagccac      720

gatggcggca agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc      780

cacggcttga ccccccagca ggtggtggcc atcgccagca atggcggtgg caagcaggcg      840

ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccggag      900

caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg      960

ctgttgccgg tgctgtgcca ggcccacggc ttgacccccc agcaggtggt ggccatcgcc     1020

agcaatggcg gtggcaagca ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc     1080

caggcccacg gcttgacccc ccagcaggtg gtggccatcg ccagcaataa tggtggcaag     1140

caggcgctgg agacggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc     1200

ccccagcagg tggtggccat cgccagcaat ggcggtggca agcaggcgct ggagacggtc     1260

cagcggctgt tgccggtgct gtgccaggcc cacggcttga ccccccagca ggtggtggcc     1320

atcgccagca ataatggtgg caagcaggcg ctggagacgg tccagcggct gttgccggtg     1380

ctgtgccagg cccacggctt gaccccccag caggtggtgg ccatcgccag caataatggt     1440

ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc     1500

ttgacccccc agcaggtggt ggccatcgcc agcaataatg gtggcaagca ggcgctggag     1560

acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ccagcaggtg     1620

gtggccatcg ccagcaataa tggtggcaag caggcgctgg agacggtcca gcggctgttg     1680

ccggtgctgt gccaggccca cggcttgacc ccggagcagg tggtggccat cgccagccac     1740

gatggcggca agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc     1800

cacggcttga ccccggagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg     1860

ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccggag     1920

caggtggtgg ccatcgccag caatattggt ggcaagcagg cgctggagac ggtgcaggcg     1980

ctgttgccgg tgctgtgcca ggcccacggc ttgacccctc agcaggtggt ggccatcgcc     2040

agcaatggcg gcggcaggcc ggcgctggag agcattgttg cccagttatc tcgccctgat     2100

ccggcgttgg ccgcgttgac caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt     2160

cctgcgctgg atgcagtgaa aaagggattg ggggatccta tcagccgttc ccagctggtg     2220

aagtccgagc tggaggagaa gaaatccgag ttgaggcaca agctgaagta cgtgccccac     2280

gagtacatcg agctgatcga gatcgcccgg aacagcaccc aggaccgtat cctggagatg     2340

aaggtgatgg agttcttcat gaaggtgtac ggctacaggg gcaagcacct gggcggctcc     2400

aggaagcccg acggcgccat ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg     2460

gacaccaagg cctactccgg cggctacaac ctgcccatcg gccaggccga cgaaatgcag     2520

aggtacgtgg aggagaacca gaccaggaac aagcacatca accccaacga gtggtggaag     2580

gtgtacccct ccagcgtgac cgagttcaag ttcctgttcg tgtccggcca cttcaagggc     2640

aactacaagg cccagctgac caggctgaac cacatcacca actgcaacgg cgccgtgctg     2700

tccgtggagg agctcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag     2760

gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa           2814


<210>  295
<211>  2829
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PD-1-right TALEN

<400>  295
atgggcgatc ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc       60

gagagacagc acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag      120

cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca ccacgaggca      180

ctggtcggcc acgggtttac acacgcgcac atcgttgcgt taagccaaca cccggcagcg      240

ttagggaccg tcgctgtcaa gtatcaggac atgatcgcag cgttgccaga ggcgacacac      300

gaagcgatcg ttggcgtcgg caaacagtgg tccggcgcac gcgctctgga ggccttgctc      360

acggtggcgg gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag      420

attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg caatgcactg      480

acgggtgccc cgctcaactt gacccccgag caagtcgtcg caatcgccag ccatgatgga      540

gggaagcaag ccctcgaaac cgtgcagcgg ttgcttcctg tgctctgcca ggcccacggc      600

cttacccctc agcaggtggt ggccatcgca agtaacggag gaggaaagca agccttggag      660

acagtgcagc gcctgttgcc cgtgctgtgc caggcacacg gcctcacacc agagcaggtc      720

gtggccattg cctcccatga cggggggaaa caggctctgg agaccgtcca gaggctgctg      780

cccgtcctct gtcaagctca cggcctgact ccccaacaag tggtcgccat cgcctctaat      840

ggcggcggga agcaggcact ggaaacagtg cagagactgc tccctgtgct ttgccaagct      900

catgggttga ccccccaaca ggtcgtcgct attgcctcaa acgggggggg caagcaggcc      960

cttgagactg tgcagaggct gttgccagtg ctgtgtcagg ctcacgggct cactccacaa     1020

caggtggtcg caattgccag caacggcggc ggaaagcaag ctcttgaaac cgtgcaacgc     1080

ctcctgcccg tgctctgtca ggctcatggc ctgacaccac aacaagtcgt ggccatcgcc     1140

agtaataatg gcgggaaaca ggctcttgag accgtccaga ggctgctccc agtgctctgc     1200

caggcacacg ggctgacccc cgagcaggtg gtggctatcg ccagcaatat tgggggcaag     1260

caggccctgg aaacagtcca ggccctgctg ccagtgcttt gccaggctca cgggctcact     1320

ccccagcagg tcgtggcaat cgcctccaac ggcggaggga agcaggctct ggagaccgtg     1380

cagagactgc tgcccgtctt gtgccaggcc cacggactca cacctgaaca ggtcgtcgcc     1440

attgcctctc acgatggggg caaacaagcc ctggagacag tgcagcggct gttgcctgtg     1500

ttgtgccaag cccacggctt gactcctcaa caagtggtcg ccatcgcctc aaatggcggc     1560

ggaaaacaag ctctggagac agtgcagagg ttgctgcccg tcctctgcca agcccacggc     1620

ctgactcccc aacaggtcgt cgccattgcc agcaacaacg gaggaaagca ggctctcgaa     1680

actgtgcagc ggctgcttcc tgtgctgtgt caggctcatg ggctgacccc cgagcaagtg     1740

gtggctattg cctctaatgg aggcaagcaa gcccttgaga cagtccagag gctgttgcca     1800

gtgctgtgcc aggcccacgg gctcacaccc cagcaggtgg tcgccatcgc cagtaacaac     1860

gggggcaaac aggcattgga aaccgtccag cgcctgcttc cagtgctctg ccaggcacac     1920

ggactgacac ccgaacaggt ggtggccatt gcatcccatg atgggggcaa gcaggccctg     1980

gagaccgtgc agagactcct gccagtgttg tgccaagctc acggcctcac ccctcagcaa     2040

gtcgtggcca tcgcctcaaa cggggggggc cggcctgcac tggagagcat tgttgcccag     2100

ttatctcgcc ctgatccggc gttggccgcg ttgaccaacg accacctcgt cgccttggcc     2160

tgcctcggcg ggcgtcctgc gctggatgca gtgaaaaagg gattggggga tcctatcagc     2220

cgttcccagc tggtgaagtc cgagctggag gagaagaaat ccgagttgag gcacaagctg     2280

aagtacgtgc cccacgagta catcgagctg atcgagatcg cccggaacag cacccaggac     2340

cgtatcctgg agatgaaggt gatggagttc ttcatgaagg tgtacggcta caggggcaag     2400

cacctgggcg gctccaggaa gcccgacggc gccatctaca ccgtgggctc ccccatcgac     2460

tacggcgtga tcgtggacac caaggcctac tccggcggct acaacctgcc catcggccag     2520

gccgacgaaa tgcagaggta cgtggaggag aaccagacca ggaacaagca catcaacccc     2580

aacgagtggt ggaaggtgta cccctccagc gtgaccgagt tcaagttcct gttcgtgtcc     2640

ggccacttca agggcaacta caaggcccag ctgaccaggc tgaaccacat caccaactgc     2700

aacggcgccg tgctgtccgt ggaggagctc ctgatcggcg gcgagatgat caaggccggc     2760

accctgaccc tggaggaggt gaggaggaag ttcaacaacg gcgagatcaa cttcgcggcc     2820

gactgataa                                                             2829


<210>  296
<211>  615
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  teIL-15

<400>  296
atggactgga cttggatact ctttctggtc gctgccgcca cacgggtgca ctctaattgg       60

gtcaacgtga tcagcgacct gaagaagatc gaggacctga tccagagcat gcacatcgac      120

gccacactgt acaccgagtc cgatgtgcac cctagctgca aagtgaccgc catgaagtgc      180

tttctgctgg aactgcaagt gatcagcctg gaaagcggcg acgccagcat ccacgatacc      240

gtggaaaatc tgatcatcct ggccaacaac agcctgtcca gcaacggcaa tgtgaccgag      300

agcggctgca aagagtgcga ggaactggaa gaaaagaaca tcaaagagtt tctgcagagc      360

ttcgtccaca tcgtgcagat gttcatcaac acctcatcag gtggcggtgg aagcggaggt      420

ggcggtagtg gcggcggagg ctcaggcggc ggaggttccg gcggaggatc tcttcagctc      480

ctgccatctt gggctatcac cctgattagt gtgaatggga tctttgtcat ctgttgtctc      540

acgtactgtt tcgctccccg gtgcagagag agaaggcgca acgaaagact gcggagagaa      600

agcgtcagac ccgtg                                                       615


<210>  297
<211>  735
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  teIL-21

<400>  297
atggattgga cctggattct gttcctggtg gccgctgcca caagagtgca tagccagggc       60

caagaccggc acatgatccg gatgagacag ctgatcgaca tcgtggacca gctgaagaac      120

tacgtgaacg acctggtgcc tgagttcctg cctgctcctg aggacgtgga aacaaattgc      180

gagtggtccg ccttcagctg cttccagaag gcccagctga aaagcgccaa caccggcaac      240

aacgagcgga tcatcaacgt gtccatcaag aagctgaagc ggaagcctcc tagcaccaat      300

gccggaagaa ggcagaagca cagactgacc tgtcctagct gcgacagcta cgagaagaag      360

cctccaaaag agttcctgga acggttcaag agcctgctgc agaagatgat ccaccagcac      420

ctgagcagca gaacccacgg ctctgaagat tctagcggag gcggaggaag tggtggcgga      480

ggttctggtg gcggtggatc aggcggtggc ggatctggcg gcggaggcag tggcggaggt      540

ggaagcggtg gtggtggctc tggcggaggc ggtagcggcg gaggcggatc tcttcaattg      600

ctgcctagct gggccatcac actgatctcc gtgaacggca tcttcgtgat ctgctgcctg      660

acctactgct tcgcccctag atgcagagag cggagaagaa acgagcggct gagaagagaa      720

tctgtgcggc ctgtt                                                       735


<210>  298
<211>  1431
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  teIL-15/IL21

<400>  298
atggattgga cctggattct gttcctggtg gccgctgcca caagagtgca tagccagggc       60

caagaccggc acatgatccg gatgagacag ctgatcgaca tcgtggacca gctgaagaac      120

tacgtgaacg acctggtgcc tgagttcctg cctgctcctg aggacgtgga aacaaattgc      180

gagtggtccg ccttcagctg cttccagaag gcccagctga aaagcgccaa caccggcaac      240

aacgagcgga tcatcaacgt gtccatcaag aagctgaagc ggaagcctcc tagcaccaat      300

gccggaagaa ggcagaagca cagactgacc tgtcctagct gcgacagcta cgagaagaag      360

cctccaaaag agttcctgga acggttcaag agcctgctgc agaagatgat ccaccagcac      420

ctgagcagca gaacccacgg ctctgaagat tctagcggag gcggaggaag tggtggcgga      480

ggttctggtg gcggtggatc aggcggtggc ggatctggcg gcggaggcag tggcggaggt      540

ggaagcggtg gtggtggctc tggcggaggc ggtagcggcg gaggcggatc tcttcaattg      600

ctgcctagct gggccatcac actgatctcc gtgaacggca tcttcgtgat ctgctgcctg      660

acctactgct tcgcccctag atgcagagag cggagaagaa acgagcggct gagaagagaa      720

tctgtgcggc ctgttagagc caagagatct ggaagcggcg ccaccaactt tagcctgctg      780

aaacaggctg gcgacgtgga agagaaccct ggacctatgg actggacttg gatactcttt      840

ctggtcgctg ccgccacacg ggtgcactct aattgggtca acgtgatcag cgacctgaag      900

aagatcgagg acctgatcca gagcatgcac atcgacgcca cactgtacac cgagtccgat      960

gtgcacccta gctgcaaagt gaccgccatg aagtgctttc tgctggaact gcaagtgatc     1020

agcctggaaa gcggcgacgc cagcatccac gataccgtgg aaaatctgat catcctggcc     1080

aacaacagcc tgtccagcaa cggcaatgtg accgagagcg gctgcaaaga gtgcgaggaa     1140

ctggaagaaa agaacatcaa agagtttctg cagagcttcg tccacatcgt gcagatgttc     1200

atcaacacct catcaggtgg cggtggaagc ggaggtggcg gtagtggcgg cggaggctca     1260

ggcggcggag gttccggcgg aggatctctt cagctcctgc catcttgggc tatcaccctg     1320

attagtgtga atgggatctt tgtcatctgt tgtctcacgt actgtttcgc tccccggtgc     1380

agagagagaa ggcgcaacga aagactgcgg agagaaagcg tcagacccgt g              1431


<210>  299
<211>  2202
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NFAT-Te-IL12 DNA seq

<400>  299
tcgaggtcga cggtatcgat aagcttgata tcgaattagg aggaaaaact gtttcataca       60

gaaggcgtca attaggagga aaaactgttt catacagaag gcgtcaatta ggaggaaaaa      120

ctgtttcata cagaaggcgt caattggtcc catcgaatta ggaggaaaaa ctgtttcata      180

cagaaggcgt caattaggag gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa      240

aactgtttca tacagaaggc gtcaattggt cccgggacat tttgacaccc ccataatatt      300

tttccagaat taacagtata aattgcatct cttgttcaag agttccctat cactctcttt      360

aatcactact cacagtaacc tcaactcctg gccaccatgg attggacctg gattctgttc      420

ctcgtggccg ccgctacccg cgtgcactcc atctgggagc tgaagaaaga cgtgtacgtg      480

gtggaattgg attggtaccc cgacgcccca ggcgagatgg tggttctgac ttgcgacacg      540

ccggaggagg acggcatcac ctggacgctg gaccagagca gcgaagtgct gggctctggt      600

aagaccttaa ccatccaggt caaggagttc ggtgatgcag gacagtacac gtgtcacaag      660

ggcggggagg tcttgtccca tagcctgctg ctcctgcaca agaaggaaga cggcatctgg      720

tctacggata tccttaaaga ccagaaggag cccaagaaca aaaccttcct gcgatgcgag      780

gctaagaatt actccgggcg ctttacctgt tggtggctca caaccatctc gaccgacctg      840

accttctccg tgaagtcttc caggggatct tctgatccgc aaggcgttac ctgcggggcc      900

gctaccctgt cggctgagcg cgtccgtggt gacaacaagg agtacgagta ctcggtggaa      960

tgccaggagg acagcgcctg cccagcggcc gaagagtcct tgcccatcga ggtgatggtg     1020

gacgctgtac acaagctcaa gtacgagaac tacacctcct ccttctttat acgcgacatc     1080

atcaagcctg acccccctaa aaacctgcag ctgaagcccc ttaaaaactc tcgacaggtc     1140

gaggtatcct gggagtaccc cgacacctgg tctactcctc attcgtattt cagcctgacc     1200

ttctgcgtgc aggtgcaggg caagtccaag cgcgagaaga aggaccgcgt gttcaccgac     1260

aaaaccagcg cgactgtcat ttgtcggaag aacgcgagca tctccgtacg ggcacaggat     1320

cgctattact ccagcagttg gtcagagtgg gcttcggttc cgtgttctgg aggaggtggc     1380

ggcggctcac gcaacctgcc cgtggcgacg ccggacccgg gtatgtttcc ttgtctgcac     1440

cactctcaga acttgctccg tgccgtctcg aatatgctgc agaaggcccg ccagactctg     1500

gagttctatc catgcactag tgaggagatc gatcatgagg acatcaccaa ggacaagaca     1560

tccaccgtgg aggcttgtct gccgctggag ttgacaaaga acgagagctg cctcaatagc     1620

cgcgagactt ccttcatcac caacggctcc tgcctcgcga gccgtaagac ctcctttatg     1680

atggcgctgt gcctgtcaag tatctacgaa gatctgaaaa tgtatcaggt ggagttcaaa     1740

actatgaacg caaaactcct gatggatccc aagcgccaaa ttttcttgga ccagaacatg     1800

cttgccgtga tcgacgagct gatgcaggcc ctgaacttca actccgagac cgtccctcag     1860

aagtcgtctc tggaggaacc cgacttttac aagacaaaga tcaagctgtg catcctgcta     1920

cacgcgttcc gcattcgggc cgtgaccatt gaccgcgtga tgtcctacct gaatgcctcg     1980

tccggcgggg ggggctccgg tgggggcggc tctggcggag gcggctcagg tggcggcggc     2040

tccggcggag gttcgcttca gcttctgccc agttgggcaa tcactctgat ttccgtcaac     2100

ggaatcttcg tcatctgctg cctgacctac tgctttgctc ccagatgtag agagcgccgc     2160

cgcaacgagc gcctgcgtcg tgagagcgtg aggcctgtgt ga                        2202


<210>  300
<211>  1014
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NFAT-Te-IL15 DNA seq

<400>  300
tcgaggtcga cggtatcgat aagcttgata tcgaattagg aggaaaaact gtttcataca       60

gaaggcgtca attaggagga aaaactgttt catacagaag gcgtcaatta ggaggaaaaa      120

ctgtttcata cagaaggcgt caattggtcc catcgaatta ggaggaaaaa ctgtttcata      180

cagaaggcgt caattaggag gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa      240

aactgtttca tacagaaggc gtcaattggt cccgggacat tttgacaccc ccataatatt      300

tttccagaat taacagtata aattgcatct cttgttcaag agttccctat cactctcttt      360

aatcactact cacagtaacc tcaactcctg gccaccatgg actggacttg gatactcttt      420

ctggtcgctg ccgccacacg ggtgcactct aattgggtca acgtgatcag cgacctgaag      480

aagatcgagg acctgatcca gagcatgcac atcgacgcca cactgtacac cgagtccgat      540

gtgcacccta gctgcaaagt gaccgccatg aagtgctttc tgctggaact gcaagtgatc      600

agcctggaaa gcggcgacgc cagcatccac gataccgtgg aaaatctgat catcctggcc      660

aacaacagcc tgtccagcaa cggcaatgtg accgagagcg gctgcaaaga gtgcgaggaa      720

ctggaagaaa agaacatcaa agagtttctg cagagcttcg tccacatcgt gcagatgttc      780

atcaacacct catcaggtgg cggtggaagc ggaggtggcg gtagtggcgg cggaggctca      840

ggcggcggag gttccggcgg aggatctctt cagctcctgc catcttgggc tatcaccctg      900

attagtgtga atgggatctt tgtcatctgt tgtctcacgt actgtttcgc tccccggtgc      960

agagagagaa ggcgcaacga aagactgcgg agagaaagcg tcagacccgt gtga           1014


<210>  301
<211>  1134
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NFAT-TeIL21 DNA seq

<400>  301
tcgaggtcga cggtatcgat aagcttgata tcgaattagg aggaaaaact gtttcataca       60

gaaggcgtca attaggagga aaaactgttt catacagaag gcgtcaatta ggaggaaaaa      120

ctgtttcata cagaaggcgt caattggtcc catcgaatta ggaggaaaaa ctgtttcata      180

cagaaggcgt caattaggag gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa      240

aactgtttca tacagaaggc gtcaattggt cccgggacat tttgacaccc ccataatatt      300

tttccagaat taacagtata aattgcatct cttgttcaag agttccctat cactctcttt      360

aatcactact cacagtaacc tcaactcctg gccaccatgg attggacctg gattctgttc      420

ctggtggccg ctgccacaag agtgcatagc cagggccaag accggcacat gatccggatg      480

agacagctga tcgacatcgt ggaccagctg aagaactacg tgaacgacct ggtgcctgag      540

ttcctgcctg ctcctgagga cgtggaaaca aattgcgagt ggtccgcctt cagctgcttc      600

cagaaggccc agctgaaaag cgccaacacc ggcaacaacg agcggatcat caacgtgtcc      660

atcaagaagc tgaagcggaa gcctcctagc accaatgccg gaagaaggca gaagcacaga      720

ctgacctgtc ctagctgcga cagctacgag aagaagcctc caaaagagtt cctggaacgg      780

ttcaagagcc tgctgcagaa gatgatccac cagcacctga gcagcagaac ccacggctct      840

gaagattcta gcggaggcgg aggaagtggt ggcggaggtt ctggtggcgg tggatcaggc      900

ggtggcggat ctggcggcgg aggcagtggc ggaggtggaa gcggtggtgg tggctctggc      960

ggaggcggta gcggcggagg cggatctctt caattgctgc ctagctgggc catcacactg     1020

atctccgtga acggcatctt cgtgatctgc tgcctgacct actgcttcgc ccctagatgc     1080

agagagcgga gaagaaacga gcggctgaga agagaatctg tgcggcctgt ttaa           1134


<210>  302
<211>  1830
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NFAT-TeIL15-IL21 DNA seq

<400>  302
tcgaggtcga cggtatcgat aagcttgata tcgaattagg aggaaaaact gtttcataca       60

gaaggcgtca attaggagga aaaactgttt catacagaag gcgtcaatta ggaggaaaaa      120

ctgtttcata cagaaggcgt caattggtcc catcgaatta ggaggaaaaa ctgtttcata      180

cagaaggcgt caattaggag gaaaaactgt ttcatacaga aggcgtcaat taggaggaaa      240

aactgtttca tacagaaggc gtcaattggt cccgggacat tttgacaccc ccataatatt      300

tttccagaat taacagtata aattgcatct cttgttcaag agttccctat cactctcttt      360

aatcactact cacagtaacc tcaactcctg gccaccatgg attggacctg gattctgttc      420

ctggtggccg ctgccacaag agtgcatagc cagggccaag accggcacat gatccggatg      480

agacagctga tcgacatcgt ggaccagctg aagaactacg tgaacgacct ggtgcctgag      540

ttcctgcctg ctcctgagga cgtggaaaca aattgcgagt ggtccgcctt cagctgcttc      600

cagaaggccc agctgaaaag cgccaacacc ggcaacaacg agcggatcat caacgtgtcc      660

atcaagaagc tgaagcggaa gcctcctagc accaatgccg gaagaaggca gaagcacaga      720

ctgacctgtc ctagctgcga cagctacgag aagaagcctc caaaagagtt cctggaacgg      780

ttcaagagcc tgctgcagaa gatgatccac cagcacctga gcagcagaac ccacggctct      840

gaagattcta gcggaggcgg aggaagtggt ggcggaggtt ctggtggcgg tggatcaggc      900

ggtggcggat ctggcggcgg aggcagtggc ggaggtggaa gcggtggtgg tggctctggc      960

ggaggcggta gcggcggagg cggatctctt caattgctgc ctagctgggc catcacactg     1020

atctccgtga acggcatctt cgtgatctgc tgcctgacct actgcttcgc ccctagatgc     1080

agagagcgga gaagaaacga gcggctgaga agagaatctg tgcggcctgt tagagccaag     1140

agatctggaa gcggcgccac caactttagc ctgctgaaac aggctggcga cgtggaagag     1200

aaccctggac ctatggactg gacttggata ctctttctgg tcgctgccgc cacacgggtg     1260

cactctaatt gggtcaacgt gatcagcgac ctgaagaaga tcgaggacct gatccagagc     1320

atgcacatcg acgccacact gtacaccgag tccgatgtgc accctagctg caaagtgacc     1380

gccatgaagt gctttctgct ggaactgcaa gtgatcagcc tggaaagcgg cgacgccagc     1440

atccacgata ccgtggaaaa tctgatcatc ctggccaaca acagcctgtc cagcaacggc     1500

aatgtgaccg agagcggctg caaagagtgc gaggaactgg aagaaaagaa catcaaagag     1560

tttctgcaga gcttcgtcca catcgtgcag atgttcatca acacctcatc aggtggcggt     1620

ggaagcggag gtggcggtag tggcggcgga ggctcaggcg gcggaggttc cggcggagga     1680

tctcttcagc tcctgccatc ttgggctatc accctgatta gtgtgaatgg gatctttgtc     1740

atctgttgtc tcacgtactg tttcgctccc cggtgcagag agagaaggcg caacgaaaga     1800

ctgcggagag aaagcgtcag acccgtgtaa                                      1830


<210>  303
<211>  601
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-12-Lr1-Ar2

<400>  303

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Ile Trp Glu Leu Lys Lys Asp Val Tyr Val Val Glu Leu Asp 
            20                  25                  30          


Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu Thr Cys Asp Thr 
        35                  40                  45              


Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln Ser Ser Glu Val 
    50                  55                  60                  


Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys Glu Phe Gly Asp 
65                  70                  75                  80  


Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val Leu Ser His Ser 
                85                  90                  95      


Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp Ser Thr Asp Ile 
            100                 105                 110         


Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe Leu Arg Cys Glu 
        115                 120                 125             


Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp Leu Thr Thr Ile 
    130                 135                 140                 


Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg Gly Ser Ser Asp 
145                 150                 155                 160 


Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser Ala Glu Arg Val 
                165                 170                 175     


Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu Cys Gln Glu Asp 
            180                 185                 190         


Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Met Val 
        195                 200                 205             


Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr Ser Ser Phe Phe 
    210                 215                 220                 


Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu Lys 
225                 230                 235                 240 


Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp Glu Tyr Pro Asp 
                245                 250                 255     


Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr Phe Cys Val Gln 
            260                 265                 270         


Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr Asp 
        275                 280                 285             


Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala Ser Ile Ser Val 
    290                 295                 300                 


Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser 
305                 310                 315                 320 


Val Pro Cys Ser Gly Gly Gly Gly Gly Gly Ser Arg Asn Leu Pro Val 
                325                 330                 335     


Ala Thr Pro Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn 
            340                 345                 350         


Leu Leu Arg Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu 
        355                 360                 365             


Glu Phe Tyr Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr 
    370                 375                 380                 


Lys Asp Lys Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr 
385                 390                 395                 400 


Lys Asn Glu Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn 
                405                 410                 415     


Gly Ser Cys Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys 
            420                 425                 430         


Leu Ser Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys 
        435                 440                 445             


Thr Met Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu 
    450                 455                 460                 


Asp Gln Asn Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn 
465                 470                 475                 480 


Phe Asn Ser Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp 
                485                 490                 495     


Phe Tyr Lys Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg 
            500                 505                 510         


Ile Arg Ala Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser 
        515                 520                 525             


Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
    530                 535                 540                 


Gly Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp 
545                 550                 555                 560 


Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu 
                565                 570                 575     


Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg 
            580                 585                 590         


Leu Arg Arg Glu Ser Val Arg Pro Val 
        595                 600     


<210>  304
<211>  1803
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered IL-12-Lr1-Ar2

<400>  304
atggattgga cctggattct gttcctcgtg gccgccgcta cccgcgtgca ctccatctgg       60

gagctgaaga aagacgtgta cgtggtggaa ttggattggt accccgacgc cccaggcgag      120

atggtggttc tgacttgcga cacgccggag gaggacggca tcacctggac gctggaccag      180

agcagcgaag tgctgggctc tggtaagacc ttaaccatcc aggtcaagga gttcggtgat      240

gcaggacagt acacgtgtca caagggcggg gaggtcttgt cccatagcct gctgctcctg      300

cacaagaagg aagacggcat ctggtctacg gatatcctta aagaccagaa ggagcccaag      360

aacaaaacct tcctgcgatg cgaggctaag aattactccg ggcgctttac ctgttggtgg      420

ctcacaacca tctcgaccga cctgaccttc tccgtgaagt cttccagggg atcttctgat      480

ccgcaaggcg ttacctgcgg ggccgctacc ctgtcggctg agcgcgtccg tggtgacaac      540

aaggagtacg agtactcggt ggaatgccag gaggacagcg cctgcccagc ggccgaagag      600

tccttgccca tcgaggtgat ggtggacgct gtacacaagc tcaagtacga gaactacacc      660

tcctccttct ttatacgcga catcatcaag cctgaccccc ctaaaaacct gcagctgaag      720

ccccttaaaa actctcgaca ggtcgaggta tcctgggagt accccgacac ctggtctact      780

cctcattcgt atttcagcct gaccttctgc gtgcaggtgc agggcaagtc caagcgcgag      840

aagaaggacc gcgtgttcac cgacaaaacc agcgcgactg tcatttgtcg gaagaacgcg      900

agcatctccg tacgggcaca ggatcgctat tactccagca gttggtcaga gtgggcttcg      960

gttccgtgtt ctggaggagg tggcggcggc tcacgcaacc tgcccgtggc gacgccggac     1020

ccgggtatgt ttccttgtct gcaccactct cagaacttgc tccgtgccgt ctcgaatatg     1080

ctgcagaagg cccgccagac tctggagttc tatccatgca ctagtgagga gatcgatcat     1140

gaggacatca ccaaggacaa gacatccacc gtggaggctt gtctgccgct ggagttgaca     1200

aagaacgaga gctgcctcaa tagccgcgag acttccttca tcaccaacgg ctcctgcctc     1260

gcgagccgta agacctcctt tatgatggcg ctgtgcctgt caagtatcta cgaagatctg     1320

aaaatgtatc aggtggagtt caaaactatg aacgcaaaac tcctgatgga tcccaagcgc     1380

caaattttct tggaccagaa catgcttgcc gtgatcgacg agctgatgca ggccctgaac     1440

ttcaactccg agaccgtccc tcagaagtcg tctctggagg aacccgactt ttacaagaca     1500

aagatcaagc tgtgcatcct gctacacgcg ttccgcattc gggccgtgac cattgaccgc     1560

gtgatgtcct acctgaatgc ctcgtccggc ggggggggct ccggtggggg cggctctggc     1620

ggaggcggct caggtggcgg cggctccggc ggaggttcgc ttcagcttct gcccagttgg     1680

gcaatcactc tgatttccgt caacggaatc ttcgtcatct gctgcctgac ctactgcttt     1740

gctcccagat gtagagagcg ccgccgcaac gagcgcctgc gtcgtgagag cgtgaggcct     1800

gtg                                                                   1803


<210>  305
<211>  248
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-18-Lr1-Ar2

<400>  305

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn 
            20                  25                  30          


Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe 
        35                  40                  45              


Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile 
    50                  55                  60                  


Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val 
65                  70                  75                  80  


Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn 
                85                  90                  95      


Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp 
            100                 105                 110         


Thr Lys Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp 
        115                 120                 125             


Asn Lys Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala 
    130                 135                 140                 


Cys Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp 
145                 150                 155                 160 


Glu Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp Ser 
                165                 170                 175     


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
            180                 185                 190         


Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala 
        195                 200                 205             


Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr 
    210                 215                 220                 


Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu 
225                 230                 235                 240 


Arg Arg Glu Ser Val Arg Pro Val 
                245             


<210>  306
<211>  744
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-18-Lr1-Ar2

<400>  306

Ala Thr Gly Gly Ala Thr Thr Gly Gly Ala Cys Cys Thr Gly Gly Ala 
1               5                   10                  15      


Thr Thr Thr Thr Gly Thr Thr Cys Cys Thr Gly Gly Thr Gly Gly Cys 
            20                  25                  30          


Thr Gly Cys Ala Gly Cys Cys Ala Cys Thr Cys Gly Gly Gly Thr Cys 
        35                  40                  45              


Cys Ala Cys Ala Gly Cys Thr Ala Cys Thr Thr Cys Gly Gly Cys Ala 
    50                  55                  60                  


Ala Gly Cys Thr Gly Gly Ala Gly Ala Gly Thr Ala Ala Ala Cys Thr 
65                  70                  75                  80  


Thr Thr Cys Cys Gly Thr Gly Ala Thr Cys Cys Gly Cys Ala Ala Cys 
                85                  90                  95      


Cys Thr Cys Ala Ala Cys Gly Ala Cys Cys Ala Ala Gly Thr Gly Cys 
            100                 105                 110         


Thr Gly Thr Thr Cys Ala Thr Thr Gly Ala Cys Cys Ala Gly Gly Gly 
        115                 120                 125             


Cys Ala Ala Cys Cys Gly Cys Cys Cys Cys Cys Thr Cys Thr Thr Thr 
    130                 135                 140                 


Gly Ala Ala Gly Ala Cys Ala Thr Gly Ala Cys Cys Gly Ala Cys Ala 
145                 150                 155                 160 


Gly Cys Gly Ala Thr Thr Gly Thr Cys Gly Thr Gly Ala Cys Ala Ala 
                165                 170                 175     


Thr Gly Cys Gly Cys Cys Cys Cys Gly Cys Ala Cys Cys Ala Thr Cys 
            180                 185                 190         


Thr Thr Thr Ala Thr Ala Ala Thr Thr Thr Cys Cys Ala Thr Gly Thr 
        195                 200                 205             


Ala Cys Ala Ala Gly Gly Ala Thr Ala Gly Cys Cys Ala Gly Cys Cys 
    210                 215                 220                 


Gly Cys Gly Gly Gly Gly Ala Ala Thr Gly Gly Cys Gly Gly Thr Ala 
225                 230                 235                 240 


Ala Cys Gly Ala Thr Cys Thr Cys Gly Gly Thr Gly Ala Ala Gly Thr 
                245                 250                 255     


Gly Thr Gly Ala Ala Ala Ala Ala Ala Thr Cys Thr Cys Gly Ala Cys 
            260                 265                 270         


Cys Cys Thr Gly Thr Cys Ala Thr Gly Cys Gly Ala Gly Ala Ala Cys 
        275                 280                 285             


Ala Ala Gly Ala Thr Cys Ala Thr Thr Thr Cys Cys Thr Thr Cys Ala 
    290                 295                 300                 


Ala Ala Gly Ala Gly Ala Thr Gly Ala Ala Thr Cys Cys Ala Cys Cys 
305                 310                 315                 320 


Cys Gly Ala Cys Ala Ala Cys Ala Thr Cys Ala Ala Gly Gly Ala Cys 
                325                 330                 335     


Ala Cys Cys Ala Ala Gly Thr Cys Cys Gly Ala Cys Ala Thr Cys Ala 
            340                 345                 350         


Thr Cys Thr Thr Cys Thr Thr Cys Cys Ala Gly Cys Gly Cys Ala Gly 
        355                 360                 365             


Cys Gly Thr Gly Cys Cys Thr Gly Gly Gly Cys Ala Thr Gly Ala Cys 
    370                 375                 380                 


Ala Ala Cys Ala Ala Gly Ala Thr Gly Cys Ala Gly Thr Thr Cys Gly 
385                 390                 395                 400 


Ala Gly Ala Gly Cys Thr Cys Gly Thr Cys Thr Thr Ala Cys Gly Ala 
                405                 410                 415     


Gly Gly Gly Cys Thr Ala Thr Thr Thr Cys Cys Thr Gly Gly Cys Cys 
            420                 425                 430         


Thr Gly Cys Gly Ala Gly Ala Ala Gly Gly Ala Gly Cys Gly Thr Gly 
        435                 440                 445             


Ala Cys Cys Thr Gly Thr Thr Cys Ala Ala Gly Cys Thr Thr Ala Thr 
    450                 455                 460                 


Cys Cys Thr Gly Ala Ala Gly Ala Ala Gly Gly Ala Gly Gly Ala Cys 
465                 470                 475                 480 


Gly Ala Gly Cys Thr Gly Gly Gly Gly Gly Ala Cys Cys Gly Cys Ala 
                485                 490                 495     


Gly Cys Ala Thr Cys Ala Thr Gly Thr Thr Thr Ala Cys Ala Gly Thr 
            500                 505                 510         


Gly Cys Ala Gly Ala Ala Cys Gly Ala Gly Gly Ala Thr Thr Cys Thr 
        515                 520                 525             


Gly Gly Thr Gly Gly Cys Gly Gly Cys Gly Gly Thr Ala Gly Cys Gly 
    530                 535                 540                 


Gly Gly Gly Gly Cys Gly Gly Gly Gly Gly Thr Thr Cys Thr Gly Gly 
545                 550                 555                 560 


Cys Gly Gly Cys Gly Gly Ala Gly Gly Cys Thr Cys Cys Gly Gly Thr 
                565                 570                 575     


Gly Gly Ala Gly Gly Ala Gly Gly Cys Thr Cys Cys Gly Gly Cys Gly 
            580                 585                 590         


Gly Cys Gly Gly Thr Thr Cys Gly Thr Thr Gly Cys Ala Gly Cys Thr 
        595                 600                 605             


Gly Cys Thr Gly Cys Cys Cys Ala Gly Thr Thr Gly Gly Gly Cys Cys 
    610                 615                 620                 


Ala Thr Cys Ala Cys Thr Cys Thr Ala Ala Thr Cys Thr Cys Cys Gly 
625                 630                 635                 640 


Thr Cys Ala Ala Cys Gly Gly Cys Ala Thr Cys Thr Thr Cys Gly Thr 
                645                 650                 655     


Cys Ala Thr Cys Thr Gly Thr Thr Gly Cys Cys Thr Gly Ala Cys Cys 
            660                 665                 670         


Thr Ala Cys Thr Gly Cys Thr Thr Thr Gly Cys Thr Cys Cys Gly Ala 
        675                 680                 685             


Gly Gly Thr Gly Thr Ala Gly Ala Gly Ala Gly Cys Gly Ala Cys Gly 
    690                 695                 700                 


Cys Cys Gly Cys Ala Ala Cys Gly Ala Gly Cys Gly Cys Cys Thr Cys 
705                 710                 715                 720 


Cys Gly Cys Cys Gly Thr Gly Ala Gly Thr Cys Cys Gly Thr Gly Cys 
                725                 730                 735     


Gly Cys Cys Cys Thr Gly Thr Thr 
            740                 


<210>  307
<211>  247
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered DR-IL-18 (6-27 variant)-Lr1-Ar2

<400>  307

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn 
            20                  25                  30          


Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe 
        35                  40                  45              


Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile 
    50                  55                  60                  


Phe Ile Ile Ser Lys Tyr Ser Asp Ser Arg Ala Arg Gly Leu Ala Val 
65                  70                  75                  80  


Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn 
                85                  90                  95      


Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp 
            100                 105                 110         


Thr Lys Ser Asp Ile Ile Phe Phe Ala Arg Val Pro Gly His Gly Arg 
        115                 120                 125             


Lys Thr Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys 
    130                 135                 140                 


Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu 
145                 150                 155                 160 


Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp Ser Gly 
                165                 170                 175     


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
            180                 185                 190         


Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile 
        195                 200                 205             


Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr 
    210                 215                 220                 


Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg 
225                 230                 235                 240 


Arg Glu Ser Val Arg Pro Val 
                245         


<210>  308
<211>  741
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered DR-IL-18 (6-27 variant)-Lr1-Ar2

<400>  308
atggattgga cctggatcct gttcctggtg gcggcggcaa ctcgcgtaca tagctatttc       60

ggcaagctgg agagcaaact atcagtgatc cgcaacctca acgaccaggt cttgtttatt      120

gaccagggca accgccccct gttcgaagac atgacagaca gcgattgtcg cgacaatgct      180

cctcgcacca tctttatcat ctccaagtac tccgattctc gagccagagg tctcgccgtg      240

accatctccg tgaagtgcga gaagatatcc actctttcat gcgagaacaa gatcatttcc      300

ttcaaggaga tgaatccacc cgacaacatc aaggacacca agtccgacat catcttcttc      360

gctcgtgtgc ctggccacgg ccgcaagacc cagttcgaga gttccagcta cgagggctac      420

ttcctggcct gtgagaaaga gcgggacctt ttcaaattga ttctgaagaa ggaggacgag      480

ctgggcgacc gtagcatcat gtttacggtg cagaacgagg attctggcgg gggcggttct      540

ggagggggtg ggtcgggcgg tggtggctcc gggggaggcg gctccggagg aggctcgctg      600

cagctgctgc ccagttgggc catcacgctc atttctgtca acggcatctt cgtcatctgt      660

tgcctgacct actgctttgc tccgaggtgt agggaacgtc gtcgcaacga gcgcctgcgc      720

cgcgagtctg ttcggccggt g                                                741


<210>  309
<211>  833
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-12/IL-15

<400>  309

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Ile Trp Glu Leu Lys Lys Asp Val Tyr Val Val Glu Leu Asp 
            20                  25                  30          


Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu Thr Cys Asp Thr 
        35                  40                  45              


Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln Ser Ser Glu Val 
    50                  55                  60                  


Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys Glu Phe Gly Asp 
65                  70                  75                  80  


Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val Leu Ser His Ser 
                85                  90                  95      


Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp Ser Thr Asp Ile 
            100                 105                 110         


Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe Leu Arg Cys Glu 
        115                 120                 125             


Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp Leu Thr Thr Ile 
    130                 135                 140                 


Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg Gly Ser Ser Asp 
145                 150                 155                 160 


Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser Ala Glu Arg Val 
                165                 170                 175     


Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu Cys Gln Glu Asp 
            180                 185                 190         


Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Met Val 
        195                 200                 205             


Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr Ser Ser Phe Phe 
    210                 215                 220                 


Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu Lys 
225                 230                 235                 240 


Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp Glu Tyr Pro Asp 
                245                 250                 255     


Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr Phe Cys Val Gln 
            260                 265                 270         


Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr Asp 
        275                 280                 285             


Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala Ser Ile Ser Val 
    290                 295                 300                 


Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser 
305                 310                 315                 320 


Val Pro Cys Ser Gly Gly Gly Gly Gly Gly Ser Arg Asn Leu Pro Val 
                325                 330                 335     


Ala Thr Pro Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn 
            340                 345                 350         


Leu Leu Arg Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu 
        355                 360                 365             


Glu Phe Tyr Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr 
    370                 375                 380                 


Lys Asp Lys Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr 
385                 390                 395                 400 


Lys Asn Glu Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn 
                405                 410                 415     


Gly Ser Cys Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys 
            420                 425                 430         


Leu Ser Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys 
        435                 440                 445             


Thr Met Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu 
    450                 455                 460                 


Asp Gln Asn Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn 
465                 470                 475                 480 


Phe Asn Ser Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp 
                485                 490                 495     


Phe Tyr Lys Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg 
            500                 505                 510         


Ile Arg Ala Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser 
        515                 520                 525             


Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
    530                 535                 540                 


Gly Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp 
545                 550                 555                 560 


Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu 
                565                 570                 575     


Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg 
            580                 585                 590         


Leu Arg Arg Glu Ser Val Arg Pro Val Arg Ala Lys Arg Ser Gly Ser 
        595                 600                 605             


Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu 
    610                 615                 620                 


Asn Pro Gly Pro Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala 
625                 630                 635                 640 


Ala Thr Arg Val His Ser Asn Trp Val Asn Val Ile Ser Asp Leu Lys 
                645                 650                 655     


Lys Ile Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr 
            660                 665                 670         


Thr Glu Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys 
        675                 680                 685             


Phe Leu Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser 
    690                 695                 700                 


Ile His Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu 
705                 710                 715                 720 


Ser Ser Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu 
                725                 730                 735     


Leu Glu Glu Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile 
            740                 745                 750         


Val Gln Met Phe Ile Asn Thr Ser Ser Gly Gly Gly Gly Ser Gly Gly 
        755                 760                 765             


Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
    770                 775                 780                 


Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn 
785                 790                 795                 800 


Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys 
                805                 810                 815     


Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro 
            820                 825                 830         


Val 
    


<210>  310
<211>  2499
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered IL-12/IL-15

<400>  310
atggattgga cctggattct gtttttggtg gcggccgcca cccgcgtcca ttccatatgg       60

gaattaaaga aggacgtgta cgtggtggag cttgactggt accctgacgc tcccggcgag      120

atggtggtcc tgacctgcga tacccccgag gaggacggca tcacctggac cctggaccag      180

agctccgagg tgctgggaag cggtaaaacc ctcaccatac aggtgaagga gttcggtgat      240

gctggccagt acacctgtca caaaggcggg gaggtacttt cccattcgct gctcctgctt      300

cacaagaagg aagacggcat ttggtcgacc gatattctga aggaccagaa ggaaccaaaa      360

aacaagacct ttttgcgttg cgaggccaag aactattccg gccgcttcac ctgctggtgg      420

ctaacgacca tctcaaccga cctgaccttc tccgttaagt ctagccgtgg tagctccgac      480

cctcaggggg taacctgcgg ggctgcgacg ctgagtgcgg agcgggtacg cggcgacaac      540

aaggagtacg agtactccgt ggaatgtcag gaggatagtg cctgcccagc ggccgaggag      600

tccctgccca tcgaggtaat ggtggacgcg gtccacaagc tgaagtacga gaactacact      660

agctccttct ttattagaga catcatcaag cccgacccgc ctaagaacct gcagctgaaa      720

cctctcaaaa actcccgcca ggttgaagtg tcgtgggagt accctgacac ctggtctaca      780

ccgcacagct atttctcgct tacattctgc gtgcaggtgc agggcaaatc caagcgcgag      840

aagaaagacc gcgtgttcac cgacaaaacc tctgctacag tgatctgccg aaagaatgct      900

tctatctccg tgcgtgctca ggaccgctac tactcatcaa gctggagtga gtgggcctcc      960

gtgccatgtt ccgggggggg cggcggtggc tcccgcaacc tgcccgttgc aacgcccgac     1020

ccgggtatgt tcccatgcct gcaccactcc cagaatctgt tacgtgctgt aagcaatatg     1080

cttcagaagg ctcgccagac tctggagttc tacccctgca cttcggagga gatcgaccac     1140

gaagacatca ccaaggacaa gacatccacc gtggaggcgt gcctcccttt ggagctcaca     1200

aagaacgagt cctgtctaaa ctcaagggag actagcttca tcactaatgg atcgtgtctg     1260

gcgtcgcgca agacctcttt catgatggcc ctgtgcctgt ccagcatcta tgaggacctt     1320

aaaatgtatc aggtcgagtt caagactatg aacgcaaagc tgctgatgga tcccaagcgg     1380

caaattttcc tggaccagaa catgctggcg gtgatcgacg agctgatgca ggccctcaac     1440

ttcaacagcg aaactgttcc tcagaagtcc tccctggagg agccggactt ttacaagacc     1500

aagatcaagc tatgtatttt gttacacgcc ttccgcatcc gcgctgtcac tattgaccgc     1560

gtgatgtctt acctgaacgc atctagtggg ggcggaggtt ccgggggagg cggctctggc     1620

ggtggcggct ctggcggtgg tggttcagga ggcgggtccc ttcagctgct cccgtcgtgg     1680

gccatcacac tgatctctgt gaacggcatc ttcgtcatct gttgtcttac ttactgcttt     1740

gcccccaggt gtagggagag acgccgcaat gaacggctga ggcgtgagag cgtgcgcccg     1800

gtgagggcta agcgcagcgg ctccggcgcg accaactttt cgctgctgaa gcaggccggg     1860

gacgtggagg agaatccagg cccgatggat tggacctgga tcctgttctt ggtggccgcg     1920

gctactcggg tgcactctaa ttgggtcaac gtgatctccg acttgaaaaa gatcgaggat     1980

ctgatccaga gcatgcatat cgacgccacg ctgtacaccg agagcgatgt gcacccctct     2040

tgcaaggtga ccgccatgaa gtgctttctg ctggagctgc aggtcatctc tcttgagtcg     2100

ggcgatgcat ctattcatga caccgtcgag aacctaatca tcctggccaa caactcactg     2160

tcttcaaacg gcaacgtgac ggagtctggg tgcaaggaat gtgaggaatt ggaggagaaa     2220

aacatcaagg agttcctgca gtccttcgtc cacatcgtgc agatgtttat taacacgagt     2280

agtggcggag gtggcagcgg aggcggcggc tccggcggtg gaggaagtgg aggcggcggc     2340

tctggtggcg gttccctaca attgcttccc tcttgggcta tcaccctcat cagcgtcaac     2400

ggtatcttcg tcatctgttg tctgacctac tgctttgccc ctcgatgccg agagcgccgt     2460

cgcaacgagc gcctgcgccg ggagtccgtg cgccccgtt                            2499


<210>  311
<211>  480
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-18/IL-15

<400>  311

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn 
            20                  25                  30          


Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe 
        35                  40                  45              


Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile 
    50                  55                  60                  


Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val 
65                  70                  75                  80  


Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn 
                85                  90                  95      


Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp 
            100                 105                 110         


Thr Lys Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp 
        115                 120                 125             


Asn Lys Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala 
    130                 135                 140                 


Cys Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp 
145                 150                 155                 160 


Glu Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp Ser 
                165                 170                 175     


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
            180                 185                 190         


Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala 
        195                 200                 205             


Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr 
    210                 215                 220                 


Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu 
225                 230                 235                 240 


Arg Arg Glu Ser Val Arg Pro Val Arg Ala Lys Arg Ser Gly Ser Gly 
                245                 250                 255     


Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn 
            260                 265                 270         


Pro Gly Pro Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala 
        275                 280                 285             


Thr Arg Val His Ser Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys 
    290                 295                 300                 


Ile Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr 
305                 310                 315                 320 


Glu Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe 
                325                 330                 335     


Leu Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile 
            340                 345                 350         


His Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser 
        355                 360                 365             


Ser Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu 
    370                 375                 380                 


Glu Glu Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val 
385                 390                 395                 400 


Gln Met Phe Ile Asn Thr Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 
                405                 410                 415     


Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser 
            420                 425                 430         


Leu Gln Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly 
        435                 440                 445             


Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg 
    450                 455                 460                 


Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val 
465                 470                 475                 480 


<210>  312
<211>  1440
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered IL-18/IL-15

<400>  312
atggattgga cctggatcct tttcttggtg gcggctgcaa cccgggttca tagctatttc       60

ggcaagctgg agtccaagct ctccgtgatc cgcaacctca acgaccaggt gctgttcatc      120

gaccagggca accgccccct gtttgaggac atgacagatt ctgattgccg cgacaacgcg      180

ccgcgcacca tcttcattat ctctatgtac aaggactccc agccacgtgg tatggccgtc      240

acgatcagcg tgaagtgcga gaagatttct accctgtcct gcgagaacaa gatcatctcg      300

ttcaaggaga tgaaccctcc cgacaatatc aaggacacca agtccgacat catcttcttc      360

cagcgatcag tgccaggcca cgacaacaag atgcagttcg agagcagcag ctacgagggc      420

tacttccttg cgtgcgagaa agagcgcgat ctgttcaaac tgatcctcaa gaaggaagac      480

gagctcgggg accgcagcat catgtttacc gtacagaacg aggacagcgg cggcggcggc      540

tccggtggag gcggtagtgg cggaggcggc tcaggcggcg gcggctccgg aggtgggtcg      600

ttgcagctct tgccgagttg ggctatcact cttatctccg taaacggcat cttcgtgata      660

tgctgcctga cgtactgttt tgctcctagg tgtcgcgagc gccgccggaa cgagagactg      720

cgacgggaat ccgtgcgccc ggtccgcgcg aagcgtagtg gctccggtgc taccaacttt      780

tctctgctga agcaggccgg cgacgtggag gagaatcccg gccctatgga ctggacatgg      840

atcctgttcc tggtggctgc ggccacccgc gtccactcaa attgggtcaa tgtgatttct      900

gacctgaaga aaattgagga tctcatccag tccatgcaca ttgacgccac tctgtacacc      960

gagagcgatg ttcacccctc ttgtaaggtg accgccatga aatgtttcct gttggagctg     1020

caggtcattt cgctcgagtc tggcgacgca tcgatccatg acaccgtgga gaacctgatt     1080

atcctggcca acaactccct ttcttcaaat ggcaacgtga ctgaaagcgg gtgcaaagag     1140

tgtgaggagc tggaagaaaa gaacatcaaa gagttcctgc aatctttcgt ccacattgtg     1200

cagatgttta ttaacacgtc ctcgggtggc ggggggtcgg gcgggggtgg ttccggcgga     1260

ggcgggtccg gaggaggggg ctctggtggg ggatccctac agctactgcc ctcttgggcc     1320

atcaccctta tctccgtcaa cggtatcttc gtgatctgtt gcctgactta ctgctttgcc     1380

ccgagatgtc gtgagcgtag gaggaacgag cgcctgcgcc gcgagagcgt gcgtcccgtg     1440


<210>  313
<211>  339
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (APX005M)

<400>  313

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro 
            20                  25                  30          


Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser 
        35                  40                  45              


Ser Thr Tyr Val Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 
    50                  55                  60                  


Trp Ile Ala Cys Ile Tyr Thr Gly Asp Gly Thr Asn Tyr Ser Ala Ser 
65                  70                  75                  80  


Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Asp Ser Ser Lys Asn Thr 
                85                  90                  95      


Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
            100                 105                 110         


Phe Cys Ala Arg Pro Asp Ile Thr Tyr Gly Phe Ala Ile Asn Phe Trp 
        115                 120                 125             


Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 
    130                 135                 140                 


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 
145                 150                 155                 160 


Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg 
                165                 170                 175     


Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Arg Leu Ala 
            180                 185                 190         


Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Lys Leu Leu Ile Tyr Arg 
        195                 200                 205             


Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 
    210                 215                 220                 


Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp 
225                 230                 235                 240 


Val Ala Thr Tyr Tyr Cys Gln Cys Thr Gly Tyr Gly Ile Ser Trp Pro 
                245                 250                 255     


Ile Gly Gly Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser 
            260                 265                 270         


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
        275                 280                 285             


Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser 
    290                 295                 300                 


Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro 
305                 310                 315                 320 


Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val 
                325                 330                 335     


Arg Pro Val 
            


<210>  314
<211>  1017
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (APX005M)

<400>  314

Ala Thr Gly Gly Ala Thr Thr Gly Gly Ala Cys Cys Thr Gly Gly Ala 
1               5                   10                  15      


Thr Cys Cys Thr Gly Thr Thr Cys Cys Thr Gly Gly Thr Gly Gly Cys 
            20                  25                  30          


Gly Gly Cys Cys Gly Cys Thr Ala Cys Ala Cys Gly Ala Gly Thr Cys 
        35                  40                  45              


Cys Ala Cys Ala Gly Cys Cys Ala Gly Gly Thr Cys Cys Ala Gly Cys 
    50                  55                  60                  


Thr Cys Gly Thr Gly Gly Ala Gly Ala Gly Cys Gly Gly Ala Gly Gly 
65                  70                  75                  80  


Cys Gly Gly Cys Gly Thr Gly Gly Thr Gly Cys Ala Gly Cys Cys Ala 
                85                  90                  95      


Gly Gly Cys Cys Gly Cys Thr Cys Gly Cys Thr Gly Cys Gly Cys Cys 
            100                 105                 110         


Thr Gly Thr Cys Ala Thr Gly Cys Gly Cys Ala Gly Cys Gly Thr Cys 
        115                 120                 125             


Cys Gly Gly Thr Thr Thr Cys Thr Cys Cys Thr Thr Cys Thr Cys Gly 
    130                 135                 140                 


Thr Cys Gly Ala Cys Cys Thr Ala Cys Gly Thr Gly Thr Gly Cys Thr 
145                 150                 155                 160 


Gly Gly Gly Thr Cys Cys Gly Cys Cys Ala Gly Gly Cys Cys Cys Cys 
                165                 170                 175     


Thr Gly Gly Cys Ala Ala Ala Gly Gly Cys Cys Thr Gly Gly Ala Gly 
            180                 185                 190         


Thr Gly Gly Ala Thr Thr Gly Cys Thr Thr Gly Thr Ala Thr Thr Thr 
        195                 200                 205             


Ala Thr Ala Cys Cys Gly Gly Cys Gly Ala Cys Gly Gly Cys Ala Cys 
    210                 215                 220                 


Cys Ala Ala Cys Thr Ala Cys Ala Gly Cys Gly Cys Ala Ala Gly Thr 
225                 230                 235                 240 


Thr Gly Gly Gly Cys Cys Ala Ala Gly Gly Gly Cys Cys Gly Thr Thr 
                245                 250                 255     


Thr Cys Ala Cys Cys Ala Thr Cys Thr Cys Cys Ala Ala Gly Gly Ala 
            260                 265                 270         


Thr Ala Gly Thr Ala Gly Cys Ala Ala Gly Ala Ala Cys Ala Cys Gly 
        275                 280                 285             


Gly Thr Ala Thr Ala Cys Cys Thr Gly Cys Ala Gly Ala Thr Gly Ala 
    290                 295                 300                 


Ala Cys Thr Cys Thr Cys Thr Thr Cys Gly Cys Gly Cys Cys Gly Ala 
305                 310                 315                 320 


Gly Gly Ala Cys Ala Cys Cys Gly Cys Cys Gly Thr Gly Thr Ala Thr 
                325                 330                 335     


Thr Thr Cys Thr Gly Thr Gly Cys Cys Cys Gly Gly Cys Cys Cys Gly 
            340                 345                 350         


Ala Cys Ala Thr Cys Ala Cys Thr Thr Ala Thr Gly Gly Cys Thr Thr 
        355                 360                 365             


Cys Gly Cys Gly Ala Thr Thr Ala Ala Cys Thr Thr Thr Thr Gly Gly 
    370                 375                 380                 


Gly Gly Cys Cys Cys Thr Gly Gly Ala Ala Cys Cys Cys Thr Gly Gly 
385                 390                 395                 400 


Thr Gly Ala Cys Cys Gly Thr Gly Thr Cys Cys Thr Cys Cys Gly Gly 
                405                 410                 415     


Cys Gly Gly Cys Gly Gly Thr Gly Gly Cys Thr Cys Thr Gly Gly Gly 
            420                 425                 430         


Gly Gly Gly Gly Gly Cys Gly Gly Gly Thr Cys Cys Gly Gly Cys Gly 
        435                 440                 445             


Gly Ala Gly Gly Cys Gly Gly Cys Ala Gly Cys Gly Gly Ala Gly Gly 
    450                 455                 460                 


Cys Gly Gly Cys Gly Gly Cys Thr Cys Cys Gly Ala Cys Ala Thr Cys 
465                 470                 475                 480 


Cys Ala Gly Ala Thr Gly Ala Cys Cys Cys Ala Gly Thr Cys Gly Cys 
                485                 490                 495     


Cys Cys Ala Gly Thr Thr Cys Thr Thr Thr Gly Thr Cys Cys Gly Cys 
            500                 505                 510         


Thr Thr Cys Cys Gly Thr Gly Gly Gly Gly Gly Ala Cys Ala Gly Gly 
        515                 520                 525             


Gly Thr Cys Ala Cys Cys Ala Thr Ala Ala Ala Gly Thr Gly Cys Cys 
    530                 535                 540                 


Ala Gly Gly Cys Thr Thr Cys Thr Cys Ala Gly Ala Gly Cys Ala Thr 
545                 550                 555                 560 


Cys Thr Cys Gly Thr Cys Cys Cys Gly Cys Cys Thr Gly Gly Cys Gly 
                565                 570                 575     


Thr Gly Gly Thr Ala Cys Cys Ala Gly Cys Ala Gly Ala Ala Gly Cys 
            580                 585                 590         


Cys Cys Gly Gly Gly Ala Ala Gly Cys Cys Cys Cys Cys Ala Ala Ala 
        595                 600                 605             


Gly Cys Thr Gly Cys Thr Cys Ala Thr Cys Thr Ala Cys Cys Gly Gly 
    610                 615                 620                 


Gly Cys Thr Thr Cys Cys Ala Cys Thr Cys Thr Gly Gly Cys Cys Ala 
625                 630                 635                 640 


Gly Cys Gly Gly Thr Gly Thr Thr Cys Cys Thr Thr Cys Cys Cys Gly 
                645                 650                 655     


Cys Thr Thr Cys Thr Cys Thr Gly Gly Cys Thr Cys Cys Gly Gly Gly 
            660                 665                 670         


Thr Cys Gly Gly Gly Cys Ala Cys Thr Gly Ala Cys Thr Thr Thr Ala 
        675                 680                 685             


Cys Ala Thr Thr Gly Ala Cys Gly Ala Thr Cys Thr Cys Thr Thr Cys 
    690                 695                 700                 


Gly Cys Thr Thr Cys Ala Gly Cys Cys Gly Gly Ala Ala Gly Ala Thr 
705                 710                 715                 720 


Gly Thr Ala Gly Cys Thr Ala Cys Thr Thr Ala Cys Thr Ala Cys Thr 
                725                 730                 735     


Gly Thr Cys Ala Ala Thr Gly Cys Ala Cys Thr Gly Gly Cys Thr Ala 
            740                 745                 750         


Cys Gly Gly Cys Ala Thr Cys Ala Gly Thr Thr Gly Gly Cys Cys Cys 
        755                 760                 765             


Ala Thr Cys Gly Gly Thr Gly Gly Ala Gly Gly Cys Ala Cys Cys Ala 
    770                 775                 780                 


Ala Gly Gly Thr Gly Gly Ala Gly Ala Thr Cys Ala Ala Ala Ala Gly 
785                 790                 795                 800 


Cys Gly Gly Gly Gly Gly Ala Gly Gly Cys Gly Gly Thr Thr Cys Thr 
                805                 810                 815     


Gly Gly Cys Gly Gly Thr Gly Gly Ala Gly Gly Gly Thr Cys Thr Gly 
            820                 825                 830         


Gly Cys Gly Gly Gly Gly Gly Thr Gly Gly Cys Thr Cys Cys Gly Gly 
        835                 840                 845             


Gly Gly Gly Cys Gly Gly Thr Gly Gly Thr Ala Gly Cys Gly Gly Thr 
    850                 855                 860                 


Gly Gly Thr Gly Gly Ala Thr Cys Cys Cys Thr Ala Cys Ala Gly Cys 
865                 870                 875                 880 


Thr Gly Cys Thr Gly Cys Cys Cys Thr Cys Thr Thr Gly Gly Gly Cys 
                885                 890                 895     


Cys Ala Thr Cys Ala Cys Gly Cys Thr Cys Ala Thr Thr Thr Cys Ala 
            900                 905                 910         


Gly Thr Thr Ala Ala Thr Gly Gly Cys Ala Thr Cys Thr Thr Cys Gly 
        915                 920                 925             


Thr Cys Ala Thr Cys Thr Gly Cys Thr Gly Cys Cys Thr Gly Ala Cys 
    930                 935                 940                 


Cys Thr Ala Cys Thr Gly Cys Thr Thr Thr Gly Cys Gly Cys Cys Gly 
945                 950                 955                 960 


Ala Gly Gly Thr Gly Thr Ala Gly Ala Gly Ala Gly Cys Gly Gly Cys 
                965                 970                 975     


Gly Thr Cys Gly Cys Ala Ala Cys Gly Ala Gly Cys Gly Cys Cys Thr 
            980                 985                 990         


Gly Cys Gly Thr Cys Gly Cys Gly  Ala Gly Ala Gly Cys  Gly Thr Gly 
        995                 1000                 1005             


Cys Gly  Cys Cys Cys Gly Gly  Thr Gly 
    1010                 1015         


<210>  315
<211>  337
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (Dacetuzumab)

<400>  315

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 
            20                  25                  30          


Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr 
        35                  40                  45              


Gly Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 
    50                  55                  60                  


Trp Val Ala Arg Val Ile Pro Asn Ala Gly Gly Thr Ser Tyr Asn Gln 
65                  70                  75                  80  


Lys Phe Lys Gly Arg Phe Thr Leu Ser Val Asp Asn Ser Lys Asn Thr 
                85                  90                  95      


Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
            100                 105                 110         


Tyr Cys Ala Arg Glu Gly Ile Tyr Trp Trp Gly Gln Gly Thr Leu Val 
        115                 120                 125             


Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
    130                 135                 140                 


Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 
145                 150                 155                 160 


Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 
                165                 170                 175     


Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Phe Leu His Trp 
            180                 185                 190         


Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Thr Val 
        195                 200                 205             


Ser Asn Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser 
    210                 215                 220                 


Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe 
225                 230                 235                 240 


Ala Thr Tyr Phe Cys Ser Gln Thr Thr His Val Pro Trp Thr Phe Gly 
                245                 250                 255     


Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Ser Gly Gly 
            260                 265                 270         


Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
        275                 280                 285             


Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn 
    290                 295                 300                 


Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys 
305                 310                 315                 320 


Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro 
                325                 330                 335     


Val 
    


<210>  316
<211>  1011
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (Dacetuzumab)

<400>  316
atggattgga cctggatcct gttcctggtg gcggcggcta cacgtgtgca ctccgaggtg       60

cagttggtgg agagcggcgg tggtctggtg cagccgggcg ggagcctgcg cctgtcgtgc      120

gccgcttccg gctactcctt caccggttat tacatccact gggtgcgaca ggccccgggc      180

aaaggcctgg agtgggtcgc tcgcgtaatt cctaacgcgg gtggcaccag ctacaaccag      240

aaatttaagg gcagattcac cctcagcgtt gacaactcca agaacacggc ctacctgcag      300

atgaactccc ttcgcgccga ggacaccgcc gtgtactact gtgctcgcga gggcatctat      360

tggtggggcc agggaactct agttaccgtg tcctccggcg gcggcggctc gggcggcggg      420

ggttctggtg ggggcggttc cggaggggga gggtccgaca tccagatgac ccagagcccc      480

tctagtctga gcgcatccgt gggggacagg gtcaccatca cctgccgctc gtcacaatcg      540

cttgtccact caaatggcaa cactttcctg cattggtacc agcagaagcc cggcaaggcg      600

cccaagctgc tcatctacac cgtgagcaac cgcttttcag gcgtgccatc ccgcttctct      660

ggctccggct ccggtacaga tttcaccctt accattagct cgttgcagcc agaagacttt      720

gccacctatt tctgttctca gacgactcac gtcccgtgga ccttcggaca gggcaccaag      780

gtggagatca agagcggcgg aggtgggagt ggaggcggcg ggtccggagg gggcggttct      840

ggcggcggtg gttctggcgg agggtctctg cagctgctac ccagttgggc catcactctc      900

atttctgtca acggcatctt cgtcatatgt tgcctgacct actgctttgc tcctaggtgt      960

cgtgagcgcc gccgcaacga gcggttgcgg cgtgaatccg tgcgccctgt a              1011


<210>  317
<211>  343
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (Lucatutuzumab)

<400>  317

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro 
            20                  25                  30          


Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 
        35                  40                  45              


Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 
    50                  55                  60                  


Trp Val Ala Val Ile Ser Tyr Glu Glu Ser Asn Arg Tyr His Ala Asp 
65                  70                  75                  80  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ile Thr 
                85                  90                  95      


Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr 
            100                 105                 110         


Tyr Cys Ala Arg Asp Gly Gly Ile Ala Ala Pro Gly Pro Asp Tyr Trp 
        115                 120                 125             


Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 
    130                 135                 140                 


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 
145                 150                 155                 160 


Val Met Thr Gln Ser Pro Leu Ser Leu Thr Val Thr Pro Gly Glu Pro 
                165                 170                 175     


Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly 
            180                 185                 190         


Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln 
        195                 200                 205             


Val Leu Ile Ser Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg 
    210                 215                 220                 


Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg 
225                 230                 235                 240 


Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Arg Gln 
                245                 250                 255     


Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Arg Ser Gly 
            260                 265                 270         


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
        275                 280                 285             


Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile 
    290                 295                 300                 


Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr 
305                 310                 315                 320 


Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg 
                325                 330                 335     


Arg Glu Ser Val Arg Pro Val 
            340             


<210>  318
<211>  1029
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (Lucatutuzumab)

<400>  318
atggactgga cctggatcct gttcctggtc gcagcggcca cccgcgtaca ttctcaggtg       60

cagctggtgg aatccggggg tggcgtggtg caaccaggcc gtagcctgcg cctgagctgt      120

gctgcgtccg gctttacttt ttcgtcttac ggcatgcact gggtgcgcca ggccccgggt      180

aaaggcttgg agtgggtcgc ggttatcagc tatgaggaga gcaaccgcta ccacgcggac      240

tccgtgaagg gccgattcac catctcgcgg gacaactcca agataaccct gtacctgcag      300

atgaactctc tgcggactga agacaccgcc gtgtactact gtgcccgcga tggcggaatc      360

gccgctcccg ggcccgacta ttggggccag ggcacactcg ttaccgtctc ctcgggaggc      420

ggcggcagtg gtggtggagg ttccggcggc gggggctccg ggggtggcgg ctctgacatc      480

gtgatgacgc agagcccttt gagcctaaca gttacccccg gggagcccgc ttcgatttca      540

tgccgctcct cccagagcct gctgtactca aatggctaca actacctgga ctggtacctc      600

cagaagccgg gtcagtcccc tcaggtgctc atctcgttgg gcagcaacag ggcctctggc      660

gtgccagacc gcttctccgg atctggcagc ggaaccgatt tcaccctgaa gatctctaga      720

gtggaggctg aggacgtggg cgtgtattac tgtatgcagg cccgacagac tcccttcacc      780

ttcggccccg ggaccaaggt ggatatccgc tcgggaggcg gcggcagcgg tgggggaggc      840

agcggtggtg gcggatccgg ggggggcggc tctggtggcg gatccctcca gctgctgccg      900

agttgggcta tcactcttat ttccgtaaat gggattttcg tcatctgctg ccttacctac      960

tgctttgcac ctagatgtcg cgagcgtagg cgcaacgagc ggcttcgtcg cgagtccgtc     1020

cgccctgtc                                                             1029


<210>  319
<211>  344
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (Selicrelumab)

<400>  319

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro 
            20                  25                  30          


Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr 
        35                  40                  45              


Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu 
    50                  55                  60                  


Trp Met Gly Trp Ile Asn Pro Asp Ser Gly Gly Thr Asn Tyr Ala Gln 
65                  70                  75                  80  


Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr 
                85                  90                  95      


Ala Tyr Met Glu Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr 
            100                 105                 110         


Tyr Cys Ala Arg Asp Gln Pro Leu Gly Tyr Cys Thr Asn Gly Val Cys 
        115                 120                 125             


Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
    130                 135                 140                 


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
145                 150                 155                 160 


Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser 
                165                 170                 175     


Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly 
            180                 185                 190         


Ile Tyr Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 
        195                 200                 205             


Asn Leu Leu Ile Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser 
    210                 215                 220                 


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
225                 230                 235                 240 


Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn 
                245                 250                 255     


Ile Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Ser 
            260                 265                 270         


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
        275                 280                 285             


Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala 
    290                 295                 300                 


Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr 
305                 310                 315                 320 


Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu 
                325                 330                 335     


Arg Arg Glu Ser Val Arg Pro Val 
            340                 


<210>  320
<211>  1032
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered anti-CD40scFV (Selicrelumab)

<400>  320
atggattgga cctggatcct gttcctggtg gctgctgcca cccgtgtgca cagccaggtg       60

cagctggtgc aatccggcgc cgaggtgaag aagcccggcg ccagcgtgaa ggtatcgtgt      120

aaggcttcgg gctacacgtt caccggctac tacatgcatt gggtccgcca ggcccccgga      180

cagggcctgg agtggatggg ctggattaac cccgactccg gcggcaccaa ctacgcgcag      240

aaatttcagg ggcgagtgac tatgacaagg gacacttcca tctccacagc ctacatggag      300

ctcaaccgcc tgcgcagcga tgacaccgca gtgtactatt gtgctcgcga ccagcctcta      360

ggttactgca ctaatggcgt atgtagctat ttcgactatt ggggccaggg caccctggtc      420

accgtgtcca gcggcggagg gggctcaggc ggaggtggct caggaggtgg cggctcgggg      480

ggcggtgggt ccgacattca gatgacccag tccccgagct cggtctctgc ttctgtggga      540

gaccgcgtga cgataacctg ccgtgcctcc cagggcatct acagttggct tgcgtggtac      600

cagcagaagc caggcaaggc gccaaacctg ctgatttaca ccgcatccac tcttcagtca      660

ggcgttcctt cccgcttcag tggctctggt tctggcaccg atttcacgct gaccatctcc      720

tccttgcagc cggaagactt tgccacttac tactgccaac aggccaacat cttccctctg      780

accttcggcg gtggcaccaa ggtggagatc aaatctggcg gagggggctc gggcgggggt      840

ggttctggcg gcgggggaag tggtgggggc ggatctggtg gtggtagcct gcagctcttg      900

ccctcctggg cgatcaccct catcagcgtc aatggcatct tcgtcatctg ttgcctgacc      960

tactgctttg cgccgagatg tcgagagcgc cggcgcaacg agcgcctgcg tcgggagtcc     1020

gtgcgccccg tg                                                         1032


<210>  321
<211>  783
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CD40L

<400>  321
atgatcgaga cctacaacca gacttcccca cgtagcgccg ccactggtct acccatctcg       60

atgaaaatct tcatgtatct gctgaccgtg ttcctgatca cccagatgat tggctccgct      120

ctgtttgccg tgtacttgca ccgccgcctg gacaaaattg aggacgagcg gaatctgcac      180

gaagatttcg tatttatgaa gaccatccag aggtgtaaca ctggcgagcg ttctctttcg      240

ttgcttaact gcgaagagat caagagccag ttcgagggct tcgtcaagga catcatgctc      300

aacaaggagg agactaagaa ggagaactcc tttgagatgc agaagggtga tcagaacccc      360

caaattgcag cgcatgtgat aagcgaggct tcctccaaga caaccagtgt gctgcagtgg      420

gcggagaagg gctactacac catgtcaaat aacctggtga ccctggagaa cggcaagcag      480

ctgacggtga agcgccaggg gctctattac atctacgcgc aggtcacgtt ctgttcgaac      540

cgcgaagcct cctctcaggc tcccttcatc gcctcactgt gcctgaaatc tccgggacgc      600

ttcgagcgaa tcctgctccg cgccgccaac acgcactcct ccgccaagcc ttgcgggcag      660

cagagcatcc accttggtgg ggtttttgag ctgcagcctg gcgcgtccgt gttcgtcaac      720

gtgaccgacc cgtcccaggt ctctcatgga accggcttca cctccttcgg cctgctcaag      780

ttg                                                                    783


<210>  322
<211>  566
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered CD40L/IL-15

<400>  322

Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly 
1               5                   10                  15      


Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu 
            20                  25                  30          


Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg 
        35                  40                  45              


Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val 
    50                  55                  60                  


Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser 
65                  70                  75                  80  


Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys 
                85                  90                  95      


Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu 
            100                 105                 110         


Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser 
        115                 120                 125             


Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly 
    130                 135                 140                 


Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln 
145                 150                 155                 160 


Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr 
                165                 170                 175     


Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser 
            180                 185                 190         


Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala 
        195                 200                 205             


Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His 
    210                 215                 220                 


Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn 
225                 230                 235                 240 


Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe 
                245                 250                 255     


Gly Leu Leu Lys Leu Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
            260                 265                 270         


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln 
        275                 280                 285             


Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe 
    290                 295                 300                 


Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg 
305                 310                 315                 320 


Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val Arg Ala 
                325                 330                 335     


Lys Arg Ser Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala 
            340                 345                 350         


Gly Asp Val Glu Glu Asn Pro Gly Pro Met Asp Trp Thr Trp Ile Leu 
        355                 360                 365             


Phe Leu Val Ala Ala Ala Thr Arg Val His Ser Asn Trp Val Asn Val 
    370                 375                 380                 


Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile Gln Ser Met His Ile 
385                 390                 395                 400 


Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His Pro Ser Cys Lys Val 
                405                 410                 415     


Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln Val Ile Ser Leu Glu 
            420                 425                 430         


Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu Asn Leu Ile Ile Leu 
        435                 440                 445             


Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val Thr Glu Ser Gly Cys 
    450                 455                 460                 


Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile Lys Glu Phe Leu Gln 
465                 470                 475                 480 


Ser Phe Val His Ile Val Gln Met Phe Ile Asn Thr Ser Ser Gly Gly 
                485                 490                 495     


Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
            500                 505                 510         


Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile Thr 
        515                 520                 525             


Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys 
    530                 535                 540                 


Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg 
545                 550                 555                 560 


Glu Ser Val Arg Pro Val 
                565     


<210>  323
<211>  1698
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered CD40L/IL-15

<400>  323

Ala Thr Gly Ala Thr Cys Gly Ala Ala Ala Cys Thr Thr Ala Cys Ala 
1               5                   10                  15      


Ala Cys Cys Ala Gly Ala Cys Gly Ala Gly Cys Cys Cys Gly Cys Gly 
            20                  25                  30          


Cys Thr Cys Cys Gly Cys Cys Gly Cys Cys Ala Cys Cys Gly Gly Gly 
        35                  40                  45              


Cys Thr Gly Cys Cys Cys Ala Thr Cys Thr Cys Thr Ala Thr Gly Ala 
    50                  55                  60                  


Ala Ala Ala Thr Cys Thr Thr Cys Ala Thr Gly Thr Ala Thr Cys Thr 
65                  70                  75                  80  


Gly Cys Thr Gly Ala Cys Cys Gly Thr Gly Thr Thr Thr Cys Thr Gly 
                85                  90                  95      


Ala Thr Cys Ala Cys Cys Cys Ala Gly Ala Thr Gly Ala Thr Cys Gly 
            100                 105                 110         


Gly Thr Thr Cys Cys Gly Cys Gly Cys Thr Gly Thr Thr Thr Gly Cys 
        115                 120                 125             


Cys Gly Thr Gly Thr Ala Cys Cys Thr Gly Cys Ala Cys Cys Gly Cys 
    130                 135                 140                 


Cys Gly Cys Cys Thr Gly Gly Ala Cys Ala Ala Gly Ala Thr Ala Gly 
145                 150                 155                 160 


Ala Ala Gly Ala Cys Gly Ala Gly Cys Gly Cys Ala Ala Cys Cys Thr 
                165                 170                 175     


Gly Cys Ala Cys Gly Ala Ala Gly Ala Thr Thr Thr Cys Gly Thr Cys 
            180                 185                 190         


Thr Thr Cys Ala Thr Gly Ala Ala Gly Ala Cys Cys Ala Thr Cys Cys 
        195                 200                 205             


Ala Gly Cys Gly Gly Thr Gly Thr Ala Ala Thr Ala Cys Cys Gly Gly 
    210                 215                 220                 


Cys Gly Ala Gly Ala Gly Gly Ala Gly Cys Cys Thr Gly Ala Gly Cys 
225                 230                 235                 240 


Thr Thr Gly Cys Thr Cys Ala Ala Cys Thr Gly Cys Gly Ala Gly Gly 
                245                 250                 255     


Ala Gly Ala Thr Cys Ala Ala Ala Ala Gly Thr Cys Ala Gly Thr Thr 
            260                 265                 270         


Cys Gly Ala Gly Gly Gly Cys Thr Thr Cys Gly Thr Thr Ala Ala Gly 
        275                 280                 285             


Gly Ala Cys Ala Thr Cys Ala Thr Gly Cys Thr Cys Ala Ala Cys Ala 
    290                 295                 300                 


Ala Gly Gly Ala Gly Gly Ala Gly Ala Cys Cys Ala Ala Gly Ala Ala 
305                 310                 315                 320 


Gly Gly Ala Gly Ala Ala Cys Thr Cys Cys Thr Thr Cys Gly Ala Gly 
                325                 330                 335     


Ala Thr Gly Cys Ala Ala Ala Ala Gly Gly Gly Gly Gly Ala Cys Cys 
            340                 345                 350         


Ala Gly Ala Ala Cys Cys Cys Thr Cys Ala Gly Ala Thr Cys Gly Cys 
        355                 360                 365             


Cys Gly Cys Gly Cys Ala Thr Gly Thr Ala Ala Thr Thr Thr Cys Cys 
    370                 375                 380                 


Gly Ala Gly Gly Cys Cys Thr Cys Ala Thr Cys Cys Ala Ala Gly Ala 
385                 390                 395                 400 


Cys Gly Ala Cys Thr Thr Cys Thr Gly Thr Cys Cys Thr Ala Cys Ala 
                405                 410                 415     


Gly Thr Gly Gly Gly Cys Ala Gly Ala Gly Ala Ala Gly Gly Gly Cys 
            420                 425                 430         


Thr Ala Cys Thr Ala Cys Ala Cys Cys Ala Thr Gly Thr Cys Thr Ala 
        435                 440                 445             


Ala Thr Ala Ala Cys Cys Thr Gly Gly Thr Cys Ala Cys Cys Cys Thr 
    450                 455                 460                 


Thr Gly Ala Gly Ala Ala Cys Gly Gly Cys Ala Ala Gly Cys Ala Ala 
465                 470                 475                 480 


Cys Thr Gly Ala Cys Ala Gly Thr Gly Ala Ala Gly Cys Gly Cys Cys 
                485                 490                 495     


Ala Gly Gly Gly Cys Cys Thr Cys Thr Ala Cys Thr Ala Cys Ala Thr 
            500                 505                 510         


Cys Thr Ala Cys Gly Cys Gly Cys Ala Gly Gly Thr Gly Ala Cys Cys 
        515                 520                 525             


Thr Thr Cys Thr Gly Cys Ala Gly Cys Ala Ala Cys Cys Gly Cys Gly 
    530                 535                 540                 


Ala Gly Gly Cys Thr Thr Cys Cys Thr Cys Cys Cys Ala Ala Gly Cys 
545                 550                 555                 560 


Thr Cys Cys Cys Thr Thr Cys Ala Thr Cys Gly Cys Ala Thr Cys Thr 
                565                 570                 575     


Cys Thr Gly Thr Gly Cys Cys Thr Gly Ala Ala Ala Ala Gly Cys Cys 
            580                 585                 590         


Cys Thr Gly Gly Cys Cys Gly Cys Thr Thr Cys Gly Ala Gly Cys Gly 
        595                 600                 605             


Gly Ala Thr Thr Cys Thr Cys Cys Thr Thr Cys Gly Thr Gly Cys Ala 
    610                 615                 620                 


Gly Cys Ala Ala Ala Cys Ala Cys Thr Cys Ala Cys Thr Cys Gly Thr 
625                 630                 635                 640 


Cys Cys Gly Cys Cys Ala Ala Gly Cys Cys Cys Thr Gly Thr Gly Gly 
                645                 650                 655     


Ala Cys Ala Gly Cys Ala Gly Ala Gly Cys Ala Thr Cys Cys Ala Cys 
            660                 665                 670         


Cys Thr Gly Gly Gly Cys Gly Gly Cys Gly Thr Gly Thr Thr Cys Gly 
        675                 680                 685             


Ala Gly Cys Thr Gly Cys Ala Gly Cys Cys Ala Gly Gly Cys Gly Cys 
    690                 695                 700                 


Cys Thr Cys Cys Gly Thr Gly Thr Thr Cys Gly Thr Cys Ala Ala Thr 
705                 710                 715                 720 


Gly Thr Gly Ala Cys Cys Gly Ala Cys Cys Cys Gly Thr Cys Cys Cys 
                725                 730                 735     


Ala Gly Gly Thr Gly Thr Cys Cys Cys Ala Thr Gly Gly Cys Ala Cys 
            740                 745                 750         


Thr Gly Gly Cys Thr Thr Cys Ala Cys Cys Thr Cys Cys Thr Thr Cys 
        755                 760                 765             


Gly Gly Cys Cys Thr Cys Cys Thr Cys Ala Ala Ala Cys Thr Gly Thr 
    770                 775                 780                 


Cys Cys Gly Gly Cys Gly Gly Cys Gly Gly Thr Gly Gly Cys Ala Gly 
785                 790                 795                 800 


Thr Gly Gly Thr Gly Gly Cys Gly Gly Gly Gly Gly Ala Thr Cys Ala 
                805                 810                 815     


Gly Gly Thr Gly Gly Cys Gly Gly Cys Gly Gly Cys Thr Cys Cys Gly 
            820                 825                 830         


Gly Ala Gly Gly Thr Gly Gly Cys Gly Gly Gly Thr Cys Cys Gly Gly 
        835                 840                 845             


Gly Gly Gly Ala Gly Gly Thr Thr Cys Thr Cys Thr Thr Cys Ala Gly 
    850                 855                 860                 


Cys Thr Thr Cys Thr Gly Cys Cys Thr Ala Gly Cys Thr Gly Gly Gly 
865                 870                 875                 880 


Cys Gly Ala Thr Cys Ala Cys Cys Cys Thr Gly Ala Thr Cys Thr Cys 
                885                 890                 895     


Cys Gly Thr Thr Ala Ala Thr Gly Gly Cys Ala Thr Cys Thr Thr Cys 
            900                 905                 910         


Gly Thr Cys Ala Thr Thr Thr Gly Thr Thr Gly Thr Thr Thr Gly Ala 
        915                 920                 925             


Cys Cys Thr Ala Thr Thr Gly Cys Thr Thr Thr Gly Cys Cys Cys Cys 
    930                 935                 940                 


Gly Ala Gly Ala Thr Gly Thr Cys Gly Ala Gly Ala Gly Cys Gly Thr 
945                 950                 955                 960 


Ala Gly Ala Cys Gly Cys Ala Ala Cys Gly Ala Gly Cys Gly Cys Cys 
                965                 970                 975     


Thr Gly Cys Gly Cys Cys Gly Thr Gly Ala Ala Ala Gly Cys Gly Thr 
            980                 985                 990         


Gly Cys Gly Ala Cys Cys Thr Gly  Thr Gly Cys Gly Cys  Gly Cys Thr 
        995                 1000                 1005             


Ala Ala  Gly Cys Gly Cys Ala  Gly Cys Gly Gly Cys  Thr Cys Cys 
    1010                 1015                 1020             


Gly Gly  Cys Gly Cys Thr Ala  Cys Cys Ala Ala Cys  Thr Thr Cys 
    1025                 1030                 1035             


Thr Cys  Ala Thr Thr Ala Cys  Thr Cys Ala Ala Gly  Cys Ala Gly 
    1040                 1045                 1050             


Gly Cys  Thr Gly Gly Ala Gly  Ala Thr Gly Thr Ala  Gly Ala Gly 
    1055                 1060                 1065             


Gly Ala  Gly Ala Ala Thr Cys  Cys Ala Gly Gly Gly  Cys Cys Ala 
    1070                 1075                 1080             


Ala Thr  Gly Gly Ala Thr Thr  Gly Gly Ala Cys Cys  Thr Gly Gly 
    1085                 1090                 1095             


Ala Thr  Cys Cys Thr Gly Thr  Thr Cys Cys Thr Gly  Gly Thr Gly 
    1100                 1105                 1110             


Gly Cys  Cys Gly Cys Cys Gly  Cys Gly Ala Cys Thr  Cys Gly Cys 
    1115                 1120                 1125             


Gly Thr  Cys Cys Ala Cys Ala  Gly Thr Ala Ala Thr  Thr Gly Gly 
    1130                 1135                 1140             


Gly Thr  Cys Ala Ala Cys Gly  Thr Gly Ala Thr Cys  Thr Cys Thr 
    1145                 1150                 1155             


Gly Ala  Cys Cys Thr Gly Ala  Ala Ala Ala Ala Gly  Ala Thr Thr 
    1160                 1165                 1170             


Gly Ala  Gly Gly Ala Cys Thr  Thr Gly Ala Thr Cys  Cys Ala Gly 
    1175                 1180                 1185             


Ala Gly  Cys Ala Thr Gly Cys  Ala Cys Ala Thr Thr  Gly Ala Cys 
    1190                 1195                 1200             


Gly Cys  Thr Ala Cys Cys Cys  Thr Gly Thr Ala Cys  Ala Cys Gly 
    1205                 1210                 1215             


Gly Ala  Gly Ala Gly Thr Gly  Ala Cys Gly Thr Gly  Cys Ala Cys 
    1220                 1225                 1230             


Cys Cys  Cys Thr Cys Gly Thr  Gly Cys Ala Ala Gly  Gly Thr Gly 
    1235                 1240                 1245             


Ala Cys  Ala Gly Cys Cys Ala  Thr Gly Ala Ala Gly  Thr Gly Cys 
    1250                 1255                 1260             


Thr Thr  Thr Thr Thr Gly Cys  Thr Gly Gly Ala Gly  Thr Thr Gly 
    1265                 1270                 1275             


Cys Ala  Gly Gly Thr Cys Ala  Thr Cys Thr Cys Thr  Cys Thr Ala 
    1280                 1285                 1290             


Gly Ala  Gly Ala Gly Cys Gly  Gly Thr Gly Ala Thr  Gly Cys Cys 
    1295                 1300                 1305             


Thr Cys  Cys Ala Thr Cys Cys  Ala Thr Gly Ala Cys  Ala Cys Cys 
    1310                 1315                 1320             


Gly Thr  Gly Gly Ala Gly Ala  Ala Cys Cys Thr Thr  Ala Thr Cys 
    1325                 1330                 1335             


Ala Thr  Cys Cys Thr Gly Gly  Cys Cys Ala Ala Cys  Ala Ala Cys 
    1340                 1345                 1350             


Ala Gly  Cys Cys Thr Gly Thr  Cys Gly Ala Gly Cys  Ala Ala Cys 
    1355                 1360                 1365             


Gly Gly  Cys Ala Ala Cys Gly  Thr Gly Ala Cys Cys  Gly Ala Gly 
    1370                 1375                 1380             


Thr Cys  Cys Gly Gly Gly Thr  Gly Cys Ala Ala Gly  Gly Ala Ala 
    1385                 1390                 1395             


Thr Gly  Thr Gly Ala Gly Gly  Ala Gly Cys Thr Gly  Gly Ala Gly 
    1400                 1405                 1410             


Gly Ala  Gly Ala Ala Ala Ala  Ala Cys Ala Thr Cys  Ala Ala Gly 
    1415                 1420                 1425             


Gly Ala  Gly Thr Thr Cys Cys  Thr Gly Cys Ala Gly  Thr Cys Gly 
    1430                 1435                 1440             


Thr Thr  Thr Gly Thr Gly Cys  Ala Cys Ala Thr Cys  Gly Thr Gly 
    1445                 1450                 1455             


Cys Ala  Gly Ala Thr Gly Thr  Thr Thr Ala Thr Thr  Ala Ala Cys 
    1460                 1465                 1470             


Ala Cys  Cys Thr Cys Thr Thr  Cys Thr Gly Gly Cys  Gly Gly Thr 
    1475                 1480                 1485             


Gly Gly  Gly Gly Gly Ala Thr  Cys Gly Gly Gly Gly  Gly Gly Gly 
    1490                 1495                 1500             


Gly Gly  Cys Gly Gly Cys Thr  Cys Cys Gly Gly Cys  Gly Gly Thr 
    1505                 1510                 1515             


Gly Gly  Cys Gly Gly Thr Thr  Cys Thr Gly Gly Ala  Gly Gly Cys 
    1520                 1525                 1530             


Gly Gly  Thr Gly Gly Thr Thr  Cys Thr Gly Gly Cys  Gly Gly Gly 
    1535                 1540                 1545             


Gly Gly  Ala Thr Cys Thr Thr  Thr Ala Cys Ala Gly  Cys Thr Gly 
    1550                 1555                 1560             


Cys Thr  Gly Cys Cys Cys Ala  Gly Thr Thr Gly Gly  Gly Cys Gly 
    1565                 1570                 1575             


Ala Thr  Cys Ala Cys Thr Cys  Thr Cys Ala Thr Thr  Thr Cys Cys 
    1580                 1585                 1590             


Gly Thr  Gly Ala Ala Cys Gly  Gly Cys Ala Thr Thr  Thr Thr Cys 
    1595                 1600                 1605             


Gly Thr  Cys Ala Thr Thr Thr  Gly Cys Thr Gly Thr  Thr Thr Gly 
    1610                 1615                 1620             


Ala Cys  Cys Thr Ala Cys Thr  Gly Cys Thr Thr Thr  Gly Cys Thr 
    1625                 1630                 1635             


Cys Cys  Gly Ala Gly Gly Thr  Gly Thr Cys Gly Cys  Gly Ala Gly 
    1640                 1645                 1650             


Cys Gly  Thr Cys Gly Cys Cys  Gly Cys Ala Ala Cys  Gly Ala Gly 
    1655                 1660                 1665             


Cys Gly  Cys Cys Thr Ala Cys  Gly Gly Cys Gly Gly  Gly Ala Ala 
    1670                 1675                 1680             


Thr Cys  Gly Gly Thr Gly Ala  Gly Gly Cys Cys Cys  Gly Thr Gly 
    1685                 1690                 1695             


<210>  324
<211>  226
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-2

<400>  324

Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 
1               5                   10                  15      


Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 
            20                  25                  30          


Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 
        35                  40                  45              


Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe 
    50                  55                  60                  


Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 
65                  70                  75                  80  


Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 
                85                  90                  95      


Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 
            100                 105                 110         


Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 
        115                 120                 125             


Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 
    130                 135                 140                 


Cys Gln Ser Ile Ile Ser Thr Leu Thr Ser Gly Gly Gly Gly Ser Gly 
145                 150                 155                 160 


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
                165                 170                 175     


Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val 
            180                 185                 190         


Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg 
        195                 200                 205             


Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg 
    210                 215                 220                 


Pro Val 
225     


<210>  325
<211>  681
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered IL-2

<400>  325
atgtatcgga tgcagctgct gtcttgtatt gctctatcac tggcgctggt gaccaactcc       60

gctcctactt ccagctcgac caagaagacc cagctccaac ttgagcacct gctgcttgat      120

cttcagatga tcctgaacgg catcaacaac tacaaaaacc ccaagctgac ccgcatgctc      180

actttcaagt tctacatgcc taaaaaggcc accgagctca agcacttgca gtgcctggag      240

gaggagttga agccgttgga agaggtgctc aacctggccc agtccaagaa tttccatcta      300

agaccccgcg acctgatctc taacatcaac gtgattgtac tggagctgaa gggctccgag      360

accaccttca tgtgcgagta cgcggacgag actgcaacca tcgtggagtt cctgaaccgc      420

tggatcacgt tctgtcagag catcatctcg acccttacat ctggcggcgg ggggtcgggc      480

ggtgggggct ctggaggagg cggtagtggg ggtggcggct ccggtggagg cagcctgcag      540

ctgctcccaa gttgggccat caccctgatt agcgtcaatg gcatcttcgt catatgttgt      600

ctgacctact gctttgcccc ccgctgccga gaacgtcgcc gcaacgagcg gctgcgcagg      660

gagtccgtgc gcccggtgtg a                                                681


<210>  326
<211>  601
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-12

<400>  326

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Ile Trp Glu Leu Lys Lys Asp Val Tyr Val Val Glu Leu Asp 
            20                  25                  30          


Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu Thr Cys Asp Thr 
        35                  40                  45              


Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln Ser Ser Glu Val 
    50                  55                  60                  


Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys Glu Phe Gly Asp 
65                  70                  75                  80  


Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val Leu Ser His Ser 
                85                  90                  95      


Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp Ser Thr Asp Ile 
            100                 105                 110         


Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe Leu Arg Cys Glu 
        115                 120                 125             


Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp Leu Thr Thr Ile 
    130                 135                 140                 


Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg Gly Ser Ser Asp 
145                 150                 155                 160 


Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser Ala Glu Arg Val 
                165                 170                 175     


Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu Cys Gln Glu Asp 
            180                 185                 190         


Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile Glu Val Met Val 
        195                 200                 205             


Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr Ser Ser Phe Phe 
    210                 215                 220                 


Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu Lys 
225                 230                 235                 240 


Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp Glu Tyr Pro Asp 
                245                 250                 255     


Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr Phe Cys Val Gln 
            260                 265                 270         


Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr Asp 
        275                 280                 285             


Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala Ser Ile Ser Val 
    290                 295                 300                 


Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser 
305                 310                 315                 320 


Val Pro Cys Ser Gly Gly Gly Gly Gly Gly Ser Arg Asn Leu Pro Val 
                325                 330                 335     


Ala Thr Pro Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn 
            340                 345                 350         


Leu Leu Arg Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu 
        355                 360                 365             


Glu Phe Tyr Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr 
    370                 375                 380                 


Lys Asp Lys Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr 
385                 390                 395                 400 


Lys Asn Glu Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn 
                405                 410                 415     


Gly Ser Cys Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys 
            420                 425                 430         


Leu Ser Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys 
        435                 440                 445             


Thr Met Asn Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu 
    450                 455                 460                 


Asp Gln Asn Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn 
465                 470                 475                 480 


Phe Asn Ser Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp 
                485                 490                 495     


Phe Tyr Lys Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg 
            500                 505                 510         


Ile Arg Ala Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser 
        515                 520                 525             


Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
    530                 535                 540                 


Gly Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp 
545                 550                 555                 560 


Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu 
                565                 570                 575     


Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg 
            580                 585                 590         


Leu Arg Arg Glu Ser Val Arg Pro Val 
        595                 600     


<210>  327
<211>  681
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered IL-12

<400>  327
atgtatcgga tgcagctgct gtcttgtatt gctctatcac tggcgctggt gaccaactcc       60

gctcctactt ccagctcgac caagaagacc cagctccaac ttgagcacct gctgcttgat      120

cttcagatga tcctgaacgg catcaacaac tacaaaaacc ccaagctgac ccgcatgctc      180

actttcaagt tctacatgcc taaaaaggcc accgagctca agcacttgca gtgcctggag      240

gaggagttga agccgttgga agaggtgctc aacctggccc agtccaagaa tttccatcta      300

agaccccgcg acctgatctc taacatcaac gtgattgtac tggagctgaa gggctccgag      360

accaccttca tgtgcgagta cgcggacgag actgcaacca tcgtggagtt cctgaaccgc      420

tggatcacgt tctgtcagag catcatctcg acccttacat ctggcggcgg ggggtcgggc      480

ggtgggggct ctggaggagg cggtagtggg ggtggcggct ccggtggagg cagcctgcag      540

ctgctcccaa gttgggccat caccctgatt agcgtcaatg gcatcttcgt catatgttgt      600

ctgacctact gctttgcccc ccgctgccga gaacgtcgcc gcaacgagcg gctgcgcagg      660

gagtccgtgc gcccggtgtg a                                                681


<210>  328
<211>  205
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-15

<400>  328

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp 
            20                  25                  30          


Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp 
        35                  40                  45              


Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu 
    50                  55                  60                  


Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr 
65                  70                  75                  80  


Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly 
                85                  90                  95      


Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys 
            100                 105                 110         


Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe 
        115                 120                 125             


Ile Asn Thr Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
    130                 135                 140                 


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Leu Gln Leu 
145                 150                 155                 160 


Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val 
                165                 170                 175     


Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg 
            180                 185                 190         


Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val 
        195                 200                 205 


<210>  329
<211>  618
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Tethered IL-15

<400>  329
atggattgga cctggatcct gttcctggtg gctgcggcca cccgtgtaca cagcaactgg       60

gtcaatgtga tctccgacct gaagaagatt gaggacctca tccagtctat gcacattgac      120

gcaacacttt acaccgagag cgatgtgcac ccctcttgca aggtgactgc catgaaatgt      180

ttcttgctcg aattgcaggt catctctctg gagagtgggg acgcttccat acatgacacc      240

gtggagaacc tgatcatcct ggccaacaac agcctctcgt caaatggcaa cgtgactgag      300

agcgggtgca aagagtgtga ggagctggag gagaagaaca tcaaggagtt cctgcagagc      360

ttcgtccaca tcgtgcagat gtttattaac acgtcgtccg gaggcggggg ctctggtggc      420

ggcggctccg ggggaggcgg ctccggtggc ggtggttccg gcggaggctc gctacagctg      480

ctgcccagtt gggccatcac ccttatttct gtcaacggca tcttcgttat ctgttgcctg      540

acctactgct ttgcgccgag gtgtcgcgag cggcgtcgca acgagcgcct gcgccgagaa      600

tccgtgcgcc ctgtgtga                                                    618


<210>  330
<211>  717
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  GFP

<400>  330
atgagcaagg gcgaggagct gttcaccggg gtggtgccca tcctggtcga gctggacggc       60

gacgtaaacg gccacaagtt cagcgtgtcc ggcgagggcg agggcgatgc cacctacggc      120

aagctgaccc tgaagttcat ctgcaccacc ggcaagctgc ccgtgccctg gcccaccctc      180

gtgaccaccc tgacctacgg cgtgcagtgc ttcagccgct accccgacca catgaagcag      240

cacgacttct tcaagtccgc catgcccgaa ggctacgtcc aggagcgcac catcttcttc      300

aaggacgacg gcaactacaa gacccgcgcc gaggtgaagt tcgagggcga caccctggtg      360

aaccgcatcg agctgaaggg catcgacttc aaggaggacg gcaacatcct ggggcacaag      420

ctggagtaca actacaacag ccacaacgtc tatatcatgg ccgacaagca gaagaacggc      480

atcaaggtga acttcaagat ccgccacaac atcgaggacg gcagcgtgca gctcgccgac      540

cactaccagc agaacacccc catcggcgac ggccccgtgc tgctgcccga caaccactac      600

ctgagcaccc agtccgccct gagcaaagac cccaacgaga agcgcgatca catggtcctg      660

ctggagttcg tgaccgccgc cgggatcact cacggcatgg acgagctgta caagtga         717


<210>  331
<211>  245
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tethered IL-21

<400>  331

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 
1               5                   10                  15      


His Ser Gln Gly Gln Asp Arg His Met Ile Arg Met Arg Gln Leu Ile 
            20                  25                  30          


Asp Ile Val Asp Gln Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu 
        35                  40                  45              


Phe Leu Pro Ala Pro Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala 
    50                  55                  60                  


Phe Ser Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn 
65                  70                  75                  80  


Asn Glu Arg Ile Ile Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro 
                85                  90                  95      


Pro Ser Thr Asn Ala Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro 
            100                 105                 110         


Ser Cys Asp Ser Tyr Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg 
        115                 120                 125             


Phe Lys Ser Leu Leu Gln Lys Met Ile His Gln His Leu Ser Ser Arg 
    130                 135                 140                 


Thr His Gly Ser Glu Asp Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 
145                 150                 155                 160 


Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 
                165                 170                 175     


Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
            180                 185                 190         


Gly Gly Gly Gly Ser Leu Gln Leu Leu Pro Ser Trp Ala Ile Thr Leu 
        195                 200                 205             


Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe 
    210                 215                 220                 


Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu 
225                 230                 235                 240 


Ser Val Arg Pro Val 
                245 


